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Summary  
Individuals with >/= 10 colorectal adenomas have traditionally been referred for 
genetic testing to identify APC and MUTYH mutations which cause Familial 
Adenomatous Polyposis (FAP) and MUTYH-Associated Polyposis (MAP) 
respectively.  Mutations are found in most patients with >100 adenomas but in only 
a minority of those with 10-100 adenomas.  The research described in this thesis 
focuses on polyposis patients with ‘no mutation identified’ (NMI).   
The aim of this project was to identify novel genetic mechanisms causing polyposis 
in a cohort of 60 unrelated NMI patients.  Genetic variants were sought outside of 
the open reading frames of APC and MUTYH, at a low frequency in APC, in other 
known and candidate ‘polyposis genes’ and in whole exomes.  Novel variants were 
characterised genetically and functionally to provide evidence for or against their 
clinical significance.    
Rare variants were found in the 5’UTR of APC, the mismatch repair (MMR) genes, 
POLE, POLD1 and AXIN2.  The 5’UTR APC variant, c.-190A>G, was associated 
with reduced transcript levels and segregated with FAP in a multiplex family, 
allowing translation to diagnostic testing.  Three additional patients had reduced 
APC transcript levels, but the cause was not determined by deep sequencing of 
their genomic APC loci.  The MMR gene variants were deemed unlikely to be 
pathogenic as associated tumours were microsatellite stable with normal MMR 
protein immunohistochemistry.  Studies into the pol gene variants are ongoing.  The 
AXIN2 mutation, c.1642G>T, p.Glu548*, was identified in a family with polyposis 
and ectodermal dysplasia.  Most of their adenomas appeared to lack APC mutations 
and in vitro studies suggested that the mutation may impair inhibition of Wnt-
signalling.    
Gene panel testing using next-generation sequencing technologies may improve 
molecular genetic diagnosis of previously NMI patients but additional 
characterisation of novel variants is likely to be required for clinical translation, with 
the ultimate aim of preventing colorectal cancer.  
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Chapter 1 General Introduction 
1.1 Background 
In 2016, cancer was the leading cause of mortality in England and Wales, 
accounting for 28.5% of all deaths (Office for National Statistics, 2017).  It is 
estimated that the lifetime risk of developing any malignant neoplasm, excluding 
non-melanoma skin cancer, is 40% for males and 37% for females (Sasieni et al 
2011).  Cancer refers to the process in which cells grow uncontrollably.  The 
transformation of a normal cell into a malignant one is a multistep process, in which 
several genetic alterations occur, allowing the cell to escape from normal control 
mechanisms (Hanahan and Weinberg, 2000).  The genetic changes involve the 
activation of oncogenes and the silencing of tumour suppressors (Hanahan and 
Weinberg, 2011).  These changes allow the cell to attain a growth advantage, for 
example through self-sufficiency in growth signals, insensitivity to growth inhibitory 
signals, evasion of apoptosis, limitless replicative potential, sustained angiogenesis, 
tissue invasion/ metastasis, reprogramming of cellular energy metabolism and 
immune evasion (Hanahan and Weinberg, 2011; Hanahan and Weinberg, 2000). 
 
In order to acquire these advantageous traits, there is a succession of alterations in 
the genomes of neoplastic cells (Hanahan and Weinberg, 2011).  Mutations may 
occur spontaneously or may be triggered by external factors such as viruses, 
radiation and chemicals.  In addition to mutation events, gene expression can be 
altered through epigenetic mechanisms such as DNA methylation, histone 
modification and micro-RNA (miRNA) expression (Berdasco and Esteller 2010; 
reviewed in Jones and Baylin 2007).  Ultimately, most cancers develop as a result 
of a complex interaction between an individual’s genetic make-up and their 
environment.   
1.2 Colorectal Carcinoma 
Colorectal carcinoma (CRC) is the fourth most common cancer in the United 
Kingdom (UK) and the second most common cause of cancer death (Cancer 
Research UK 2015).  Between 2013- 2015, approximately 41 700 people were 
diagnosed with CRC, which is more than 110 people every day (Cancer Research 
UK 2015).  An individual’s lifetime risk of developing CRC is 5%, but this figure 
  20 
increases dramatically with age (reviewed in Fodde 2002).  The incidence of CRC is 
generally high in developed countries, with a 20-fold difference in incidence rates 
between high- and low-risk geographical areas (reviewed in Fodde 2002).  The 
difference is thought to largely result from environmental factors, in particular 
differences in diet (Fodde 2002). 
 
The majority of CRCs occur sporadically, but in 15-35% of patients, hereditary 
factors are important (reviewed in Mishra and Hall 2012; Burt 2007).  In 
approximately 5% of cases, the disease is caused by a highly penetrant dominantly 
inherited syndrome (reviewed in Mishra and Hall 2012).  The most common is 
Lynch Syndrome, due to inherited defects in the mismatch repair (MMR) system.  
This accounts for 2-5% of cases of CRC (reviewed in Mishra and Hall 2012).  
Familial Adenomatous Polyposis (FAP), due to germline mutations in the APC gene, 
is responsible for <1% of the disease burden and non-syndromic familial 
presentations comprise 20% of cases (reviewed in Mishra and Hall 2012).      
 
CRCs result from the progressive accumulation of genetic and epigenetic alterations 
which cause normal colonic epithelium to transform into adenocarcinoma (Grady 
and Carethers 2008).  Recent work based on gene expression profiling (Guinney et 
al 2015) suggests that CRC can be classified into 4 molecular subtypes: MSI 
Immune, Canonical, Metabolic and Mesenchymal.  However, the traditional 
approach has been to categorise tumours into 3 groups:  those with chromosomal 
instability (CIN), those with microsatellite instability (MSI) and those with a 
hypermethylated phenotype (CpG Island Methylator Phenotype or ‘CIMP’).  There is 
considerable overlap between the latter two groups.   
1.2.1 Chromosomal Instability (CIN), APC and the Wnt-
Pathway 
The vast majority of CRCs develop from pre-existing adenomas.  Such tumours are 
characterised by chromosomal instability, which is seen in 80-85% of colorectal 
tumours (reviewed in Grady and Carethers 2008).  There are certain key genetic 
mutational events which occur, allowing the progression from normal epithelium, to 
dysplasia, and finally invasive malignancy.  The loss of adenomatous polyposis coli 
(APC) gene function seems to be the initiating event, followed by mutations in 
KRAS, SMAD4 and p53 (Fodde 2002).  In keeping with Knudson’s two hit 
hypothesis of tumourigenesis, two mutational events are required to knock out the 
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functioning of a tumour suppressor gene (Knudson 1971), whilst activation of an 
oncogene requires only one mutation. 
 
 
Figure 1.1:  Image from Walther et al (2009) illustrating the progressive accumulation of 
genetic changes involved in the malignant progression of colorectal tumours 
1.2.1.1 Adenomatous Polyposis Coli (APC) 
The APC gene is found on chromosome 5 (5q22.2).  It consists of 8535 coding base 
pairs, encoding a 2843 amino acid multidomain protein.  Exon 15 is responsible for 
more than 75% of the coding sequence of the gene and is the most common site for 
germline and somatic mutations (reviewed in Fearnhead et al 2002; reviewed in 
Fearnhead et al 2001).  95% of CRC-associated APC mutations are nonsense or 
frameshift mutations, creating a truncated protein with abnormal function (Bodmer 
1999).   
The APC protein is a 312kDa tumour suppressor, which is involved in many cellular 
processes including intercellular adhesion, signal transduction, proliferation, 
apoptosis and migration.  One of its major roles is in regulating cytoplasmic levels of 
β-catenin, thus negatively regulating Wnt signalling (Mishra and Hall 2012; reviewed 
in Fearnhead et al 2002; Fodde 2002; Fearnhead et al 2001). 
 
1.2.1.2 The Wnt pathway 
The Wnt proteins are a family of signalling proteins which are involved in 
developmental events during embryogenesis and in adult tissue homeostasis 
(Logan and Nusse 2004).  They have multiple effects within a cell, including 
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triggering cell division, cell fate specification and differentiation (Logan and Nusse 
2004).  
 
Wnt proteins bind to Frizzled/ low density lipoprotein receptor-related proteins, 
which are found on cell surface membranes (Logan and Nusse 2004).  This 
transduces a signal to intracellular proteins, including Dishevelled (Dsh), Glycogen 
Synthase Kinase-3β (GSK-3), AXIN, APC and β-catenin (Logan and Nusse 2004). 
In the absence of Wnt signalling, β-catenin levels are usually low:  a complex 
composed of GSK-3, APC and AXIN targets it for ubiquitin-mediated degradation 
(Logan and Nusse 2004; reviewed in Fearnhead et al 2002; reviewed in Fearnhead 
et al 2001).  When cells receive Wnt signals, the degradation pathway is inhibited.  
This allows β-catenin to accumulate in the cytoplasm and nucleus.  In the nucleus, it 
complexes with one of the T cell factor (TCF) or lymphoid enhancer factor (LEF) 
transcription factors, to initiate transcription of a range of genes, including c-myc 
and cyclin D1 (Logan and Nusse 2004; reviewed in Fearnhead et al 2002; reviewed 
in Fodde 2002; reviewed in Fearnhead et al 2001). Myc and cyclin D1 are both 
relevant to tumourigenesis as they have roles in proliferation, apoptosis and cell-
cycle progression (reviewed in Fodde 2002).   
 
 
 
Figure 1.2: Image from Logan and Nusse (2004) illustrating the Wnt pathway in both the 
absence and presence of Wnt stimulating molecules 
 
In the normal intestinal epithelium, nuclear β-catenin expression is higher in the 
proliferative component, and APC levels are higher in post-replicative cells 
(reviewed in Fodde 2002).  These findings support β-catenin signalling having a role 
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in maintaining stem cell properties and controlling differentiation in the bowel 
(reviewed in Fodde 2002).  As cells move along the crypt-villous axis, increasing 
levels of APC counteract β-catenin signalling and allow differentiation to occur 
(reviewed in Fodde 2002).  APC mutations hence allow increased numbers of stem 
cells and reduced cellular differentiation (Fodde 2002). 
 
In addition to their roles in the initial stages of the adenoma-carcinoma sequence, 
APC mutations remain important throughout malignant progression.  Nuclear β-
catenin staining strongly correlates with tumour size and dysplasia, and high levels 
of nuclear β-catenin have been found at the invasive fronts of adenocarcinomas 
(reviewed in Fodde 2002).  The APC protein is also involved in chromosomal 
stability at mitosis:  it has an EB1-binding domain in its C-terminal end, which 
associates with the growing ends of cytoplasmic and spindle microtubules, as well 
as centrosomes.   APC mutant cells are hence characterised by chromosomal 
instability which is observed in the majority of CRCs (reviewed in Grady and 
Carethers 2008; reviewed in Fodde 2002). 
 
APC mutations can therefore be seen to have a key role in both initiating and 
promoting CRC:  activation of the Wnt pathway affects cell proliferation, apoptosis, 
and possibly differentiation of intestinal stem cells (Fodde 2002) and at later stages 
of carcinogenesis, CIN resulting from APC mutations can accelerate tumour 
progression (Fodde 2002). 
 
1.2.1.3 KRAS, SMAD4 and P53 
As illustrated in Figure 1.1, further genes involved in colorectal tumourigenesis 
include KRAS, SMAD4, and p53.  The importance of ras gene mutations in 
colorectal carcinogenesis was first reported in 1987 (Bos et al 1987; Forrester et al 
1987).  The K-ras oncogene has been found to be mutated in 10-15% of adenomas 
<1cm, and in 30-60% of adenomas >1cm and carcinomas (reviewed in Brink et al 
2003; reviewed in Fearon and Vogelstein 1990).  The gene encodes a 21kDA 
protein located in the inner plasma membrane, with intrinsic GTPase activity.  It is 
involved in the transduction of mitogenic signals (reviewed in Brink et al 2003).  It is 
activated by a diverse spectrum of extracellular stimuli, such as growth factors, 
cytokines and hormones (reviewed in Brink et al 2003; Shields et al 2000).  Once 
activated, it stimulates a multitude of downstream signalling cascades, including the 
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Raf serine/ threonine kinases, phosphoinositide 3-kinases (PI3Ks) and a family of 
GDP-GTP exchange factors (reviewed in Shields et al 2000).   
Mutant KRAS has impaired GTPase activity, meaning that it is constitutively active 
(reviewed in Brink et al 2003).  This can cause uncontrolled cell growth and 
proliferation.  A KRAS mutation in a colonic epithelial cell which already has APC 
mutations results in a clonal expansion and increased risk of progression to cancer 
(reviewed in Vogelstein and Kinzler 2004). 
 
The SMAD4 gene is on chromosome 18q.  It was first identified as a tumour 
suppressor gene in pancreatic cancer in 1996 (Hahn et al 1996).  SMAD4 mediates 
the TGFβ signalling pathway to suppress epithelial growth (reviewed in Miyaki and 
Kuroki 2003).  The SMAD4 protein acts as a trimer and forms complexes with 
additional SMAD proteins:  receptor-phosphorylated SMAD2 and SMAD3 
(Woodford-Richens et al 2001).  These complexes then translocate from the 
cytoplasm to the nucleus and associate with DNA binding factors to facilitate the 
transcription of target genes, including cyclin-dependent kinase inhibitors such as 
p15(ink4B) and the inhibitory SMAD7 (Woodford-Richens et al 2001).  Loss of 
SMAD4 function may result in the loss of transcription of genes necessary for cell-
cycle control (Woodford-Richens et al 2001).  Cells may therefore become TGF-β 
resistant and escape from TGF-β-mediated growth control and apoptosis 
(Woodford-Richens et al 2001).  SMAD4 is mutated in a significant proportion of 
colorectal tumours, with the frequency of mutational events increasing with the 
progression of carcinogenesis: it is mutated in 0% of adenomas, 10% of 
‘intramucosal carcinomas’, 7% of carcinomas without metastases and 35% of 
carcinomas with distant metastases (reviewed in Miyaki and Kuroki 2003).   
 
In 1988, it was reported that 73% of CRCs, 47% of ‘advanced adenomas’ and 11-
13% of ‘early stage adenomas’ had a deletion of part of chromosome 17 (Vogelstein 
et al 1988).  This region was subsequently shown to include the p53 gene (17p13.1) 
(Baker et al 1989).  The p53 protein is a transcription factor which has a vital role in 
maintaining genomic stability (reviewed in Sarasqueta et al 2013).  Following DNA 
damage, p53 activation causes arrest of the cell cycle to allow DNA repair (reviewed 
in Sarasqueta et al 2013).  If the damage is too extensive, p53 can drive a cell 
towards senescence or apoptosis (reviewed in Sarasqueta et al 2013; reviewed in 
Vogelstein and Kinzler 2004).  The functional loss of p53 is a key event in the 
malignant progression of a colorectal adenoma to CRC (reviewed in Iacopetta 2003; 
Vogelstein et al 1988).   
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1.3 Microsatellite Instability (MSI) 
The human mismatch repair system (MMR) involves 7 key genes: MSH2, MSH6, 
MSH3, MLH1, PMS1, PMS2 and MLH3.  Their protein products are able to 
recognise and repair nucleotide mismatches which have escaped the normal editing 
function of DNA polymerase (reviewed in Grady and Carethers 2008).  If such 
mismatches are not repaired, nucleotide transitions or transversions result, allowing 
potentially oncogenic mutations to occur more frequently, leading to a 
‘hypermutable phenotype’ (reviewed in Grady and Carethers 2008).   
 
Lynch Syndrome (LS) is an autosomal dominant (AD) disease, which accounts for 
approximately 5% of cases of CRC (reviewed in Mishra and Hall 2012).  Patients 
also have an inherited predisposition to a range of other malignancies, in particular 
endometrial carcinoma (Lynch et al 2015).  LS occurs due to inherited mutations of 
MSH2, MSH6, MLH1 or PMS2 (reviewed in Grady and Carethers 2008).  In 15-20% 
of sporadic colon cancers, inactivation of the mismatch repair (MMR) system 
occurs, either though methylation of MLH1 or point mutations in MLH1/ MSH2/ other 
members of the MMR family (reviewed in Grady and Carethers 2008).  This leads to 
microsatellite instability (MSI).   
 
It is thought that certain key tumour suppressor genes drive the pathogenesis of 
MSI tumours, and these are different to those which are mutated in CIN tumours 
(reviewed in Grady and Carethers 2008).  In around 85% of colorectal tumours with 
MSI, a repeat of 10 adenines undergoes a frameshift mutation in the TGFBR2 gene.  
This allows tumour cells to escape the growth suppressing effects of TGF-β1 
(reviewed in Grady and Carethers 2008).  Another gene commonly mutated in MSI 
CRC is BAX, which plays a role in apoptosis.  It is mutated in 50% of MSI CRC 
(reviewed in Grady and Carethers 2008).  Interestingly, frameshift mutations within 
coding mononucleotide repeats are also seen in APC (reviewed in Lynch et al 
2015). 
 
MSI CRCs tend to have a certain clinical and pathological phenotype.  They 
generally occur in the right side of the colon, and microscopically they have a 
mucinous appearance with large numbers of tumour-infiltrating lymphocytes 
(reviewed in Grady and Carethers 2008). 
 
  26 
1.4 CpG Island Methylator Phenotype (CIMP) 
Epigenetic regulation of gene expression can be achieved through methylation of 
CpG islands found in gene promoters, causing silencing of the downstream gene.  
Such silencing of tumour suppressors and/ or DNA repair genes is a common 
feature of human neoplasia (reviewed in Hughes et al 2012).  Widespread CpG 
island promoter methylation is referred to as the CpG island methylator phenotype 
(CIMP) and was first described in 1999 (Toyota et al 1999).  The cause of CIMP 
remains to be elucidated but may potentially result from aberrant de novo 
methylation or through the loss of protection against de novo methylation (reviewed 
in Toyota et al 1999).  Environmental factors, such as anthropometry and physical 
activity, smoking and alcohol may also play a role (reviewed in Hughes et al 2012). 
 
CRC which exhibit CIMP are thought to arise via the ‘serrated pathway of 
neoplasia’.  The precursor lesions are hyperplastic polyps, rather than adenomas, 
and an early event is a mutation of the BRAF oncogene (reviewed in Guarinos et al 
2012).  BRAF is a component of the MAPK signalling pathway.  The pathway 
involves activation of cell membrane signalling molecules with subsequent 
stimulation of cytoplasmic protein kinases (Seger and Krebs 1995).  The transmitted 
signals eventually activate cellular processes such as proliferation, differentiation 
and development (Seger and Krebs 1995).  Activating mutations of BRAF increase 
its kinase activity, which drives the proliferation of malignant cells (reviewed in 
Bollag et al 2012). 
 
Most CIMP CRCs have epigenetic silencing of MLH1, leading to microsatellite 
instability (reviewed in Hughes et al 2012), and may have silencing of tumour 
suppressor genes such as p16 (Toyota et al 1999). 
 
Typically, CIMP tumours are associated with older age, female sex and occurrence 
in the right side of the bowel (reviewed in Hughes et al 2012), as is seen with MSI 
CRC. 
1.5 The Colorectal Polyposis Syndromes 
Colorectal polyps are masses of tissue which are found projecting from the mucosa 
of the large bowel.  They are classified according to their microscopic appearance, 
and include adenomas, hyperplastic polyps and hamartomatous polyps.  Most 
polyps occur sporadically, but some are seen as part of a genetic ‘polyposis 
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syndrome’ (Figure 1.3).  Colorectal polyps are benign but are clinically significant as 
they may confer a risk of malignancy.
   
2
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Figure 1.3:   Diagram illustrating relationships between genes and signalling pathways involved in inherited colorectal polyposis syndromes. FAP, Familial 
Adenomatous Polyposis; HMPS, Hereditary Mixed Polyposis Syndrome; JPS, Juvenile Polyposis Syndrome; LS, Lynch Syndrome; MAP, MUTYH-Associated 
Polyposis; NTHL1, NTHL1-Associated Polyposis; PJS, Peutz-Jegher’s Syndrome; PPAP, Polymerase Proofreading-Associated Polyposis.  Image modified 
from Short et al (2015)  
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1.5.1 Colorectal Adenomas 
Colorectal adenomas are common.  They are found in between 1.72% and 63% of 
autopsies (Pendergrass et al 2008; Paspatis et al 2001; Correa et al 1977; Arminski 
and McLean 1964; Chapman 1963).  In asymptomatic patients undergoing 
colonoscopies, adenoma prevalence is between 6.3% and 41% (Chung et al 2010; 
Rundle et al 2008; Lin et al 2006; Strul et al 2006; Soon et al 2005; reviewed in 
Giacosa 2004; Yamaji et al 2004; DiSario et al 1991).  They occur more frequently 
in males than in females, and their prevalence increases with age (Chung et al 
2010; Pendergrass et al 2008; Lin et al 2006; Strul et al 2006; Soon et al 2005; 
Yamaji et al 2004; Paspatis et al 2001; DiSario et al 1991; Correa et al 1977; 
Chapman 1963). 
 
The significance of colorectal adenomas is that they are pre-malignant lesions.  The 
majority of colorectal CRCs are thought to develop from pre-existing adenomas.  
The probability that an adenoma will become malignant depends upon its size, 
morphology and degree of dysplasia.  Large villous lesions harbouring high grade 
dysplasia confer the highest risk (Terry et al 2002; O’Brien et al 1990; Shinya and 
Wolff 1979; Muto et al 1975).   
 
Most colorectal adenomas occur sporadically.  However, there are syndromes of 
colorectal polyposis, in which patients develop multiple polyps as a result of an 
underlying genetic mutation.  These include Familial Adenomatous Polyposis (FAP), 
MUTYH-Associated Polyposis (MAP), Polymerase Proofreading-Associated 
Polyposis (PPAP),  NTHL1-Associated Polyposis/ CRC and MSH3-Associated 
Polyposis/ CRC.   
 
1.5.1.1 Familial Adenomatous Polyposis (FAP)  
FAP is a dominantly inherited Mendelian trait, in which patients develop hundreds to 
thousands of colorectal adenomas during adolescence or the third decade of life 
(reviewed in Fearnhead et al 2002; Bodmer 1999). All such patients will invariably 
develop CRC if they are left untreated (Bodmer 1999; reviewed in Fearnhead et al 
2002).     
The first case of histologically verified adenomatous polyposis was published in 
1881 by Sklifasowski (reviewed in Bülow et al 2006).  The following year Harrison-
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Cripps described ‘disseminated polypus of the rectum’ in two teenage siblings, both 
of whom had 20-30 colorectal polyps (reviewed in Bülow et al 2006; Harrison-Cripps 
1882).  In the late 1800s there were numerous case reports describing patients with 
multiple colorectal adenomas, and an association with colorectal malignancy was 
noted (reviewed in Bülow et al 2006).  In 1925, Lockhart-Mummery stated that the 
‘condition of multiple adenomata was invariably antecedent to carcinoma’ and that 
‘the condition of multiple adenomata is often hereditary in a marked degree’ 
(Lockhart-Mummery 1925). 
 
It is now known that FAP, and an attenuated form of the disease, AFAP, are due to 
germline or somatic mosaic mutations in APC.  Over 1500 different mutations in 
APC have been identified to date (Kadiyska et al 2013).  The majority of mutations 
are inherited.  It used to be thought that approximately one quarter of cases 
occurred de novo (reviewed in Fearnhead et al 2001), but this is an overestimate, 
as this figure included apparent de novo patients who actually had MUTYH-
Associated Polyposis (MAP).  A third of all germline mutations occur at codons 1061 
and 1309, with the remainder spread relatively uniformly between codons 200 and 
1600 (reviewed in Fearnhead et al 2001).  The nature of the germline mutation 
determines the nature of the second somatic hit to APC (reviewed in Fearnhead et 
al 2002; reviewed in Fearnhead et al 2001).  Germline mutations occurring between 
codons 1194 and 1392 tend to be followed by allelic loss of APC as a second hit 
(loss of heterozygosity, LOH), whereas germline mutations lying outside of this 
region tend to be associated with truncating mutations in the mutation cluster region 
(MCR) between codons 1286 and 1513 (reviewed in Fearnhead et al 2002).  The 
reason for this may be related to the resultant level or functional characteristics of 
APC protein produced:  it is proposed that to allow efficient tumourigenesis, the 
function of APC must be impaired sufficiently to allow a certain level of nuclear β-
catenin accumulation, but that β-catenin levels must not be too great, or this can 
result in apoptosis (Albuquerque et al 2002).   
 
The incidence of FAP is approximately 1 per 8000, and it accounts for around 0.5% 
- 1% of CRC (Mishra and Hall 2012; reviewed in Fearnhead et al 2002; reviewed in 
Bodmer 1999).  In addition to colorectal adenomas, FAP patients may develop 
extra-intestinal manifestations of their disease, for example congenital hypertrophy 
of the retinal pigment epithelium (CHRPE), duodenal and peri-ampullary tumours, 
desmoid tumours, papillary carcinoma of the thyroid, medulloblastoma, 
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hepatoblastoma, osteomas and epidermoid cysts (Mishra and Hall 2012; reviewed 
in Fearnhead et al 2002). 
1.5.1.2 MUTYH-Associated Polyposis (MAP) 
Prior to 2002, inherited defects of base excision had not been associated with any 
human genetic disorder (Al-Tassan et al 2002).  That year, mutations in the MUTYH 
gene were shown to cause an inherited predisposition to colorectal tumours (Al-
Tassan et al 2002). 
 
The MUTYH gene is located on the short arm of chromosome 1 (1p32.1-p34.3) 
(Poulsen and Bisgaard 2008).  It consists of 16 exons and encodes a protein of 535 
amino acids, the MUTYH glycosylase (Poulsen and Bisgaard 2008).  MUTYH 
glycosylase is part of the base excision repair (BER) system.  It is involved in 
repairing DNA mismatches occurring as a result of oxidative DNA damage (Mazzei 
et al 2013).  Each human cell metabolises approximately 1012 molecules of oxygen 
per day (reviewed in Nohmi et al 2005).  About 1% of oxygen metabolism results in 
the production of reactive oxygen species (ROS) which include superoxide, 
hydrogen peroxide, hydroxyl radicals and singlet oxygen (reviewed in Nohmi et al 
2005).  ROS can damage DNA, producing 8-hydroxyguanine (8-oxodG).  This 
frequently pairs with dAMP.  Under normal circumstances, this mispairing would be 
repaired by MUTYH, to create C: 8-oxodG base pairs.  Another enzyme, OGG1 will 
then remove the 8-oxodG.  Hence the combined effects of MUTYH and OGG1 will 
prevent GC > TA transversions (Mazzei et al 2013). 
 
 
 
Figure 1.4: Image from David et al (2007) illustrating the actions of MUTYH in the repair of 
oxidative DNA damage 
  
 32 
 
Patients with biallelic germline MUTYH mutations are predisposed to mutations in 
genes including APC and KRAS.  The clinical manifestation of this is MAP.  MAP is 
an autosomal recessive (AR) disease, in which patients develop multiple colorectal 
adenomas.  The mean age of diagnosis is 45-50 years, and patients typically have 
between 10 and 100 polyps (reviewed in Mazzei et al 2013; reviewed in Poulsen 
and Bisgarrd 2008; Croitoru et al 2007; Nielsen et al 2007; Gismondi et al 2004; 
Wang et al 2004; Sampson et al 2003; Sieber et al 2003).  Some patients do not 
develop polyps but present with cancer (Farrington et al 2005; Wang et al 2004; 
Enholm et al 2003).  Although the majority of polyps are adenomas, hyperplastic 
polyps (HPPs) and sessile serrated adenomas (SSAs) are also seen (reviewed in 
Mazzei et al 2013; Boparai et al 2008; Lipton et al 2003a). 
 
Patients with MAP have an increased risk of developing CRC.  Malignancy has 
been reported with varying frequencies:  one paper reported a prevalence of 
19.47% at 50 years, and 42.89% at 60 years (Lubbe et al 2009); another found that 
48% of patients with MAP developed CRC with a mean age of diagnosis of 49.7 
years (Sampson et al 2003).  It has been suggested that biallelic inactivation of 
MUTYH imparts an overall 93-fold excess risk and that all homozygotes/ compound 
heterozygotes will develop CRC by age 60 (Farrington et al 2005).  Win et al (2014) 
estimated that males carrying biallelic MUTYH mutations had a 75.4% risk of 
developing CRC by age 70, and females had a 71.7% risk (Win et al 2014). 
 
MAP may also have extra-colonic manifestations, although these are generally not 
part of the characteristic phenotype (Poulsen and Bisgaard 2008).  The lesions 
which have been reported include duodenal adenomas and carcinoma, fundic gland 
polyps, stomach cancer, CHRPE, osteomas and breast cancer (reviewed in 
Venesio et al 2012; reviewed in Poulsen and Bisgaard 2008).  The incidence of 
extra-intestinal malignancies is almost double that of the general population, with a 
significant increase in ovarian, bladder and skin cancers (reviewed in Venesio et al 
2012). 
 
By 2013, >300 MUTYH variants among MAP patients and/ or controls had been 
described (Ruggieri et al 2013).  The mutations observed in MUTYH vary according 
to the ethnic group studied, suggesting population specific ancestral variants 
(Dolwani et al 2007; Sieber et al 2003).  In Caucasian populations, P.Tyr165Cys 
and p.Gly382Asp are the common mutations (Jones et al 2002; Sampson et al 
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2003; Enholm et al 2003; Sieber et al 2003).  These account for 73% of all 
mutations reported and have been described in Swiss (Russell et al 2006), Italian 
(Gismondi et al 2004; Venesio et al 2004), French (Küry et al 2007), Swedish 
(Kanter-Smoler et al 2006; Zhou et al 2005), Canadian (Croitoru et al 2007), 
Australian (Kairupan et al 2005), Portuguese (Isidro et al 2004), Czech (Šulová et al 
2007), British, American and Dutch populations (reviewed in Cheadle and Sampson 
2007). There is evidence for strong founder effects for these mutations:  it is 
suggested that they derive from ancestors who lived between 5-8000 years and 6-
9000 years BC respectively (Aretz et al 2014). 
 
Numerous other pathogenic variants in MUTYH have been reported, including 
c.1395delGGA in Italians (Gismondi et al 2004), p.Glu466* and p.TyrY90* in Asians 
(Sampson et al 2003; Jones et al 2002) and p.Arg231Cys in the Japanese (Miyaki 
et al 2005).   
 
1.5.1.3 Polymerase Proofreading Associated Polyposis 
(PPAP) 
PPAP is a relatively recently defined clinical entity.  POLE and POLD1 code for 
DNA polymerases with exonuclease (proofreading) activity.  Mutations in these 
genes are thought to cause a defect in correcting mispaired bases inserted during 
DNA replication (Palles et al 2013).  In 2012, Palles et al undertook whole-genome 
sequencing of probands who had at least 10 colorectal adenomas by age 60, who 
had previously had known Mendelian cancer syndromes excluded in a clinical 
diagnostic setting.  They also sequenced several affected relatives (Palles et al 
2013).  The group found that a genetic variant, POLE p.Leu242Val, was associated 
with multiple colorectal adenomas and carcinoma (Palles et al 2013).  The trait 
showed dominant inheritance, with high penetrance (Palles et al 2013).  Another 
variant, POLD1 p.Ser478Asn, predisposed to colorectal tumours, endometrial 
cancer, and possibly brain tumours (Palles et al 2013).  
 
In 2014, Valle et al sought to determine the prevalence of these mutations in 858 
patients with unexplained familial/ early-onset CRC or polyposis.  They didn’t 
identify either mutation in any of their CRC cases.  However, the POLE p.Leu424Val 
mutation was found in a polyposis family, in which case it had occurred as a de 
novo mutation in the proband.  This accounted for 0.52% of the polyposis cases.   
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The group also reported a novel variant, POLD1 c.1421T>C (p.Leu474Pro) in a 
MMR-proficient family.  This mutation occurs in the proofreading domain of a DNA 
polymerase and was predicted to be pathogenic (Valle et al 2014).  
 
Valle’s group sought to further characterise the phenotypic spectrum of patients 
carrying germline POLE/ POLD1 mutations (Bellido et al 2016).  They sequenced 
the entire exonuclease domains of POLE/ POLD1 in 544 CRC cases from 529 
families, including those from Valle’s original paper (Valle et al 2014).  Although no 
additional POLE mutations were identified, 4 of 6 novel/ rare nonsynonymous 
POLD1 variants detected were believed to be pathogenic: p.Asp316His, 
p.Asp316Gly, p.Arg409Trp and p.Leu474Pro.  The group reviewed the phenotypic 
data from all 69 carriers of POLE/ POLD1 mutations that had been reported to date.  
They observed that the associated phenotype was characterised by attenuated/ 
oligo- adenomatous polyposis, with >80% of POLE and >60% of POLD1 mutation 
carriers being diagnosed with >/= 2 adenomas, with an average of 19 lesions.  CRC 
was diagnosed in 60-64% of carriers, and brain tumours in 5.8%.  Gastroduodenal 
(mostly duodenal) adenomas were identified in 57.1% of carriers who underwent 
gastroduodenoscopies.  For patients harbouring POLD1 mutations, the phenotypic 
spectrum was extended to include endometrial tumours (57.1% of carriers) and 
breast tumours (14.3% of carriers).  
 
1.5.1.4 NTHL1-Associated Polyposis 
A further gene involved in the pathogenesis of colorectal neoplasia is NTHL1.  In 
2015 Weren et al carried out whole exome sequencing on 51 patients with multiple 
colorectal adenomas +/- CRC, who had tested negative for APC and MUTYH 
mutations (Weren et al 2015).  The group found that 7 individuals were homozygous 
for a NTHL1 nonsense mutation, c.268C>T, which triggers nonsense-mediated 
decay (NMD).  The patients harbouring the mutations all had multiple colorectal 
adenomas, ranging from 8-50, and 4 also had multiple CRCs.  All 3 affected women 
developed complex endometrial hyperplasia or endometrial cancer. 
 
NTHL1 is a base excision repair gene, and homozygous mutations cause an 
increase in C:G>T:A changes in genes such as APC, p53, KRAS and PI3K (Weren 
et al 2015). 
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1.5.1.5 MSH3-Associated Polyposis 
The most recently identified polyposis syndrome is MSH3-Associated Polyposis 
(Adam et al 2016).  Adam’s group performed whole exome sequencing on germline 
DNA extracted from 102 unrelated individuals with unexplained adenomatous 
polyposis.  They found two different individuals with different compound 
heterozygous mutations in the mismatch repair gene, MSH3.  Both index persons 
had an affected sibling carrying the same mutations.  The mutations were 
associated with tumours which displayed Elevated Microsatellite Alterations At 
Selected Tetranucleotide Repeats (EMAST), a type of microsatellite instability.   
 
The phenotypic spectrum in MSH3 mutation carriers was reported to include 
colorectal and duodenal adenomas, CRC, gastric cancer and an early onset 
astrocytoma (Adam et al 2016). 
 
1.5.2 Hyperplastic Polyps (HPPs) 
HPPs are a frequent finding, seen in between 1% and 73% of autopsies (Paspatis 
et al 2001; Williams et al 1982; reviewed in Correa et al 1977).  In asymptomatic 
individuals undergoing colonoscopy, HPPs are observed in 21% - 34% of cases 
(Forsberg et al 2012; DiSario et al 1991).  They are more common in males than 
females, and their prevalence increases with age (Williams et al 1982; Williams et al 
1980; Correa et al 1977).   
 
Until approximately 1990, hyperplastic (or ‘metaplastic’) polyps were regarded as a 
homogeneous group of tumours with no malignant potential (Rosty et al 2013a).  
Since that time, it has been increasingly recognised that hyperplastic lesions are not 
a single entity – they differ in their morphology and their clinical significance, in 
particular their risk for progressing to carcinoma.  In 2010, the World Health 
Organisation published a classification system which subdivides hyperplastic 
lesions into 3 groups based upon their microscopic appearance:  Hyperplastic 
Polyps (HPPs), Sessile Serrated Adenomas/ Polyps with or without cytological 
dysplasia (SSA) and Traditional Serrated Adenomas (TSA) (reviewed in Rosty et al 
2013a; reviewed in Leggett and Whitehall 2010). 
 
It is now known that hyperplastic lesions may be the precursors to CRC developing 
along the serrated pathway of carcinogenesis, which accounts for approximately 
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10% of CRCs (Yamane et al 2014).  In contrast to the CRC which follow the 
traditional ‘adenoma carcinoma’ pathway, tumours arising from the serrated 
pathway tend not to display CIN, but instead exhibit MAPK pathway activation, 
through BRAF mutations, and they commonly develop CIMP (Yamane et al 2014; 
Rosty et al 2013a; Leggett and Whitehall 2010).   
 
1.5.2.1 Serrated Polyposis Syndrome 
Although most HPPs are sporadic lesions, there is a condition in which patients 
develop multiple and/ or large lesions.  One of the first descriptions was in 1980 by 
Williams et al (Williams et al 1980).  They observed 7 patients, with a mean age of 
37.4 years, who each had at least 50 lesions throughout their large bowel.  At that 
time, the authors concluded that ‘it is impossible to deduce whether or not 
‘metaplastic polyposis’ is a distinct entity.  There is no good evidence that it is 
familial in this small series, but the appearance of numerous metaplastic polyps of 
an unusually large size and configuration, predominantly in young males, might 
suggest a specific ‘disease’’.   
 
As increasing evidence came to light that there seemed to be a syndrome in which 
patients developed numerous hyperplastic lesions throughout their large bowel, it 
was named ‘hyperplastic polyposis syndrome’ (HPS).  In 2000, a definition of HPS 
was proposed by Jass and Burt in the World Health Organisation classification of 
tumours (Jass and Burt 2000).  This definition was modified in 2010, and the 
disease was officially renamed Serrated Polyposis Syndrome (SPS).  It appears in 
the 2010 World Health Organisation classification of tumours of the digestive 
system (Snover DC et al 2010).  In order to meet the diagnostic criteria for SPS, 
patients must fulfil at least one of the following criteria: 
 
1. At least 5 serrated (hyperplastic) polyps proximal to the sigmoid colon, 2 of 
which are >10mm diameter 
2. Any number of serrated polyps proximal to the sigmoid colon in an individual 
who has a first degree relative with serrated polyposis 
3. More than 20 serrated polyps of any size distributed throughout the colon 
 
(reviewed in Rosty et al 2013a; reviewed in Guarinos et al 2012; reviewed in 
Leggett and Whitehall 2010; Snover DC et al 2010) 
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It was thought that SPS affected 1 in 3000 asymptomatic individuals between the 
ages of 55 and 64 years (reviewed in Rosty et al 2013b).  However, most studies 
report a broad age distribution of the disease (17 to 85 years) with a mean age of 
diagnosis of 47.7-56 years, so it is possible that the prevalence of SPS in the 
general asymptomatic population is higher than 1/3000 (Rosty et al 2013b).  Recent 
data suggest that the prevalence may be as high as 1/151 patients who have a 
colonoscopy following a positive faecal occult blood test (reviewed in Rosty et al 
2013a). 
 
SPS shows no sex predilection, and the mean age of diagnosis is 55 years 
(Guarinos et al 2012; Kalady et al 2011).  As well as hyperplastic lesions, up to 85% 
of patients also have conventional adenomas present in the bowel (Rosty et al 
2013a; Rosty et al 2012).  Patients with SPS have an increased risk of developing 
CRC, which generally occurs between 50 and 60 years of age (reviewed in 
Guarinos et al 2012).  Malignancy is associated with a larger number of polyps, the 
presence of dysplasia (reviewed in Guarinos et al 2012; Yeoman et al 2007) and the 
presence of conventional adenomas in addition to HPPs (Rosty et al 2013b).  The 
incidence of CRC in SPS patients varies from 14% to 58% (reviewed in Rosty et al 
2013b; Yeoman et al 2007; Hyman et al 2004;  Lage et al 2004) and the incidence 
is greater in females than in males, with a ratio of 2.4:1 (Rosty et al 213b).  When 
carcinoma develops in an SPS patient, it is likely to have a proximal location: 64% 
of CRC are identified proximal to the descending colon (Rosty et al 2013b). 
Interestingly, a large proportion of CRCs seen in patients with SPS do not develop 
through the ‘serrated pathway of carcinogenesis’ driven by BRAF mutation (Rosty et 
al 2013b).  The tumours show various molecular changes, including those more 
likely to be associated with the traditional adenoma-carcinoma pathway, for 
example β-catenin activation and/ or overexpression of p53 (Rosty et al 2013b).   
 
SPS is thought to be a genetic disease, but the mode of inheritance is unclear 
(reviewed in Guarinos et al 2012).  There are papers which report germline 
mutations in the Wnt inhibitor RNF43, an E3 ubiquitin ligase, in individuals and 
families with features of SPS (Yan et al 2017; Taupin et al 2015; Gala et al 2014).  
However, Buchanan et al note that mutations in RNF43 may account for only a 
small proportion of SPS, and that additional genetic risk factors are yet to be 
identified (Buchanan et al 2017).     
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1.5.3 Hamartomatous Polyps 
Hamartomas are overgrowths of the tissue which is native to the site of the lesion.  
Polyposis syndromes which are characterised by hamartomas include Peutz-
Jegher’s Syndrome (PJS), Juvenile Polyposis Syndrome (JPS) and Cowden’s 
Disease. 
 
1.5.3.1 Peutz-Jeghers Syndrome (PJS) 
In 1921, a Dutch physician, Dr. Peutz, first described the combination of 
gastrointestinal polyps and mucocutaneous pigmentation (Peutz 1921).  In 1949, Dr. 
Jeghers published an article describing 10 patients who had a combination of 
pigmentation of the oral mucosa/ lips/ digits, and intestinal polyps (Jeghers et al 
1949).  The observations made by Peutz and Jeghers led to the definition of an AD 
syndrome characterised by gastrointestinal polyposis and mucocutaneous 
pigmentation, now known as Peutz-Jeghers Syndrome (PJS) (Westerman et al 
1999). 
 
PJS is inherited in an AD manner and has variable penetrance.   It is a rare 
condition, with a prevalence of approximately 1 in 200 000 (reviewed in Omundsen 
and Lam 2012).  The disease is characterised by hamartomatous polyps throughout 
the gastrointestinal tract and mucocutaneous pigmentation.  Patients present at a 
median age of 11 years, and this is often as a result of a complication of their GI 
polyps, for example intussusception, small bowel obstruction, rectal bleeding or 
volvulus (reviewed in Omundsen and Lam 2012). 
 
Approximately 50% of cases of PJS are caused by germline mutations in the 
nuclear serine threonine kinase gene LKB1/ STK11 (Jenne et al 1998; reviewed in 
Omundsen and Lam 2012).  This gene regulates cell polarisation, growth and 
metabolism.  Most mutations are small insertions or deletions, resulting in a 
truncated protein with no kinase activity (reviewed in Omundsen and Lam 2012). 
 
Patients with PJS are at increased risk of developing cancer, both at gastrointestinal 
and extra-intestinal sites.  The most common tumours are CRCs, but there is also 
an increased risk of other gastrointestinal (GI) carcinomas (oesophageal, gastric, 
small bowel and pancreas), breast cancer, cervical cancer and sex cord tumours 
(Hizawa et al 1993; reviewed in Omundsen and Lam 2012).   
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1.5.3.2 Familial Juvenile Polyposis Syndrome 
In 1914, Hertz described four family members who had rectal polyps in childhood, 
the youngest being only 8-years-old (Hertz 1914).  That report is regarded as the 
first instance of juvenile polyposis in the medical literature (Calva and Howe 2009). 
Juvenile polyps are common hamartomatous lesions which occur in the large bowel.  
They are usually solitary and sporadic.  If multiple juvenile polyps are present, the 
patient may have Juvenile Polyposis Syndrome (JPS).  JPS is an AD disease with 
variable penetrance and which has an incidence of 1 per 100 000 births (reviewed 
in Omundsen and Lam 2012).  Patients can present in infancy with GI bleeding, 
intussusception, rectal prolapse or a protein losing enteropathy.  Around 15% will 
have an associated congenital birth defect, such as gut malrotation, cardiac and 
cranial abnormalities, cleft palate, polydactyly or genitourinary defects.  If 
presentation is as an adult, the patient is likely to suffer from GI bleeding (reviewed 
in Omunsden and Lam 2012). 
 
For a diagnosis of JPS, patients must fulfil one of the following criteria: 
1. More than 5 juvenile polyps of the colon or rectum 
2. Juvenile polyps in other parts of the GI tract 
3. Any number of juvenile polyps and a positive family history 
 
(reviewed in Omundsen and Lam 2012) 
 
Germline mutations in SMAD4 and BMPR1A are seen in JPS, and it is suggested 
that ENG mutations may also have a role (Sweet et al 2005), although this is not 
certain (Howe et al 2007).  All of these genes are involved in transforming growth 
factor β (TGFβ) signalling.  The TGFβ family of cytokines are growth inhibitors, and 
loss of sensitivity to these factors promotes tumourigenesis (reviewed in Fleming et 
al 2013).  As such, patients with JPS are at increased risk of developing CRC 
(Rozen and Baratz 1982; Järvinen and Franssila 1984; Giardiello et al 1991).  In 
additional to colorectal malignancies, patients are also at risk of developing gastric 
and duodenal cancer (reviewed in Omundsen and Lam 2012). 
 
1.5.3.3 Cowden’s Syndrome 
In 1963 Lloyd and Dennis reported a 20-year old female with multiple pathologies, 
including multiple thyroid adenomas, extensive fibrocystic change of both breasts 
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and ‘space occupying lesions in the liver and bone’ (Lloyd and Dennis, 1963).  At 
that time, it was noted that ‘whether this case represents a new familial disease … 
has not been established’ (Lloyd and Dennis, 1963), although they named the 
syndrome ‘Cowden’s Disease’.  It is now established that Cowden’s Syndrome is an 
AD disease, affecting approximately 1 in 200 000 births.  It is commonly diagnosed 
in the second decade of life, but age of onset may vary from 4 to 75 years (reviewed 
in Lam-Himlin et al 2014).  Patients develop multiple hamartomas in multiple organ 
systems.  Lesions can be found in the skin, GI tract, breast, thyroid gland and 
central nervous system (reviewed in Omunsden and Lam 2012; Hanssen and Fryns 
1995).  
 
80% of patients have a germline mutation in the PTEN gene (reviewed in 
Omunsden and Lam 2012).  PTEN is a tumour suppressor: its product is a 
phosphatase which negatively regulates the phosphatidylinositol 3-kinase-AKT and 
mammalian target of rapamycin (mTOR) signalling pathways, which are involved in 
cell growth and proliferation, cell cycle progression and apoptosis (reviewed in Lam-
Himlin et al 2014).  PTEN mutations are involved in the pathogenesis of several 
carcinomas, including breast, endometrial, thyroid, large bowel and kidney 
(reviewed in Lam-Himlin et al 2014).  As such, patients with Cowden’s Syndrome 
are at increased risk of these malignancies (Hanssen and Fryns 1995). 
 
1.5.3.4 Hereditary Mixed Polyposis Syndrome (HMPS) 
Hereditary Mixed Polyposis Syndrome (HMPS) is a relatively recently defined entity.  
In 1971, Kaschula described an 11-year-old girl who had profuse diarrhoea mixed 
with blood and mucus.  She was found to have polyps throughout her large bowel, 
and the polyps had both adenomatous and juvenile morphologies (Kaschula 1971).  
Over a decade later, in 1987, the term ‘mixed familial polyposis syndromes’ was 
used as the title of a report by Sarles et al (Sarles et al 1987).  This article described 
3 patients, including a father and son, who all had multiple polyps of different 
histopathological types.   
 
In HMPS, patients develop multiple polyps with mixed morphologies.  This is an AD 
disease, and patients may have adenomas, hyperplastic polyps and hamartomatous 
polyps.  There is a high risk of developing CRC (Jaeger et al 2012).  The disease is 
caused by a duplication spanning part of the SCG5 gene and a region upstream of 
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the GREM1 locus.  This duplication causes increased expression of GREM1, which 
acts as a bone morphogenetic protein (BMP) antagonist.  The subsequent reduction 
in BMP signalling is thought to play a role in tumourigenesis (Jaeger et al 2012). 
 
1.6 Clinical Management of Patients with Colorectal 
Polyposis  
This thesis is focused on patients with multiple colorectal adenomas.  In view of the 
possible genetic diagnoses which may underlie such a phenotype it has been 
common clinical practice for patients with >10 colorectal adenomas to be referred to 
a regional genetics centre for genetic counselling and for consideration of diagnostic 
analysis of the APC and/ or MUTYH genes.  The diagnostic testing carried out will 
depend upon the individual’s phenotype and their family history.   
 
Up to 90% of patients with a phenotype of typical FAP have a pathogenic APC 
germline mutation identified through sequencing of coding exons and deletion/ 
duplication analysis via multiplex ligation-dependent probe amplification (MLPA) 
(Spier et al 2012).  Of those with a phenotype of AFAP, APC or biallelic MUTYH 
germline mutations are detected in only 20-50% of cases (Spier et al 2012).   
 
1.6.1 Why Might Some Genetic Variants Be Missed? 
Since 1991, when APC was recognised as the causative gene of FAP (Groden et al 
1991; Joslyn et al 1991; Kinzler et al 1991; Nishisho et al 1991), several screening 
and diagnostic strategies have been developed to identify pathogenic APC 
mutations (Scott et al 2001) in patients with multiple colorectal adenomas.  These 
have included denaturing gradient gel electrophoresis analysis (DGGE) (Scott et al 
2001; Olschwang et al 1993), ribonuclease protection analysis (Miyoshi et al 
1992a), single strand conformation polymorphism analysis (SSCP) (Cottrell et al 
1992; Groden et al 1993), heteroduplex analysis (HA) (Cottrell et al 1992) and the 
protein truncation test (PTT)/ in vitro synthesised protein assay (IVSP) (Powell et al 
1993).  The characterisation of a genetic mutation identified through screening 
requires DNA sequencing.  Sanger sequencing has been the gold standard of 
sequencing for several decades, and until very recently was the main approach 
used for the molecular diagnosis of colorectal polyposis.  In the last few years, next-
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generation sequencing (NGS) technologies have progressively replaced Sanger 
sequencing.  
 
Genetic diagnostic protocols used in patients with polyposis typically include 
sequencing of APC and/ or MUTYH and dosage analysis of the genes using a 
technique such as MLPA.  These approaches could miss pathogenic variants 
located in promoter regions, deep within introns (Spier et al 2012) or in untranslated 
regions (UTRs), which may have effects on gene expression mediated through 
effects on transcription, mRNA splicing or mRNA stability.  Similarly, diagnostic 
protocols may miss low frequency variants in patients with somatic mosaicism. 
Protocols used in the National Health Service (NHS) in Wales would also not 
identify epigenetic phenomenon such as promoter methylation, they would not 
detect mutations in genes which are established but rare causes of polyposis (e.g. 
POLE/ POLD1) and they would not identify novel polyposis genes. 
 
1.6.1.2 Promoter Variants and Allelic Imbalance (AI)  
The APC gene has two promoter regions, 1A and 1B (reviewed in Rohlin et al 
2011).  The major transcript is initiated by the major promoter, 1A (reviewed in 
Charames et al 2008).  It is possible that genetic variants occurring in these 
promoters could lead to reduced gene expression, therefore predisposing to tumour 
formation.  Such variants might not be identified through standard genetic 
diagnostics as the promoter is not typically included in diagnostic sequencing 
protocols. 
 
There are several reports of APC promoter mutations in the literature.  However, 
these typically describe deletions, which would be detected through diagnostic 
MLPA (Yamaguchi et al 2016; Pavicic et al 2014; Rohlin et al 2011; Charames et al 
2008).  At the time of writing, there is a paucity of literature describing APC 
promoter point mutations or methylation as a cause of colorectal polyposis.    
 
Allelic imbalance (AI) refers to a situation in which the two alleles of a given gene 
are expressed at different levels in a given cell (Wagner et al 2010).  It can occur 
due to epigenetic inactivation of one of the alleles, or because of genetic variation in 
regulatory regions (Wagner et al 2010).  AI can involve complete inactivation of one 
allele, for example in parent-of-origin imprinting, when a specific allele at a given 
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locus is silenced through epigenetic mechanisms depending on whether it was 
inherited from the mother or father (Wagner et al 2010).  Allele expression can also 
be partially reduced, which can occur when different alleles have differing affinities 
for transcription factors (Wagner et al 2010), or through cis- acting genetic variants, 
for example in promoters (Wagner et al 2010).   
  
As well as being important in normal phenotypic variation, AI can also contribute to 
tumourigenesis.  There is some evidence that BRCA1 and BRCA2 AI plays a role in 
the pathogenesis of ovarian and breast cancer (Chen et al 2008; Shen et al 2011). 
Whilst only a small number of studies have considered APC AI in the context of 
colorectal neoplasia, those which have been performed have found it may make an 
important contribution.  As early as 1993, Powell et al (Powell et al 1993) used an 
allele-specific expression assay to show that 3/11 APC NMI patients with clinical 
FAP had significantly reduced expression of one APC allele.  In 1999 Laken et al 
(Laken et al 1999) used monoallelic mutation analysis (MAMA) to reveal that 
7/9 APC NMI patients had reduced/ no expression from one of their APC alleles.  
More recently Yan et al (2002b) identified a patient with colorectal tumours who was 
known to have reduced levels of the APC protein.  The group quantified the relative 
levels of mRNA transcripts from each APC allele using Digital-SNP.  They found 
that gDNA yielded the expected 50% allelic ratio, but that cDNA from 
lymphoblastoid cells showed a skewed distribution, with a ratio of approximately 
66% (Yan et al 2002b).  Linkage analysis showed that the allele whose mRNA was 
expressed in lower amounts was the one linked to disease (Yan et al 2002b).  
Further work confirmed that the skewed allelic ratio was also present in 4 affected 
family members, but that the ratio was normal in 24 unrelated unaffected 
individuals.  The group continued to investigate expression levels of APC: in four 
patients with clinical FAP who had no abnormalities with the in vitro synthesised 
protein assay (IVSP) or allele sequencing, one was found to have an abnormal 71% 
allelic ratio in cDNA.  When tumours from the patients with AI were studied, 30/38 
had LOH of APC, and in 29 of these cases, it was the normal allele which had been 
lost.  Yan et al concluded that an allele which causes a decrease in transcript levels 
can result in a predisposition to severe disease, but that there needs to be a second 
hit to the normal allele for a disease to manifest (Yan et al 2002b).  Interestingly the 
cause of the decreased expression was not determined: the sequences of the 
coding regions, promoter and 3’UTR were normal, so the group assumed that the 
pathogenic variant must lie within an intron or upstream of the gene (Yan et al 
2002b).  These early findings regarding APC AI have been supported by 
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Castellsagué et al (2010).  Of 23 APC/ MUTYH NMI polyposis families who were 
heterozygous for rs2229992, 2 were shown to harbour APC AI.  The AI in one family 
was suggested to result from promoter variants (Castellsagué et al 2010). 
 
1.6.1.3 Intronic Variants 
Intronic mutations may affect RNA splicing and introns are not screened as part of 
most routine genetic diagnostic protocols.  In 2000 Su et al sought to identify novel 
intragenic rearrangements of APC in patients with a clinical phenotype of FAP or 
AFAP.  They found four germline APC mutations, one of which was a deletion 27-
1627bp downstream of exon 14, which was replaced with a novel sequence of 
about 180bp.  The deletion was completely within intron 14, but it affected the 
splicing of exon 14 (Su et al 2000).  In 2010 Tuohy et al used Southern Blot analysis 
of the APC gene to identify a 1.4kb deletion within intron 14 in a family with AFAP.  
Subsequent PCR amplification from exon 13 to exon 15 of cDNA showed that the 
intronic deletion resulted in abnormal splicing, and that exon 14 was deleted.  This 
caused a frameshift and protein truncation at codon 673 of the normal reading 
frame resulting in a truncated product that lacked all of the β-catenin, microtubule 
and EB-1 binding domains (Tuohy et al 2010).   
 
In 2012 transcript analysis in a sample of 125 mutation negative patients with 
colorectal adenomatous polyposis found that 8% had a reproducible aberrant 
transcript pattern, suggesting an intronic mutation at a genomic level (Spier et al 
2012).  80% of these were found to have transcript insertions between two exons 
originating from exonised sequences deep within the corresponding intron (Spier et 
al 2012).  All pseudoexons were predicted to result in out-of-frame transcripts with 
premature stop codons (Spier et al 2012).  In those patients who had insertions, the 
underlying genomic mutations were identified:  they comprised 3 different 
heterozygous point mutations (c.532-941G>A, c.1408+731C>T, c.1408+735A>T) 
which activated cryptic splice sites.  A pre-existing complementary cryptic splice site 
was predicted at the other end of the insertion (Spier et al 2012).  
 
1.6.1.4 Untranslated Region (UTR) Variants 
A pre-RNA molecule undergoes several steps of processing before it becomes a 
functional mRNA molecule (Mignone et al 2002).  Mature mRNA consists of a 5’ 
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untranslated region (5’UTR), a coding region, and a 3’ UTR (Mignone et al 2002).  
UTRs, particularly 3’UTRs, have multiple roles in the post-transcriptional regulation 
of gene expression, including effects on mRNA transport out of the nucleus, 
translation efficiency, subcellular localisation and mRNA stability (reviewed in 
Mignone et al 2002).  In addition to normal physiological intracellular effects, there is 
increasing evidence that UTR variants can be involved in disease, for example an 
expanded number of trinucleotide repeats in the 3’UTR of the DMPK gene is 
thought to play a role in the pathogenesis of in myotonic dystrophy (Conne et al 
2000), and a somatic 5’UTR variant has been reported to reduce translation 
efficiency of BRCA1 in a highly aggressive sporadic breast cancer (Signori et al 
2001).   
In the context of colorectal neoplasia, Wilding et al have shown that in microsatellite 
unstable cancer, deregulation of mRNA stability due to mutations in regulatory 
3’UTR sequences can lead to a marked difference in gene expression profiles when 
compared to microsatellite stable tumours (Wilding et al 2010).   
 
1.6.1.5 Mosaicism 
A mosaic is an individual who has at least two genetically different cell lines despite 
developing from a single zygote.  Mosaic mutations may be missed with standard 
mutation diagnostic techniques, for example if they occur at a low frequency within 
the individual or if they do not occur in the part of the body which is being analysed. 
 
It is reported that somatic mosaicism can occur in 10-20% of sporadic cases of FAP 
(reviewed in Rohlin et al 2009; Hes et al 2008; Aretz et al 2007).  The timing at 
which an APC mutation occurs will have an important bearing on the patient’s 
phenotype:  if it arises in a single colonic epithelial stem cell, the only consequence 
will be adenomatous polyps in the segment of the colon that becomes populated 
with descendants of the stem cell (Tuohy and Burt 2008).  At the other extreme, if 
the mutation occurs early in embryogenesis, it may be found in all three germ cell 
layers.  This would result in multiple clinical manifestations seen throughout multiple 
organ systems, potentially including mutations in reproductive cells, which could 
then be passed on to future generations (Tuohy and Burt 2008).   
 
Depending on the frequency of the mutation, it is likely that a significant proportion 
will be missed using current diagnostic sequencing protocols and DNA extracted 
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from whole blood.  Rohlin et al (2009) carried out a study to evaluate the different 
mutation screening/ diagnostic techniques in terms of their sensitivity in detecting 
mosaicism.  They looked at Sanger sequencing, single-strand conformation 
polymorphism (SSCP)/ heteroduplex analysis (HA), the protein truncation test 
(PTT), denaturing high performance liquid chromatography (DHPLC) and massively 
parallel sequencing.  A total of 9 mutations were addressed – 8 in APC and 1 in 
NF2.  The group constructed 7 artificial mosaics in APC through serial dilutions of 
DNA, with a non-mosaic heterozygous mutation being defined as 100%.  The two 
remaining samples were from naturally occurring mosaics.  All of the dilutions of all 
of the mutations were analysed with SSCP, DHPLC and Sanger sequencing.  Three 
were included in the PTT assay (these were mutations in exon 18, which is readily 
screened by PTT).  Only four artificial mosaics, at various concentrations, and both 
natural mosaics underwent massively parallel sequencing, due to cost limitations.  
The group found that SSCP and DHPLC were able to detect mutant alleles at 
frequencies between 5% and 25%, whereas Sanger sequencing required 
frequencies between 15% and 50% for detection.  The mutations included in the 
PTT assay were detected at frequencies between 10 and 100%.  The Genome 
Sequencer FLX was used for massively parallel sequencing, and this achieved 
coverage between 648 and 8313 reads.  Mutation frequencies as low as 1% could 
be detected, but this required a high coverage (Rohlin et al 2009). 
 
The results from this study showed that Sanger sequencing, which has been 
commonly used in a diagnostic setting, was the least sensitive method at detecting 
mosaics.  Dependent upon the type of mutation being analysed, this technique may 
require mutation frequencies as high as 50% in order for them to be detected 
(Rohlin et al 2009). 
 
Genetic testing in the diagnostic setting is usually carried out on DNA extracted from 
whole blood.  For some patients, a mosaic mutation may only be present in colonic 
tissue so will not be detectable through testing blood-derived DNA (Jansen et al 
2017). 
 
1.6.1.6 The Involvement of Additional Genes 
Standard diagnostic protocols carried out in the context of adenomatous colorectal 
polyposis typically examine the APC and MUTYH genes, although an increasing 
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number of laboratories are screening DNA for the recurrent mutations in POLE and 
POLD1.  It is only in recent years that the pathogenic effects of mutant POLE, 
POLD1, NTHL1 and MSH3 have been discovered.  It is therefore feasible that there 
may be further genes involved in the development of heritable colorectal polyposis, 
which are yet to be identified.   
Furthermore, mutations in genes such as APC, MUTYH, POLE, POLD1, NTHL1 
and MSH3 are all highly penetrant.  It may be the case that some patients with 
unexplained colorectal polyposis have a phenotype which results from the complex 
interplay of several low/ moderate penetrance genetic variants. 
 
1.7 Summary 
Colorectal carcinoma (CRC) is the fourth most common cancer in the United 
Kingdom (UK) and the second most common cause of cancer death (Cancer 
Research UK 2015).  Most CRCs occur sporadically, but in approximately a third of 
patients, hereditary factors are important (reviewed in Mishra and Hall 2012; Burt 
2007).  Some patients with an inherited predisposition to CRC will be diagnosed 
with a ‘genetic polyposis syndrome’ such as FAP, MAP, PPAP, NTHL1-Associated 
Polyposis, MSH3-Associated Polyposis or a hamartomatous polyposis syndrome.  It 
is important to identify these patients, and to define the mutations causing their 
polyposis, so that the individuals and their relatives can be managed appropriately.   
 
1.8 Aims of Thesis 
The genetic bases for several ‘polyposis syndromes’ are known and have been 
described above.  However, there are numerous patients with a ‘polyposis 
phenotype’ who have had no genetic mutation identified (NMI) through standard 
genetic diagnostic protocols.   
 
The aim of this thesis is to: 
 
1. Identify novel genetic variants/ molecular mechanisms responsible for 
colorectal polyposis using a cohort of polyposis patients who have had no 
mutation identified during clinical genetic diagnostic testing.  This will 
involve: 
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a. searching for APC and MUTYH variants which are outside of the 
open reading frame (ORF)  
b. searching for mosaic APC mutations 
c. searching for novel variants in the other known or candidate 
‘polyposis genes’ 
d. searching for new polyposis genes 
e. characterising novel variants using genetic and functional 
approaches, to provide additional evidence for or against their clinical 
significance 
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Chapter 2 Materials and 
Methods 
2.1 Materials, Equipment and their Suppliers 
2-Propanol Sigma Aldrich 
2X iproof HF Mastermix BioRad 
25cm2 flask ThermoFisher 
96-well Assay plate Fisher Scientific 
96-well PCR plates 4titude 
96-well PCR seals 4titude 
ABI Prism Genetic Analyser Applied Biosystems 
Acetic Acid Sigma Aldrich 
Agarose ThermoFisher 
Agarose plates Millipore 
Ampligase Illumina 
Ampligase DNA Ligase Buffer Illumina 
Anti--Actin Antibody (A5411) Sigma 
Anti-Mouse Antibody (NXA931) GE Healthcare 
Anti-Myc-Tag Antibody (9B11) Cell Signalling Technologies 
-mercaptoethanol Stratagene 
BCA ThermoScientific 
Big Dye Terminator Reaction Mix v1.1 ThermoFisher 
BioDoc-IT Imaging System AnalytikJena 
BSA Promega 
Cell Scraper ThermoFisher 
Centrifuge PIC017 ThermoScientific     
Chemagic STAR DNA Extraction Kit  ThermoFisher 
Complete protease inhibitor Roche 
Control Methylated DNA Qiagen 
Control Unmethylated DNA Qiagen 
DMEM (1X)-GlutaMax Life Technologies 
dNTPs ThermoFisher 
DTT ThermoFisher 
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EDTA Sigma Aldrich 
Epitect Bisulfite Kit Qiagen 
Epitect Mastermix Qiagen 
Eppendorf Tubes ThermoFisher 
Exonuclease I/III New England Biolab 
Falcon Tubes ThermoFisher 
FBS ThermoFisher 
FS Buffer ThermoFisher 
G Storm Labtech Model GS0002M Labtech 
Gel Red  Cambridge Bioscience 
Gel Tank  
ThermoScientific AB0708 100V/  
Clever Scientific 
Gene Read FFPE Kit Qiagen 
Gene Ruler 1kb Plus Ladder ThermoFisher 
Glo-Lysis Buffer and Substrate Promega 
Glycerol Sigma Aldrich 
Haloplex Assay Agilent 
Hemo Klen Taq DNA Polymerase New England Biolab 
HiDi Formamide ThermoFisher 
HiSeq 2500 Illumina 
Iblot Invitrogen 
IGEPAL CA630 Sigma Aldrich 
Incubator Millipore 
Light Microscope 
Both Olympus BX43 and Leica models 
have been used 
Lipofectamine Life Technologies 
LB Agar Lennox Invitrogen 
LB Broth Base Lennox Invitrogen 
Milk Powder Marvel 
MiniPrep Kit Qiagen 
MiSeq Illumina 
MLPA Kit P043-B1 MRC Holland 
MLPA Kit P378-A2 MRC Holland 
MMG Microzone 
NaCl Solution Sigma Aldrich 
Nextera Rapid Capture Exome v1.2 Illumina 
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Novex Sharp Pre-Stained Protein Standard Invitrogen 
NuPAGE 4-12% Bis Tris Mini Gel Invitrogen 
NuPAGE MES SDS Running Buffer Invitrogen 
NuPAGE LDS Sample Buffer Invitrogen 
Orange G Sigma Aldrich  
Orange G Solution (20ml) 
4 ml 0.5 M EDTA, 8 g Sucrose, pinch of 
Orange G, Water 
Optimem Life Technologies 
PBS Santa Cruz Biotech 
PhosphoSTOP Phosphatase Inhibitor Roche 
Pipettes and Tips Rainin 
Platinum PFX PCR Kit Invitrogen 
Power Supply  BioRad 200/2.0 
QBD2 Heat Block Grant 
Quantstudio 12K Real Time PCR System Life Technologies 
Qubit dsDNA BR Assay Kit ThermoFisher 
Qubit dsDNA HS Assay Kit ThermoFisher 
Qubit 2.0 Fluorometer ThermoFisher 
Qubit RNA Assay Kit ThermoFisher 
QuikChange II SDM Kit Agilent 
Random Primers ThermoFisher 
Restore Plus Western Blot Stripping Buffer ThermoFisher 
RNASin ThermoFisher 
R-Spondin PeproTech 
Shaking Incubator Kühner 
Shrimp Alkaline Phosphatase Affymetrix 
SOC Medium Invitrogen 
Sucrose Sigma Aldrich 
Superscript II ThermoFisher 
Supersignal West Pico Chemiluminescent 
Substrate 
ThermoFisher 
TAE (1L) 
48.4 g Tris, 3.72 g EDTA, 17 ml Acetic 
Acid, Water 
Taqman Gene Expression Mastermix ThermoFisher 
TBS Fisher BioReagents 
TC Hood HeraSafe 
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TC Incubator (37˚C, 5% CO2, 21% O2) Binder 
TE Buffer Invitrogen 
Tempus Blood RNA Tube Life Technologies 
Tempus Spin RNA Isolation Reagent Kit Applied Biosystems 
Tris Sigma Aldrich 
Trypsin (0.05%) Life Technologies 
Trypan Blue (0.4%) Life Technologies 
Vortex Genie 2  Scientific Industries 
Waterbath Clifton 
Wnt3a  R&D Systems 
WST-1 Sigma Aldrich 
XL-1 Blue Cells Agilent 
Zymoclean Gel DNA Recovery Kit Zymo Research 
 
2.2 Patient Information 
This study is approved by the Research Ethics Committee for Wales (REC 3, study 
12/WA/0071).  To date, 306 patients of the 350 target have been recruited. A subset 
of these patients was used for the work described in this thesis. 
 
2.2.1 Inclusion Criteria 
Eligible participants included: 
1) adult patients who are affected by polyposis (>/= 10 polyps)/ other phenotypes 
consistent with APC mutations who have had genetic testing to determine the 
genetic cause of their disease that proved negative by routine tests in NHS genetic 
diagnostic laboratories or  
2) adult patients who are affected by polyposis who have previously had genetic 
testing to determine the genetic cause of polyposis of the bowel that found an 
uncharacterised variant of unknown pathogenicity by routine tests by NHS genetic 
diagnostic laboratories or  
3) adult patients who have been identified as carrying a known polyposis-causing 
gene and who were having a screening or a surgical procedure at which polyp or 
other tumour or cancer tissue may be removed or 
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4) unaffected adult (aged 18 years or over) family members of these patients whose 
DNA could serve as a control to assess the association of genetic variants with 
polyposis  
 
Participants were recruited from a pool of patients who had previously been referred 
for diagnostic genetic testing and/ or genetic counselling at the Institute of Medical 
Genetics, Cardiff, or at other regional clinical genetics centres. They were identified 
by consultant clinical geneticists or genetic counsellors. 
 
2.2.2 Exclusion Criteria 
The study exclusion criteria were as follows: 
1) unaffected family members under the age of 18 years of age 
 
2.2.3 Individuals Participating in this Study 
Of the 306 patients recruited to the Genetic Mechanisms of Polyposis study, 60 
affected individuals were included in the work described within this thesis.  When 
the project started in 2013, these were the recruited patients for whom phenotypic 
information was available.  I have included 45 patients with a predominantly 
adenomatous phenotype (>/= 10 adenomas); 8 patients with a mixed adenoma/ 
HPP phenotype; and 7 patients for whom histopathological information was scanty.  
 
2.2.3.1 No Mutation Identified (NMI) Polyposis Patients 
The 60 NMI polyposis patients included in this thesis have not had a pathogenic 
genetic mutation identified by standard genetic diagnostic protocols in the NHS 
(although the cohort does include two patients who are carriers of monoallelic 
MUTYH mutations).  In the genetic diagnostic service, patients have undergone 
APC sequence analysis of all the coding exons and up to 20 bases of flanking 
intronic sequences.  Dosage analysis for all coding exons and the promoter had 
been completed using the MRC-Holland MLPA kit P043-B1.  All the patients have 
also undergone MUTYH analysis.  This involved a real time allelic discrimination 
assay for the two common European MUTYH mutations (c.536A>G (p.Tyr179Cys) 
and c.1187G>A (p.Gly396Asp)) and Sanger sequencing of exons 3 and 14 for the 
  
 54 
two common Asian MUTYH mutations (c.312C>G, p.Tyr104* and c.1432G>T, 
p.Glu480*).  If this failed to identify any mutations, patients had sequence analysis 
of all coding exons and up to 20 bases of flanking intronic sequence.  Dosage 
analysis for all coding exons was undertaken with the MRC-Holland MLPA kit P378-
A2.  
 
Blood samples for DNA were obtained for all 60 NMI patients. Blood samples for 
RNA were obtained for 45 of the NMI patients.  
 
2.2.3.2 Control Samples 
The control samples in this study included: 
 13 unaffected relatives of NMI patients 
 10 control FAP patients, with known APC mutations 
 5 control MAP patients, with known MUTYH mutations 
 37 healthy individuals recruited through a local study: Causes of Bowel 
Polyps: Recruitment of Healthy Controls (approved by Cardiff University 
School of Medicine Ethics Committee).  The inclusion criteria were being 
over the age of 18 with no personal/ family history of colorectal polyposis/ 
CRC 
 
DNA was available for all unaffected relatives, FAP controls and MAP controls.  
RNA was prepared from blood samples for 7 unaffected relatives, 3 FAP patients, 4 
MAP patients and 37 healthy individuals. 
 
2.2.3.4 Demographic Details and Clinical Phenotypes 
The demographic details and clinical phenotypes of the participants are in Tables 
2.1 (patients and their unaffected relatives) and 2.2 (further controls).  The age of 
the participants refers to the age at which they were recruited to the study.  This 
was deemed the most unambiguous way to describe age, as it was often unclear at 
what age the patients had initially developed polyposis, and the DNA samples used 
throughout this project had frequently been obtained at multiple historical time 
points.  The phenotypic information was obtained from the patient’s genetic files/ 
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hospital records, if they had been recruited from Wales, or was supplied by referral 
centre if they had been recruited from another region. 
 
Unique 
Identifier 
Age at 
Recruitment 
and Sex 
 Clinical Phenotype RNA  Relative(s) 
Halo04 
30-year-old 
female 
>100 adenomas in 30s Yes 
Halo02 
(mother):  
unaffected, 
negative 
colonoscopy 
Halo05 
46-year-old 
female 
Aged 39 had multiple 
adenomas (at least 19): one 
contained pT1 CRC 
No  
Halo06 
77-year-old 
male 
11 polyps: 10 adenomas, 1 
HPP 
Yes  
Halo07 
70-year-old 
male 
17 adenomas Yes  
Halo08 
70-year-old 
female 
629 adenomas Yes 
S_Halo08 
(son) 42-year-
old male, over 
100 polyps.  
He has not 
been included 
in the NMI 
patient total as 
he was 
recruited at a 
late stage of 
the project, so 
DNA was not 
available for 
most of the 
study 
protocols  
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Halo13 
73-year-old 
male 
>10 adenomas Yes  
Halo14 
33-year-old 
male 
Subtotal colectomy and 
ileorectal anastomosis abroad 
for adenomatous polyposis.  
Has had a further 40 polyps 
removed from rectal stump 
?morphology 
Yes 
Halo09 
(sister): 
unaffected, 
negative 
colonoscopy 
Halo15 
84-year-old 
male 
12 adenomas No  
Halo17 
66-year-old 
male 
25 mixed polyps: adenomas 
and hyperplastic lesions (exact 
numbers of each is not clear). 
2 CRC aged 63 (pT2, pT3) 
Yes  
Halo18 
72-year-old 
male 
Referred from screening 
programme.  27 polyps: 
adenomas with 4 HPPs   
No  
Halo19 
62-year-old 
female 
>10 adenomas and CRC (no 
further information available) 
Yes  
Halo20 
71-year-old 
male 
Referred from screening 
programme. 12 adenomas, 
plus additional hyperplastic 
lesions (?number and type) 
Yes  
Halo22 
73-year-old 
female 
Referred from screening 
programme. Aged 72 had 40+ 
adenomas and 2 CRC 
(?stage) 
No  
Halo23 
73-year-old 
female 
>20 adenomas Yes  
Halo24 
68-year-old 
male 
>10 adenomas (?19) Yes  
Halo25 
66-year-old 
male 
12 adenomas Yes  
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Halo26 
85-year-old 
female 
21 adenomas Yes  
Halo27 
67-year-old 
female 
17 adenomas Yes  
Halo28 
61-year-old 
male 
1990: sigmoid colectomy for a 
probable diverticular 
perforation.  Multiple 'benign 
metaplastic polyps' were noted 
?number.  2012: subtotal 
colectomy for >30 polyps.  The 
majority of the polyps were TA; 
2 were serrated adenomas 
with LG dysplasia 
No  
Halo29 
80-year-old 
male 
17 polyps: at least 9 confirmed 
adenomas and 7 HPPs 
Yes  
Halo30 
73-year-old 
male 
20 polyps: at least 13 
adenomas 
Yes  
Halo31 
70-year-old 
male 
12 TA with LGD, 3 HPP Yes  
Halo32 
66-year-old 
female 
pT2 CRC + 12 adenomas Yes  
Halo33 
 
36-year-old 
female 
Heterozygous for a non-
pathogenic APC variant: 
c.6363_6365dupTGC.   
pT3N1M1 CRC, 4 adenomas 
and the patient notes describe 
"multiple polyps in the sigmoid, 
smaller numbers of polyps in 
the proximal left colon, a 
couple of tiny polyps in the 
transverse colon and a 
number of small polyps in the 
right colon" but there is no 
more detail 
No  
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Halo34 
69-year-old 
male 
11 adenomas plus 6 polyps of 
unknown morphology 
Yes  
Halo35 
68-year-old 
male 
15 adenomas Yes  
Halo36 
67-year-old 
male 
At least 10 adenomas Yes  
Halo40 
70-year-old 
female 
18 adenomas, 3 HPPs 
Carrier of monoallelic MUTYH 
mutation  (MUTYH c.920G>A, 
pR307G) 
Yes  
Halo41 
51-year-old 
male 
10 adenomas, 10 HPPs 
Carrier of a monoallelic 
MUTYH mutation (MUTYH 
c.1187G>A G396D) 
Yes  
Halo43 
67-year-old 
male 
Referred from bowel 
screening.  Colonoscopy 
showed 18 polyps and CRC.  
It is not clear how many polyps 
were examined 
microscopically (at least 5) but 
these all showed adenoma.  
The CRC was moderately 
differentiated ?stage 
No  
Halo44 
72-year-old 
female 
8 TAs, 2 HPPs, one 'mixed 
HPP/ TA' 
Yes  
Halo45 
77-year-old 
male 
27 adenomas, 7 HPP Yes  
Halo46 
44-year-old 
female 
Clinical FAP – has had a 
colectomy and proctectomy 
Yes  
Halo47 
51-year-old 
female 
Colonoscopy found in excess 
of 50 sessile polyps 
throughout the colon.  2 of 
these were biopsied: TVA.  
The patient had a subtotal 
Yes 
Halo68 
(sister):  54-
year-old 
female. 14 TA 
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colectomy - ?4 polyps were 
sampled: 2 TA, 2 serrated 
adenomas.  Subsequent 
completion colectomy 
identified a CRC (pT4N2Mx) 
with LGD and 
6 HPPs 
Halo48 
71-year-old 
male 
Referred from screening. 30 
polyps: 4 have been biopsied:  
all adenoma  
Yes  
Halo49 
57-year-old 
female 
Rectal cancer age 32 (?stage), 
ameloblastoma age 38. 22 
polyps: mixture of adenomas 
and hyperplastic lesions 
No  
Halo50 
64-year-old 
male 
10 adenomas No  
Halo51 
43-year-old 
female 
208 adenomas Yes 
Halo77 
(mother), 
Halo78 
(father): 
unaffected 
Both are 
described as 
unaffected by 
St. Mark’s 
Hospital, 
where a 
colonoscopy 
was 
presumably 
performed, but 
this is 
unconfirmed.  
RNA available 
for both 
Halo52 
59-year-old 
male 
Over 1000 adenomas Yes  
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Halo53 
51-year-old 
male 
Approximately 400 adenomas, 
CRC age 27 (Duke’s C) 
Yes 
Halo75 
(mother), 
Halo76 
(father): 
unaffected. 
Both have had 
negative 
colonoscopies.  
RNA available 
for both 
Halo54 
70-year-old 
male 
Approximately 260 polyps, 
rectal cancer age 46 (Duke’s 
A) 
No  
Halo55 
54-year-old 
male 
18 polyps: 9 adenomas, 9 
serrated lesions 
Yes 
M_Halo55 
(mother), 
F_Halo55 
(father): 
unaffected 
according to 
clinical history.  
RNA available 
for both 
Halo56 
38-year-old 
female 
57 adenomas Yes 
Halo73 
(mother), 
Halo74 
(father): 
unaffected. 
Mother had 
one polyp in 
2002 but 2 
clear 
colonoscopies 
subsequently.  
Father had 2 
polyps at 
colonoscopy 
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Halo57 
40-year-old 
male 
Approximately 3500 
adenomas 
No  
Halo58 
64-year-old 
male 
Approximately 100 polyps:  
mixture of adenomas and 
HPPs 
Yes  
Halo61 
60-year-old 
female 
11 polyps:  2 SAs, 7 TA, 1 
TVA, and 1 HPP 
Yes  
Halo62 
76-year-old 
female 
Ileorectal anastomosis, but the 
indication for prior surgery is 
unclear.  10 rectal adenomas 
Yes  
Halo63 
68-year-old 
male 
At least 24 polyps.  5 biopsies 
show 4 adenomas and 1 HPP 
Yes  
Halo64 
54-year-old 
female 
Thousands of colorectal 
polyps.  Those which have 
been biopsied showed 
adenomas.  CRC aged 23 
(?stage) 
Yes  
Halo65 
33-year-old 
male 
117 adenomas  Yes  
Halo66 
70-year-old 
male 
23 adenomas, 4 HPPs Yes  
Halo67 
73-year-old 
male 
At least 15 adenomas Yes  
Halo69 
73-year-old 
female 
At age 72 had CRC, pT4, and 
at least 24 polyps.  It is not 
clear how many were 
removed, but they included 
adenomas, HPPs and one SA 
No  
Halo70 
71-year-old 
male 
15 polyps.  11 shown to be 
adenomas on microscopy 
Yes  
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Halo71 
65-year-old 
female 
14 adenomas Yes  
Halo72 
61-year-old 
male 
At least 10 adenomas, one of 
which contained moderately 
differentiated CRC (?stage).  
Additionally, had Duke’s A 
sigmoid carcinoma age 53 
Yes  
Halo79 
80-year-old 
male 
Colectomy for polyposis.  No 
other information 
No  
Halo80 
76-year-old 
female 
38 adenomas Yes  
Halo81 
65-year-old 
male 
17 polyps: 8 adenomas (4 TA 
with LGD, 3 TVA with LGD, 1 
TVA arising in a SSL) and 9 
HPPs 
No  
 
Table 2.1:  Table describing the demographic details and clinical phenotype of the NMI 
polyposis patients and their relatives included in this study 
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Unique 
Identifier 
Sample 
Details 
Genotype RNA  Further Information 
Halo01 Control FAP 
APC c.3631-
3632delAT 
No  
F014_M_
004_1 
Control FAP APC  c.2805 C>A  No  
F014_M_
005_1 
Control FAP  
APC c.4393-
4394delGA 
No  
F014_M_
006_1 
Control FAP 
FAP mosaic: 5% 
mosaic APC 
c.4393-
4394delGA 
No  
Halo10 Control FAP 
APC 
c.3183_3187delA
CAAA 
No  
Halo12 Control FAP 
APC c.3927-
3931delAAAGA 
No  
Halo16 Control FAP  APC c.3408delA No  
FAPPol51 Control FAP  
APC promoter 1B 
deletion 
Yes  
FAPPol14
1 
Control FAP  
Deletion of APC 
exons 11 and 12 
Yes  
Halo42 
Control FAP, 
monoallelic 
MUTYH 
mutation 
APC c.1187dupA, 
MUTYH 
c.536A>G 
Yes  
Halo37 Control MAP 
Compound 
heterozygous for 
MUTYH 
Yes  
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c.536A>G and  
c.649C>T  
Halo39 Control MAP 
Compound 
heterozygous for 
MUTYH 
c.303G>T and 
c.312C>A  
No  
Halo59 Control MAP  
MUTYH 
c.1187G>A 
homozygote 
Yes  
MAPPol71 Control MAP  
Compound 
heterozygous for 
MUTYH 
c.303G>T and 
c.312C>A 
Yes  
MAPPol90 Control MAP 
Compound 
heterozygous for 
MUTYH 
c.1187G>A and 
c.536A>G 
Yes  
Halo03 
89-year-old 
male  
Healthy 
control 
 No 
Father of a patient 
with jaw osteomas 
recruited to the study 
but not included in 
this thesis 
Halo11 
79-year-old 
female 
Healthy 
control 
 No 
Mother of a patient 
with jaw osteomas 
recruited to the study 
but not included in 
this thesis 
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Halo95 
62-year-old 
female 
Healthy 
control 
 Yes 
Mother of a patient 
with HPPs recruited to 
the study but not 
included in this thesis 
 
Table 2.2: Table describing the sample details and the genotype of control samples included in 
this study.   
 
2.3 General Techniques 
2.3.1 Agarose Gel Electrophoresis 
Agarose gels were made with 1x TAE buffer to a concentration of 0.8-1.5%.  The 
appropriate mass of agarose was added to 100 ml of 1x TAE and heated in a 
microwave for 2 minutes to allow it to melt.  The liquid was cooled by running it 
under a cold tap for 2-5 minutes.  5 µl of Gel Red was added, and the liquid poured 
into a gel mould to set.  The gel was completely submerged in 1x TAE buffer in an 
AB0708 100 V gel tank or a Cleaver Scientific gel tank.  Unless otherwise stated,  
5 µl of Orange G loading dye was added to 5 µl of sample, and the entire volume 
was loaded onto the gel.  A 1Kb plus DNA ladder (ThermoFisher) was loaded 
alongside the samples.  Electrophoresis was performed at 100 V for 30 minutes 
using the BioRad 200/2.0 power supply.  Following electrophoretic separation of the 
samples, visualisation was achieved using the BioDoc-It Imaging System Benchtop 
UV Transilluminator. 
 
2.3.2 Germline DNA Extraction 
Genomic DNA was extracted from venous blood using the Chemagic Star 
Automated Extraction Method by the All Wales Medical Genetics Service 
(AWMGS).  At least 4 ml of peripheral blood was collected in an EDTA tube.  The 
blood was then transferred into a 50 ml tube and lysis buffer added for up-front DNA 
extraction. The Chemagic Star instrument uses polyvinyl alcohol particles (M-PVA 
Magnetic Beads), which have a hydrophilic surface, to bind to nucleic acids.  Once 
bound, the nucleic acids were transferred with a magnetisable rod to different wash 
buffers and finally to an elution buffer 
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(http://www.hamiltonrobotics.com/fileadmin/user_upload/Standard_Solutions/B-
1110-03_Chemagic_STAR_web.pdf.  Accessed 21/5/14).  DNA was stored at -
20⁰C. 
 
2.3.3 RNA Extraction 
RNA was extracted from whole blood using a Tempus Spin RNA Isolation Reagent 
Kit (Applied Biosystems).  3 ml peripheral blood was collected in a Tempus blood 
RNA tube (Life Technologies) and shaken vigorously for 30 seconds.  The blood 
sample was poured into a clean 50 ml conical tube.  1x Phosphate Buffered Saline 
(PBS) was added to bring the volume up to 12 ml.  The tube was vortexed for 30 
seconds, then centrifuged at 4⁰C for 30 minutes at 3000 x g.  The supernatant was 
poured into a disinfectant solution. The tube was inverted on absorbent paper for 1 
to 2 minutes, and any remaining liquid was blotted from the rim of the tube with 
absorbent paper.  400 μl of RNA purification re-suspension solution was added to 
the tube, and the tube was vortexed briefly to re-suspend the RNA pellet.  RNA was 
then purified according to the manufacturer’s protocol.  Briefly, this involved pre-
wetting a filtration membrane with RNA purification wash solution 1, pipetting the re-
suspended RNA onto the filter, centrifuging the sample for 30 seconds at 16 000 x 
g, discarding the liquid waste, pipetting 500 µl wash solution 1 onto the filter and 
centrifuging.  The liquid waste was discarded, then the process was repeated twice 
with wash solution 2.  The filter was centrifuged to dry it, then 90 µl elution solution 
was added.  The tube underwent centrifugation, and the eluted RNA was 
subsequently pipetted back onto the filter, which was centrifuged again.  All 
centrifugation steps were performed at 16 000 x g for 30 seconds, apart from the 
final centrifugation, which was carried out for 2 minutes.  Eluted RNA was 
transferred to a fresh tube and stored at -80⁰C. 
 
2.3.3.1 Assessment of RNA Quality 
RNA integrity was assessed by electrophoresing 3 µl RNA, along with 8 µl Orange 
G loading dye, though a 0.8% agarose gel for 40 minutes at 120 V.  Images of the 
gel were taken using the BioDoc-It Imaging System Benchtop UV Transilluminator.  
Any degraded samples were omitted from further analysis.  If the RNA sample 
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contained a significant amount of genomic DNA, it was omitted from further 
analysis. 
2.3.3.2 RNA Conversion to cDNA 
Following RNA extraction, conversion to cDNA was carried out by making a 12 µl 
reaction mix containing 2 µl random primers (100 ng/µl), 1 µl dNTPs (10 mM) and 9 
µl RNA (2.5 µg/µl).  This was incubated for 5 minutes at 65⁰C on the G Storm to 
disrupt any template secondary structures.  It was then placed on ice to prevent the 
re-formation of secondary structures.  To the reaction mixture, 1 µl of reverse 
transcriptase was added (Superscript II 200 U/µl), and the mixture incubated for 2 
minutes at 25⁰C on the G Storm.  Subsequently, 4 µl 5x first strand buffer, 2 µl  
0.1 M DTT and 1 µl RNAsin was added, and the reaction mix was incubated for 10 
minutes at 25⁰C, 50 minutes at 42⁰C and 15 minutes at 70⁰C on the G Storm.  
cDNA was stored at -20⁰C. 
 
2.3.4 DNA Extraction from FFPE Tissue  
To extract DNA from FFPE tissue, the GeneRead FFPE Kit (Qiagen) was used.  10 
μm tissue sections were cut by the Cellular Pathology Department, University 
Hospital of Wales.  Excess paraffin was trimmed using a sterile scalpel, and the 
tissue was placed in a 1.5 ml Eppendorf tube. 160 μl deparaffinisation solution was 
added, and the tube was vortexed vigorously for 10 seconds then centrifuged briefly 
to bring the sample to the bottom of the tube.  DNA extraction was carried out 
following the manufacturer’s protocol.  Briefly, this involved incubating the solution 
at 56⁰C for 3 minutes, then allowing it to cool to room temperature.  55 μl RNase-
free water, 25 μl Buffer FTB, and 20 μl proteinase K were added to the solution, 
which was vortexed and briefly centrifuged.  The solution was incubated at 56⁰C for 
1 hour, then at 90⁰C for 1 hour.  The solution was briefly centrifuged to remove 
drops from inside the lid.  The lower, clear phase was transferred to a new 
microcentrifuge tube.  115 μl RNase-free water was added and the solution mixed.  
35 μl UNG was added, and the solution was vortexed and incubated at 50⁰C for 1 
hour in a thermomixer.  Again, the mix was briefly centrifuged to remove drops from 
inside the lid.  2 μl RNase A (100 mg/ml) was added, and the solution was mixed 
and incubated for 2 minutes at room temperature.  250 μl Buffer AL was added to 
the sample, which was mixed thoroughly by vortexing.  250 μl ethanol (96–100%) 
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was added and the mixture vortexed and centrifuged.  Subsequently 700 μl of lysate 
was transferred to the QIAamp MinElute column, in a 2 ml collection tube.  The lid 
was closed and the tube centrifuged.  The flow-through was discarded and the 
collection tube re-used.  The process of transferring the lysate/ centrifugation/ 
discarding the flow-through was repeated until the lysate was used up.  500 μl 
Buffer AW1 was added to each spin column and the mixture centrifuged.  The flow-
through was discarded and the collection tube re-used.  The process was repeated 
using 500 μl Buffer AW2, then 250 μl ethanol.  The spin column was then placed 
into a new 2 ml collection tube and centrifuged to remove any residual liquid.  The 
QIAamp MinElute column was transferred into a clean 1.5 ml microcentrifuge tube.  
40 μl Buffer ATE was pipetted on to the centre of the membrane.  The tube was 
incubated at room temperature for 5 minutes, then centrifuged.  All centrifugations 
were performed for 1 minute at full speed.  DNA was stored at -20⁰C. 
 
2.3.5 Quantification of Nucleic Acids 
Two platforms were used to quantify nucleic acids – the Nanodrop and the Qubit 2.0 
Fluorometer. In both cases, 2 µl of sample was used for quantification, following the 
manufacturer’s protocol. 
 
2.3.6 Primer Design 
Unless otherwise stated, all primers were designed using Primer3 v0.4.0 (Rozen 
and Skaletsky 2000) and were supplied by Eurogentec or Eurofins.  The specificity 
of primer pairs was determined using UCSC In Silico PCR software 
(https://genome.ucsc.edu/cgi-bin/hgPcr). 
 
2.3.7 Bisulfite Conversion of DNA  
Sodium bisulfite conversion of DNA is a technique which allows the detection of 
unmethylated versus methylated cytosines.  It involves the deamination of 
unmodified cytosines to uracil, leaving the methylated cytosines intact.   
DNA was bisulfite-converted using the Epitect Bisulfite Kit (Qiagen) following the 
manufacturer’s protocol.  Briefly, this involved making a mixture of 2 µg DNA, 85 µl 
Bisulfite Mix, 35 µl DNA protect buffer and an appropriate volume of RNase-free 
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water to make the total volume 140 µl.  The mixture was vortexed.  The bisulfite 
conversion was carried using the G Storm thermal cycler for 5 minutes at 95⁰C, 25 
minutes at 60⁰C, 5 minutes at 95⁰C, 85 minutes at 60⁰C, 5 minutes at 95⁰C and 175 
minutes at 60⁰C.  The PCR tubes were briefly centrifuged, then the complete 
reaction was transferred to a clean tube.  560 µl Buffer BL containing 10 µg/ml 
carrier RNA was added to each sample.  This was then vortexed and briefly 
centrifuged.  The entire reaction mix was transferred into an Epitect spin column, 
which was centrifuged at maximum speed for 1 minute.  The flow-through was 
discarded and the spin column placed back in the collection tube.  The process was 
repeated with 500 µl Buffer BW.  500 µl Buffer BD was added and the mixture 
incubated for 15 minutes at room temperature.  The spin columns were centrifuged 
at maximum speed for 1 minute.  The flow-through was discarded, and the spin 
columns were placed back in the collection tubes.  The process was repeated two 
further times, using 500 µl Buffer BW.  The spin columns were then placed in clean 
collection tubes and centrifuged at maximum speed for 1 minute to remove any 
residual liquid.  The spin columns were placed with the lids open into clean 
microcentrifuge tubes and incubated for 5 minutes at 56⁰C in a heating block.  Spin 
columns were then placed into clean microcentrifuge tubes.  20 µl Buffer EB was 
pipetted onto the centre of each membrane, and the purified DNA was eluted by 
centrifugation for 1 minute at 15 000 x g.  To complete the process, 20 µl of Buffer 
EB was pipetted to the centre of each membrane and centrifuged for 1 minute at 
maximum speed.  The resultant bisulfite-converted DNA was stored at -20⁰C. 
 
2.3.8 Standard PCR and Sanger Sequencing 
The standard steps for PCR and Sanger Sequencing are: 
1. PCR 
2. Gel Electrophoresis 
3. ExoSap PCR Purification 
4. Big Dye Reaction 
5. Isopropanol Clean Up 
6. Sequencing and Data Analysis  
 
These shall be described in sections 2.3.8.1-2.3.13. 
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2.3.8.1 Standard Reagents for PCR 
Water     11 µl    
Forward primer (10 µM)  0.25 µl  
Reverse primer (10 µM)  0.25 µl  
Megamix Gold (MMG)  12.5 µl  
DNA/ cDNA (5 ng/µl)   1 µl  
 
2.3.8.2 Reagents for PCR for FFPE Tissue DNA 
Water     Variable    
Forward primer (10 µM)  0.25 µl  
Reverse primer (10 µM)  0.25 µl  
Megamix Gold (MMG)  15 µl  
DNA     10 ng  
 
2.3.8.3 Reagents for Fast-COLD-PCR 
Water     11 µl    
Forward primer (10 µM)  0.25 µl  
Reverse primer (10 µM)  0.25 µl  
Megamix Gold (MMG)  12.5 µl  
DNA (5 ng/µl)    1 µl  
 
2.3.8.4 Reagents for Full-COLD-PCR 
Water     11 µl    
Forward primer (10 µM)  0.25 µl  
Reverse primer (10 µM)  0.25 µl  
Megamix Gold (MMG)  12.5 µl  
DNA (5 ng/µl)    1 µl  
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2.3.8.5 Standard PCR Reaction Conditions: 
95⁰C for 5 minutes 
95⁰C for 1 minute 
Annealing temperature: 58⁰C for 1 minute 
Elongation temperature 72⁰C for 1 minute 
Number of cycles:  35 
72⁰C for 5 minutes 
 
2.3.8.6 Reaction Conditions for Fast-COLD PCR: 
95⁰C for 5 minutes 
70⁰C - 95⁰C for 1 minute 
58⁰C for 1 minute 
72⁰C for 1 minute 
Number of cycles:  35 
72⁰C for 5 minutes 
 
2.3.8.7 Reaction Conditions for Full-COLD-PCR: 
Cycle 1 95⁰C for 5 minutes 
95⁰C for 1 minute 
58⁰C for 1 minute 
72⁰C for 1 minute 
Number of cycles:  10 
72⁰C for 5 minutes 
 
Cycle 2: 95⁰C for 1 minute 
70⁰C for 5 minutes 
70-95⁰C for 1 minute 
58⁰C for 1 minute 
72⁰C for 1 minute 
Number of cycles:  25 
72⁰C 5 for minutes 
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For both the fast and the full protocols, the initial COLD-PCR protocol allowed the 
determination of the lowest denaturation temperature over a wide range of 
temperatures (70-95°).  Once this was ascertained, the protocol was repeated using 
a narrower temperature gradient to further specify the lowest denaturation 
temperature.  
 
2.3.9 Gel Electrophoresis 
To confirm that PCR reactions had worked and that the PCR products were the 
correct size, products were electrophoresed through a 1.5% agarose gel, with a 
current of 120 V for 30 minutes.  Images of the gel were taken using the BioDoc-It 
Imaging System benchtop UV transilluminator (see 2.3.1). 
 
2.3.10 ExoSap PCR Purification 
The ExoSap PCR purification reaction involves an exonuclease enzyme degrading 
excess primers and any ssDNA present, and an alkaline phosphatase enzyme 
degrading any dNTPs.  The ExoSap stock was made from Exonuclease and Shrimp 
Alkaline Phosphatase at a ratio of 1:2.  1 μl of ExoSap was added to PCR products.   
These were incubated on the G Storm for one hour at 37⁰C , then for 15 minutes at 
85⁰C .   
 
2.3.11 Big Dye Reaction 
The Big Dye Terminator v3.1 Sequencing Kit was used for the sequencing reaction.  
1 μl of PCR product was added to a reaction mixture containing: 
 
Big Dye v.3.1  0.75 μl 
Water   5.25 μl 
Primer (10 μM) 1 μl 
BD Buffer  2 μl 
 
This then underwent thermal cycling on the G Storm:  25 cycles of 95⁰C for 10 
seconds, 50⁰C for 5 seconds, 60⁰C for 3 minutes and 30 seconds. 
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2.3.12 Isopropanol Clean-Up Protocol 
Isopropanol was used to precipitate DNA to allow purification.  40 μl of 75% 
isopropanol was added to each sample, which were incubated for 30 minutes at 
room temperature before being centrifuged for 45 minutes at 4000 revolutions per 
minute (rpm).  The samples were inverted, placed into the centrifuge upside down 
and spun for 30 seconds at 500 rpm.  Once this was complete, they were left in the 
dark to dry for 10 minutes before 10 μl of Hi-Di was added to re-suspend the DNA.   
 
2.3.13 Sequencing and Data Interpretation 
The samples were sequenced on the ABI Prism 3100 Genetic Analyser.  
Sequencing data was read using Sequencher 5.2.4 software. 
 
2.3.14 Methylation-Specific PCR (MSP) 
Methylation-specific PCR is a technique used to detect DNA methylation.  Primers 
are designed to bind to bisulfite-converted DNA dependent upon whether the 
original DNA molecule was methylated/ unmethylated.  The presence or absence of 
a PCR product will therefore indicate the methylation status of the original DNA.  In 
this thesis, MSP was used to determine the methylation status of the APC 1A and 
1B promoters.  
  
2.3.14.1 Reagents for APC Promoter 1A MSP 
Epitect Mastermix  25 µl 
Forward primer 500 ng 
Reverse primer 500 ng 
Water   Variable 
DNA   50 ng 
Total:   50 µl 
 
2.3.14.2 Reaction Conditions for APC Promoter 1A MSP 
95⁰C  10 minutes 
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35 cycles of: 
95⁰C  30 seconds 
53.9⁰C  30 seconds 
72⁰C  30 seconds 
 
72⁰C 10 minutes 
 
2.3.14.3 Reagents for APC Promoter 1B MSP 
Epitect Mastermix  25 µl 
Forward primer 250 ng 
Reverse primer 250 ng 
Water   Variable 
DNA   100 ng 
Total:   50 µl 
 
2.3.14.4 Reaction Conditions for APC Promoter 1B MSP 
95⁰C  10 minutes 
35 cycles of: 
95⁰C   30 seconds 
50.1⁰C  30 seconds 
72⁰C  30 seconds 
 
72⁰C 10 minutes 
 
2.3.15 Quantitative PCR (qPCR) 
Quantitative PCR (qPCR) is a PCR technique in which the reaction is monitored in 
real time.  This allows the quantification of the input sample, as higher sample 
concentrations will result in PCR products which can be detected at an earlier stage.  
This study used Taqman technology (ThermoFisher).  The principles underpinning it 
are that sample DNA is denatured, at the appropriate annealing temperature 
primers bind, along with a Taqman probe which includes a fluorescent dye and a 
non-fluorescent quencher (NFQ).  During DNA synthesis, using the primers and the 
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template DNA, the 5’nuclease activity of the Taq polymerase will cleave the probe, 
separating the dye from its quencher.  The dye will then emit a signal which is 
detected.  With each cycle of PCR amplification, increasing amounts of dye are 
released, therefore the fluorescent signal will increase. 
 
Prior to performing qPCR reactions, the basic foundations for this work were 
established, i.e. 
 
1. Determination of optimal RNA input 
2. Determination of reaction efficiencies, to ensure that that ΔΔCt 
method could be used for data analysis 
 
The details of this are described in Appendix 2.1. 
 
2.3.15.1 qPCR Reagents 
20X Taqman Gene Expression Assay  1 µl 
2X Taqman Gene Expression Master Mix  10 µl 
cDNA template     4 µl 
Water       5 µl 
 
2.3.15.2 qPCR Reaction Conditions 
Hold 50⁰C for 2 minutes 
Hold 95⁰C for 10 minutes 
Cycle (40 cycles):  95⁰C for 15 seconds, 60⁰C for 1 minute 
 
The thermal cycler used was the QuantStudio 12K Flex Real-Time PCR System 
(Life Technologies).  qPCR reactions were carried out in triplicate for each sample.  
A no-template control was included for each assay. 
 
2.3.16 APC and MUTYH Expression in Healthy Controls 
This study involved comparing the cDNA levels of APC and MUTYH in NMI 
polyposis patients to a cohort of healthy controls.   
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2.3.16.1 qPCR in a Healthy Control Cohort 
Venepuncture was performed on the healthy control cohort after each volunteer had 
given informed consent.  RNA was extracted (2.3.3, 2.3.3.1) and reverse 
transcribed to cDNA (2.3.3.2).  A total of 44 cDNA samples from healthy relatives 
and healthy controls underwent qPCR.  The reagents and reaction conditions are 
described above (2.3.15.1, 2.3.15.2). The Taqman assays used are listed in Table 
2.3:  
 
Gene Designation Taqman Assay 
GAPDH Endogenous control HS02758991_g1 
ACTB Endogenous control HS99999903_m1 
APC Target HS01568269_m1 
MUTYH Target HS01014856_m1 
 
Table 2.3:  Taqman assays used for qPCR 
2.3.16.2 Data Analysis 
Results were interpreted using ThermoFisher Cloud software 
(https://apps.thermofisher.com/apps/dashboard/#/).  The first stage of analysis was 
a quality assessment.  Any results which were flagged as outliers were examined.  
This usually referred to results which had a CT value which deviated significantly 
from the CT values in the associated replicate group, or whole replicate groups 
which had a significant deviation within them.    
  
The individual replicate results which deviated significantly from their replicate group 
were excluded as this was likely due to experimental error and would unfairly skew 
results.  Those replicate groups which had a significant deviation within them were 
excluded as the results were not tight enough for robust analysis.  If a sample had a 
complete replicate group for one of the endogenous controls excluded, that sample 
was removed from further analysis as we were seeking to normalise results to two 
different endogenous controls.  Therefore, some samples needed to undergo qPCR 
a second time to obtain usable results.  
 
The final 40 samples included in this study are listed in the Table 2.4: 
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Sample ID Sample group 
C2-C27, C30-C33, C35, C37, C39 Healthy Controls 
M_Halo55 Healthy Controls 
F_Halo55 Healthy Controls 
Halo75 Healthy Controls 
Halo76 Healthy Controls 
Halo77 Healthy Controls 
Halo78 Healthy Controls 
Halo79 Healthy Controls 
 
Table 2.4: Healthy control samples used for qPCR studies 
2.4 Next Generation Sequencing (NGS) 
 
2.4.1 Haloplex Assay  
The probes for the Haloplex assay were designed using Agilent’s Sure Design 
software (https://earray.chem.agilent.com/suredesign/home.htm).  The probes 
generate read lengths of 250 base pairs. 
 
2.4.2 Target Gene Capture and Sequencing 
The concentration of the DNA samples to be examined were determined using the 
Qubit 2.0 Fluorometer.  The DNA was diluted to a concentration of 5 ng/μl.  
Sequencing was carried out by Dr. James Colley, WGP, using the HiSeq 2500 
(Illumina).  The protocol involved digesting gDNA with 16 different restriction 
enzymes to create a library of restriction fragments.  Digested DNA was hybridised 
to Haloplex probes for target enrichment and sample indexing.  The DNA-Haloplex 
probe hybrids were captured by streptavidin beads, prior to the ligation of the 
circularised fragments.  DNA was eluted with sodium hydroxide and underwent PCR 
to amplify the target libraries.  Target libraries were purified, quantified and pooled 
before sequencing. 
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2.4.3 Bioinformatic Analysis Following UDS 
Bioinformatic analysis was performed by Dr. Peter Giles, WGP.   
Reads were analysed using the following procedure: 
 
1. Raw reads (in fastq format) were transferred from the sequencer to the local 
computer cluster 
2. Reads were mapped against the hg19 genome using bwa-mem, producing a 
BAM file 
3. Quality control was reviewed using 10% of reads using a combination of in-house 
scripts, FastQC and circos for visualisation 
4. GATK was then used to recalibrate quality scores and to apply a localised 
realignment around indels before filtering for artefactual duplicates using samtools 
5) Variant calling was performed using GATK (Unified Genotyper) and varscan (for 
low frequency variants) producing VCF files 
6) Variants were annotated, including the following parameters: 
- Coverage 
- Allele balance 
- UCSC genes 
- 1000 genomes 
- dbsnp137 
- Gene description 
7) Variants were visualised using Integrative Genomics Viewer (IGV) 
 
2.4.4 Whole Exome Sequencing (WES) 
Sequencing was performed by the WGP.  Briefly, 50 ng of gDNA was used as the 
input template.  Sequencing libraries were prepared using the Illumina Nextera 
Rapid Capture Enrichment kit.  Subsequent steps included tagmentation of the 
gDNA, clean-up of the tagmented DNA, amplification of DNA, clean-up of amplified 
DNA, hybridisation of probes, capture of the hybridised probes, second hybridisation 
of probes, second capture, clean-up of the captured library, amplification of enriched 
library, clean-up of the enriched library, validation of the complete library. 
The manufacturer’s instructions were largely followed with extra quantitation steps 
prior to the hybridisation of the probes to ensure that close to 50 ng of each sample 
was pooled. The libraries were validated using the Agilent 2100 Bioanalyser and a 
high-sensitivity kit (Agilent Technologies) to ascertain the insert size, and the Qubit 
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2.0 Fluorometer was used for quantitation. Following validation, the libraries were 
normalised to 4 nM, pooled together and clustered on the cBot™2 following the 
manufacturer’s recommendations. The pool was sequenced using a 75-base 
paired-end (2x75bp PE) dual index read format on the Illumina HiSeq 2500 in high-
output mode according to the manufacturer’s instructions. 
 
2.4.5 Bioinformatic Analysis Following Whole Exome 
Sequencing 
Bioinformatic analysis was performed by Dr. Kevin Ashelford (WGP).   
Reads were analysed following the steps outlined below: 
 
1. The raw output from the HiSeq 2500 were BCL files.  These, once transferred 
from the sequencing rig, were converted to fastq.gz using the Illumina tool bcl2fastq 
(version 2.17.1.14; https://support.illumina.com/content/dam/illumina-
support/documents/documentation/software_documentation/bcl2fastq/bcl2fastq_lett
erbooklet_15038058brpmi.pdf) 
2. Initial quality control was performed on 10% of the data (for speed) using a 
combination of an in-house script and FastQC (version 
0.11.2; http://www.bioinformatics.babraham.ac.uk/projects/fastqc/).  The in-house 
script performed a quick mapping of the data using BWA-MEM (version 
0.7.4; http://bio-bwa.sourceforge.net) and then calculated percentage mapped and 
insert size 
3. Reads were trimmed with Trimmomatic (version 
0.35; http://www.usadellab.org/cms/?page=trimmomatic) to remove any adapter and 
poor-quality base calls from the ends of reads 
4. Trimmed reads were then mapped with BWA-MEM (version 0.7.10).  Mapping 
was performed against standard human reference hg19 (Feb. 2009 (GRCh37/hg19) 
— http://genome-euro.ucsc.edu/cgi-
bin/hgGateway?db=hg19&redirect=manual&source=genome.ucsc.edu) 
5. Mapping outputs were then post-processed using several GATK (version 
3.3.0; https://software.broadinstitute.org/gatk/) tools: (i) RealignerTargetCreator 
and IndelRealigner to realign reads around indels, (ii) BaseRecalibrator 
and PrintReads to recalibrate raw Quality Values.  The Picard toolkit (version 
1.118; https://broadinstitute.github.io/picard/) tool MarkDuplicates was then used to 
flag duplicate reads 
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6. After post-processing a further round of quality control was performed using 
FastQC as before and an in-house script to calculate on-target mapping metrics 
7. Raw variant calls were called on each sample separately using GATK 
HaplotypeCaller in GVCF mode followed by GenotypeGVCFs to produce a final 
combined vcf file.  Raw variant calls were then filtered using VariantRecalibrator to 
provide Variant Quality Score Recalibration (VQSR) which allows for dynamic 
filtering of variants using machine learning techniques 
8. Variants were then annotated against databases dbSNP version 138, 
1000Genomes, COSMIC and SIFT using ANNOVAR (version 
20150322; http://annovar.openbioinformatics.org). In-house scripts were used to 
format the output and extract additional filtering criteria including coverage depths, 
allele balance, and gene descriptions  
 
2.4.6 Single Molecule Molecular Inversion Probe Gene 
Capture, Sequencing and Bioinformatic Analysis 
1. A reaction mixture composed of the following reagents was prepared: 
 DNA (5 ng/µl)     10.0 µl 
 Hemo Klen Taq DNA Polymerase (10 U/µl) 0.32 µl 
 Ampligase DNA ligase (100 U/µl)  0.01 µl 
 smMIP      3.49 µl 
 10X Ampligase DNA ligase buffer   2.5 µl 
 dNTPs (0.25 mM)    0.32 µl 
 Water      8.36 µl 
To make the reaction mix, the ligase, buffer and dNTPs were combined.  To 
this, the smMIPs and water were added, then finally the DNA 
2. The mix was incubated at 95⁰C for 10 minutes, and then at 60⁰C for 18 hours 
3. To ensure that the gene capture was successful, 5 µl of the reaction mixture 
was electrophoresed through a 3% agarose gel for 30 minutes.  Images of the 
gel were taken with the Bio Rad Gel Doc XR+ System 
4. The reaction mixture was cooled and kept on ice.  An exonuclease reaction 
mixture was added to each sample.  This was composed of: 
 EXOI    0.5 µl 
 EXOIII    0.5 µl 
 Ampligase buffer   0.2 µl 
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 Water   0.8 µl 
5. The mixture was incubated at 37⁰C for 45 minutes and then at 95⁰C for 10 
minutes 
6. A test PCR was carried out on a subset of the reactions, to ensure that PCR 
amplification would be successful. The following reagents were used: 
 2X iProof HF Mastermix     12.5 µl 
 Illumina forward primer* (100 µM)  0.125 µl 
 Barcoded reverse primer PGM* (100 µM) 0.125 µl 
 Water      7.25 µl 
 Template MIP reaction    5 µl 
(*Test PCR primers:   SLXA_PE_MIPBC_FOR: 
AATGATACGGCGACCACCGAGATCTACACATACGAGATCCGTAATCGGGAAGC
TGAAG;   
SLXA_PE_MIPBC2_REV_001: CAAGCAGAAGACGGCATACGAGATGTTAAGAC
ACACGCACGATCCGACGGTAGTGT Bold: sample barcode) 
7. The reaction mixture underwent the following reaction: 
 98⁰C for 30 seconds 
Cycles of:  tumour tissue: 24 cycles, normal tissue 21 cycles: 
 98⁰C for 10 seconds 
 60⁰C for 30 seconds 
 72⁰C for 2 seconds 
8. 5 µl of PCR products were electrophoresed through a 3% agarose gel for 30 
minutes.  The PCR bands were visualised using the Bio Rad Gel Doc XR+ 
System.  Provided that PCR had been successful, all samples underwent the 
reaction.  The reagents for each reaction were as follows: 
 2X iProof HF Mastermix     37.5 µl 
 Illumina forward primer* (100 µM)  0.375 µl 
 Barcoded reverse primer PGM* (100 µM) 5.0 µl 
 Water      18.375 µl 
 Template MIP reaction    15 µl 
9. Reaction conditions are as described in Step 7 
10. 5 µl of PCR products were electrophoresed through a 3% agarose gel for 30 
minutes.  The PCR bands were visualised using the Bio Rad Gel Doc XR+ 
System 
11. Each sample was given a score based on the intensity of its PCR band:  High, 
Medium, Low 
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12. The samples were pooled so that approximately equivalent amounts of each 
sample were included.  There were separate pools for tumour DNA and 
germline DNA 
13. The pools were run on a 3.5% agarose gel for 30 minutes.  Images of the gel 
were taken with the Bio Rad Gel Doc XR+ System 
14. The PCR products were extracted from the gel using a Zymoclean Gel DNA 
Recovery Kit 
15. PCR products were assessed using the TapeStation to confirm that products of 
the correct size were present.  If the TapeStation was suggestive of >1 product 
in the reaction mix, steps 13-15 were repeated to try and purify the desired 
product 
16. The samples were quantified using the Qubit Fluorometer 2.0, following the 
manufacturer’s protocol 
17. All pools were combined into a megapool, and the concentration was quantified 
using the Qubit Fluorometer 2.0 
18. The megapool was diluted to 2nM 
19. Sequencing was performed using the MiSeq (Illumina) 
 
Following sequencing, bioinformatic analysis was carried out by Laura Chegwidden, 
Oxford University/ Birmingham University.  The protocol is outlined below: 
Samples were demultiplexed using basespace. The FASTQ files were downloaded 
for each sample. Each FASTQ file was processed using Perl scripts from Roland 
Arnold to:  
1. remove MIP backbones from read 1 (R1) and read 2 (R2)  
2. remove reads that were <55bp long after processing  
3. remove reads whose mate had been filtered out to leave paired reads only  
Next, tools were used as suggested by the MIPGEN pipeline builder 
(https://github.com/shendurelab/MIPGEN/tree/master/tools):  
1.  Use PEAR to join R1 and R2  
2.  Use a python script to move the single molecule tag to the FASTQ header 
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Mapping and basic quality control was performed following the processes described 
below:  
1. BWA mem was used to align reads to hg19  
2. Python script was employed to collapse reads into single molecule tag 
defined read groups 
3. Statistics were generated on the number of panel targets covered at 20X to 
identify samples that had failed. A sample was considered as having 
“passed” basic sequence QC if >50% of targets were covered at 20x 
Samtools was used to make BAM files.  
For Indel realignment, pre-processing was carried out as per the lofreq website.  
This involved Viterbi realignment, adding indel quality scores to files and adding 
alnqual.  Variants were called using Lofreq-star: 
 call-indels  
 m 60 (filtering on mapping quality >60)  
 no-default-filter (these were set at a later stage)  
Following calling, variants were filtered according to the following criteria: 
 cov-min 10 (min coverage 10)  
 sb-thresh 60 (strand bias phred 60)  
 a 0.01 (MAF>0.01)  
Formatting/ further filtering involved: 
 Filtering the data so that calls with >5 reads in either Forward OR Reverse 
remained. Those with <5 reads were omitted 
 Assigning genotypes (VAF<0.75=HET; VAF>=0.75=HOM)  
 MAF>0.05  
 Assessing strand bias: if there were reference reads in Forward/Reverse, 
but there were no variant reads in the opposite strand, the variant was 
omitted 
 Annotation using VEP  
 Removing likely germline variants 
 Filter "ExAC.r0.3.nonTCGA_AF > 0.01"  
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 Filter "UK10K_AF > 0.01"  
 Filter "EUR_MAF > 0.01"  
 Adjusting formats & layouts so that vcf (original lofreq call) columns were 
reported first, then VEP annotations  
 Filtering to remove intronic, synonymous and splice region variants  
 Variants were removed if they were part of a homopolymer repeat >4 in 
length  
 Variants were removed if they were discovered as part of a search for panel 
artefacts- poorly performing molecular inversion probe/ hard to sequence 
region  
 The high confidence call sets had a depth > 20 and VAF support > 5% 
 
2.5 Molecular Biology Techniques 
2.5.1 Plasmid Retrieval from Filter paper 
The demarcated spot containing plasmid was cut out from the filter paper using a 
clean razor blade.  It was immersed in 30 µl TE and mixed with a pipette.  It was left 
for at least 10 minutes at room temperature prior to bacterial transformation.  If it 
was not used immediately, DNA was stored at -20C. 
 
2.5.2 Preparation of Lysogeny Broth (LB) 
To prepare LB, 20 g LB Broth Base was added to 1 L distilled water.  It was 
autoclaved at 126⁰C for 45 minutes.  An appropriate antibiotic, at 1:1000 dilution, 
was added when the solution had cooled down.  The broth was stored at room 
temperature. 
 
2.5.3 Preparation of Lysogeny Broth (LB) Agar 
To prepare LB agar, 10.5 g LB Agar was added to 300 ml distilled water.  It was 
autoclaved at 126⁰C for 45 minutes.  It was allowed to cool slightly, prior to adding 
an appropriate antibiotic, at 1:1000 dilution, when hand-warm.  It was poured into 
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plates next to a naked flame.  Once the agar had set, it was turned upside down to 
prevent condensation from dripping onto the agar.  The plates were stored at 4⁰C . 
 
2.5.4 Bacterial Transformation of XL1-Blue Competent Cells 
All steps of the protocol were carried out next to a naked flame, and the equipment 
openings/ lids were quickly waved through the flame.  Bacterial transformation 
followed the protocol detailed below: 
 
1. The waterbath was warmed to 42⁰C  
2. SOC medium was warmed to room temperature 
3. The agarose plates containing the desired antibiotic were warmed to 
37⁰C in an incubator 
4. Competent E. Coli cells were thawed on ice 
5. 25 µl bacteria was transferred into a pre-cooled 1.5 ml Eppendorf 
tube 
6. 0.4 µl -mercaptoethanol was added to each tube, which were kept 
on ice 
7. 1 µl circularised DNA was added and the solution and mixed gently 
8. The mix was incubated on ice for 30 minutes 
9. The Eppendorf was placed into the water bath at 42⁰C for 45 
seconds to allow transformation 
10. The Eppendorf was then put back onto ice for 2 minutes, to reduce 
damage to the bacteria 
11.  250 µl SOC medium (without antibiotics) was added 
12. The tubes were incubated at 37⁰C for one hour while shaking using a 
shaking incubator 
13. Approximately 200 µl of the culture was spread onto LB plates with 
the appropriate antibiotic.  It was grown overnight at 37⁰C in an 
incubator 
14. After 12-16 hours, one clone was picked up using a pipette tip.  The 
tip was placed into a 25 ml Falcon tube with 5 ml LB + antibiotic 
15. The Falcon tube was incubated at 37⁰C overnight in an incubator 
prior to DNA extraction 
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2.5.5 Plasmid Extraction from Transformed Bacteria  
Plasmid extraction from bacteria was achieved using the MiniPrep Kit (Qiagen) 
following the manufacturer’s protocol.  Briefly, the bacterial culture was pelleted by 
centrifugation at >8000 rpm for 3 minutes at room temperature.  The pellet was re-
suspended in 250 µl Buffer P1 and transferred to a microcentrifuge tube.  250 µl 
Buffer P2 was added, and the solution mixed by inverting the tube 6 times.  350 µl 
Buffer N3 was added, and the solution mixed by inverting the tube 6 times.  The 
solution was centrifuged at 13000 rpm for 10 minutes.  The supernatant was added 
to a QIAprep spin column and centrifuged at 13000 rpm for 1 minute.  The flow-
through was discarded.  500 µl Buffer PB was applied to the membrane and the 
tube was spun at 13000 rpm for 1 minute.  The flow-through was discarded.  750 µl 
Buffer PE was added and the tube was spun at 13000 rpm for 1 minute.  The flow-
through was discarded.  The tube was spun again at 13000 rpm for 1 minute, and 
the flow-through discarded.  The QIAprep column was placed into a clean 
microcentrifuge tube.  To elute the DNA, 50 µl Buffer EB was added.  The tube was 
left to stand for 1 minute and was then spun for 1 minute at 13000 rpm.  
 
2.5.5 Sequencing of Plasmid DNA 
Sequencing of plasmid DNA was carried out by Dundee Sequencing 
(https://www.dnaseq.co.uk/).  600 ng of DNA in 20 µl double distilled water was 
submitted to the laboratory, which use plasmid-appropriate sequencing primers. 
 
2.5.6 Site Directed Mutagenesis (SDM) and Transformation of 
XL-1 Blue Competent Cells 
Site directed mutagenesis was performed using the QuikChange II Kit (Agilent).  All 
primers were designed using Agilent’s online primer-design tool 
(www.agilent.com/genomics/qcpd).  Briefly, the protocol involved carrying out a 
mutant-strand synthesis reaction, using the following reagents: 
 
10X Reaction Buffer  5 µl 
dsDNA Template  5-50 ng 
125 ng Forward primer Variable 
125 ng Reverse primer Variable 
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dNTP mix   1 µl 
Water    Variable to a final volume of 50 µl 
 
1 µl of PfuUltra HF DNA polymerase (2.5 U/µl) was added and the reaction mix 
underwent thermal cycling using the conditions outlined as follows: 
 
95⁰C   30 seconds 
16 cycles of: 
95⁰C   30 seconds 
55⁰C   1 minute 
68⁰C   7 minutes 
 
After thermal cycling, the reaction mixes were placed on ice for 2 minutes. 
1 µl of Dpn1 restriction enzyme was added. 
 
The mutant dsDNA was subsequently used to transform XL-1 Blue Competent cells 
using the following protocol: 
 
1. XL1-Blue cells were thawed on ice.  50 µl of cells were transferred to a pre-
chilled 14 ml BD Falcon polypropylene round-bottom tube 
2. 1 µl of the SDM reaction mixture was added to the cells 
3. The cells underwent a heat pulse for 45 seconds at 42⁰C in the waterbath 
and were then placed on ice for 2 minutes 
4. SOC media was preheated to 42⁰C in the waterbath, and 0.5 ml was added 
to the cells.  The cells were incubated at 37⁰C for 1 hour whilst shaken at 
225-250 rpm in the shaking incubator 
5. 250 µl of each transformation reaction was then plated onto ampicillin-
containing agar plates 
6. The transformation plates were incubated at 37⁰C for at least 16 hours in an 
incubator 
 
Following the transformation reactions, colonies were selected and grown as 
described in section 2.5.4, steps 14 and 15.  DNA was extracted using the MiniPrep 
Kit (2.5.5). 
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2.5.7 Defrosting HEK293 TCF-Luc Cells 
HEK293 TCF-Luc cells were kept in 1 ml aliquots at -80⁰C .   
 
They were defrosted following the protocol detailed below.  Where possible, all 
steps were performed using a sterile technique in a TC hood: 
 
1. DMEM (1X)-GlutaMax-10% FBS media was warmed to 37⁰C in the 
waterbath 
2. The HEK293 TCF-Luc cells were thawed at 37⁰C in the waterbath for 1-3 
minutes 
3. 9 ml of pre-warmed media and 1ml cells were pipetted into a 15 ml 
Falcon tube 
4. Mixing was carried out by gentle inversion 
5. The cells underwent centrifugation for 5 minutes at 250 x g 
6. The supernatant was discarded 
7. The pellet was re-suspended with 10 ml media 
8. The cells underwent centrifugation for 5 minutes at 250 x g 
9. The supernatant was discarded 
10. The pellet was re-suspended in 5 ml media 
11. The suspension was transferred to a 25 cm2 flask 
12. It was kept at 37⁰C in an incubator 
 
2.5.8 Splitting Cells 
Cells were kept in an incubator at 37⁰C with 5% CO2.  Once they reached 
approximately 70% confluence, they were split as described below.  Where 
possible, all steps were performed using a sterile technique in the TC hood.   
Prior to the reactions, DMEM-Glutamax-10% FBS, PBS and Trypsin were pre-
warmed to 37⁰C in the waterbath. 
  
1. The media was removed from the flask 
2. 10 ml PBS was added, and the flask was gently agitated to wash the 
cells 
3. The PBS was removed 
4. 3 ml 0.05% Trypsin was added 
5. The flask was incubated at 37⁰C for 1 minute in the incubator  
  
 89 
6. 7 ml DMEM-Glutamax-10% FBS was added 
7. The solution was transferred to a 15 ml Falcon tube 
8. The Falcon tube was centrifuged for 5 minutes at 250 x g to create a 
pellet 
9. The cells were re-suspended in 10 ml DMEM-Gluatamax-10% FBS 
10. To maintain cells, they were diluted an appropriate amount (e.g. 1:4, 1:6, 
1:10 depending on when they were required for the next reaction.  Cells 
were diluted in DMEM-Glutamax-10% FBS) and kept in a 25 cm2 flask 
11. The flask was incubated at 37⁰C in an incubator 
 
2.5.9 Plating the Cells for Transfection 
Once the cells reached approximately 70% confluence, they were plated for 
transfection.  Steps 1-6 from Section 2.5.8 were followed.  Once the DMEM-
Glutamax-10% FBS had been added to the cells, they were counted. 
20 µl cells were mixed with 20 µl Trypan Blue.  20 µl of the solution was pipetted 
onto a haemocytometer, and the cells were counted using a light microscope 
(Leica).  
 
For a full 96-well assay plate, 1 500 000 cells were pipetted from the solution and 
added to a 15 ml Falcon tube.  10 ml DMEM-Glutamax-10% FBS was added, and 
the solution was centrifuged for 5 minutes at 250 x g.  Following centrifugation, the 
supernatant was discarded.  10 ml DMEM-Glutamax-10% FBS was added to re-
suspend the cells.  100 µl of cell solution (15 000 cells) was added to each well of a 
96-well Assay plate.  The plate was stored at 37⁰C in an incubator. 
 
2.5.10 Transfection 
Once the cells were 70-80% confluent they were transfected. 
 
For the Luciferase assays, transfection was performed with the following plasmids: 
 
WT-AXIN2, Fearon-AXIN2 (c.1989G>A), Short-AXIN2 (c.1642G>T), WT/Short-
AXIN2.  The WT-AXIN2 and Fearon-AXIN2 had kindly been supplied by Professor 
Eric Fearon, University of Michigan, and were N-terminal 6xmyc-tagged AXIN2 in 
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pCS2+MT.  Short-AXIN2 was generated by SDM of the WT-AXIN2 as described in 
2.5.6.  For the WT/ Short mix, WT and Short plasmids were used at a ratio of 1:1. 
 
To carry out the reactions, Lipofectamine was diluted in Optimem and incubated for 
5 minutes at room temperature.  For each well of 15 000 cells, the following 
volumes were required: 
 
Lipofectamine  0.3 µl 
Optimem  24.7µl 
 
A total of 100 ng/well of plasmid was used for transfection. 
For each AXIN2 plasmid, a series of 3-fold dilutions were made, with a maximum 
amount of 90 ng plasmid (90 ng, 30 ng, 10 ng, 3.33 ng, 1.11 ng, 0.37 ng, 0.12 ng, 
0.04 ng). A control with no AXIN2-plasmid was also employed.  To make the total 
plasmid mass 100 ng, pcDNA was added to AXIN2 plasmid.   
The reaction volume for each well was made up to 25 µl with Optimem: 
 
AXIN2-Plasmid Variable:  90-0 ng 
pcDNA   Variable:  10-100 ng 
Total plasmid:  100ng 
 
Optimem  Variable to make volume up to 25 µl 
 
The Lipofectamine solution was added to the plasmid solution and incubated at 
room temperature for 20 minutes.  The entire reaction mix (50 µl) was subsequently 
added to a well of cells, and incubated overnight at 37⁰C. 
 
For the Luciferase assays, each of the transfection reactions underwent 3 biological 
replicates, separated in time, and each of the biological replicates underwent three 
technical replicates.  Every experiment included control samples:  cells were 
transfected with empty plasmid, and subsequently did or did not undergo Wnt3a/ R-
Spondin stimulation (2.5.11).  
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2.5.11 Stimulation with Recombinant Human Wnt-3a and 
Human R-Spondin-1 
Following transfection, the cells were stimulated with Recombinant Human Wnt3a 
and Human R-Spondin-1.  100 µl media was initially removed from each well.  50 µl 
DMEM-Glutamax-10% FBS was added, containing 20ng/ml R-Spondin and 200 
ng/ml Wnt3a. 
 
The cells were incubated at 37⁰C overnight. 
 
2.5.12 WST and Luciferase Assays 
10 µl WST-1 was added to each well, and the cells were incubated at 37⁰C for one 
hour.  WST-1 activity was measured using the Fluorostar Optima.  Readings were 
taken at 450 nm and 590 nm. 
 
The assay plate was subsequently inverted, and all liquid tapped out.  35 µl Glo-
Lysis buffer was added to each well, and the assay plate was mixed using the 
Stuart Gyro Rocker for 15 minutes at 45 rpm.  35 µl Glo-Substrate was then added 
to each well.  Luciferase activity was read using the Fluorostar Optima.  Luciferase 
activity was normalised to the WST-Score (Luciferase score/ (WST 450/WST 590)).   
 
The normalised luciferase activity in the cells which had been transfected with 
empty vector and which had been stimulated with R-Spondin/ Wnt3a was given a 
score of 1.  The normalised luciferase activity in the cells transfected with AXIN2 
plasmid was compared to this. 
 
2.5.13 Cell Lysis and Protein Extraction 
The cell culture dish was placed on ice and the media removed.  Cells were washed 
with ice cold PBS, which was then removed.  150 µl of cell lysis buffer was added to 
each well.  10 ml buffer was composed of: 
 
NaCl (5 M)  0.3 ml 
Tris (1 M)  0.5 ml 
IGEPAL CA630 0.05 ml 
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Roche Complete protease inhibitor (1 tablet per 10 ml) 
Roche PhosphoSTOP phosphatase inhibitor (1 tablet per 50 ml) 
Glycerol (10%) 1 ml 
Water   8.15 ml 
 
Adherent cells were scraped off the dish using a cold cell scraper.  The cell 
suspension was transferred to a pre-cooled microcentrifuge tube and was agitated 
at 4⁰C for 30 minutes.  The microcentrifuge tubes were subsequently centrifuged at 
4⁰C for 30 minutes at 13 000 rpm.  The tubes were then placed on ice.  The 
supernatant was aspirated and placed into a fresh microcentrifuge tube.  Protein-
containing lysate was stored at -80⁰C. 
 
2.5.14 Protein Quantification using a Bicinchoninic Acid 
(BCA) Assay 
A BSA protein standard was prepared according to the following volumes: 
 
Standard (µg/ml) µl of 10 mg/ml BSA µl H2O 
500 25 475 
400 20 480 
300 15 485 
200 10 490 
100 5 495 
50 2.5 497.5 
0 0 500 
 
Table 2.5:  BSA protein standards 
 
50 µl of each standard was added in duplicate to a 96-well plate. 
 
1 µl of protein lysate was added to 199 µl water, to make a 1:200 dilution.  50 µl of 
this was added in duplicate to the 96-well plate.  The stock solution was then diluted 
by a factor of 2 to give a 1:400 dilution.  50 µl of this was added in duplicate to the 
96-well plate. 
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The BCA reagent was prepared by mixing components A and B at a ratio of 50:1.  
75 µl of BCA reagent was added to each well of standard or sample.  The plate was 
incubated at room temperature for 30 minutes with gentle agitation. 
 
The absorbance was read at 590 nm using the Fluorostar Optima, and a standard 
curve was used to calculate the protein content in each sample. 
2.5.15 Western Blotting 
677 µg of each protein in 15 µl water was mixed with 5 µl NuPAGE LDS Sample 
Buffer.  Samples were heated for 5 minutes at 95⁰C using the QBD2 heating block. 
They were loaded onto a NuPAGE 4-12% Bis Tris Minigel.  The protein marker 
used was the Novex Sharp Pre-Stained Protein Standard.  The samples were 
electrophoresed for 1.5 hours at 200 V using NuPAGE MES SDS running buffer. 
 
The protein was transferred from the gel to a nitrocellulose membrane using the 
iblot system (Invitrogen). 
 
The membrane was blocked with 5% non-fat powdered milk in TBS for one hour at 
room temperature, with constant agitation.  The membranes were then incubated 
with anti-myc-tag primary monoclonal antibody (9B11 New England Biolabs) diluted 
in TBS-Milk overnight at 4⁰C with constant agitation. 
 
The membrane was washed twice in water, and was incubated with anti-mouse 
secondary antibody (NXA931 Sigma Aldrich) diluted in TBS-milk, for one hour at 
room temperature with constant agitation. 
 
The membrane was washed twice in water.  It was incubated for 5 minutes at room 
temperature with 8 ml Supersignal West Pico Chemiluminescent Substrate. 
 
Antibody detection was achieved using the BioRad ChemiDoc MP Imaging System. 
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2.5.16 Stripping Nitrocellulose Membranes and -Actin 
Detection 
The nitrocellulose membrane was washed with TBS.  It was immersed in Restore 
Plus Western Blot Stripping Buffer and incubated for 15 minutes at room 
temperature.  The buffer was removed, and the membrane washed with TBS. 
 
The membrane was blocked with 5% non-fat powdered milk in TBS for one hour at 
room temperature, with constant agitation.  To detect -actin, the primary antibody 
used was A5441 (Sigma Aldrich), and the further steps followed are those described 
above (2.5.15). 
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Chapter 3 APC and MUTYH in 
Colorectal Polyposis  
3.1 Introduction 
The aim of this chapter was to identify missed or novel genetic variants in APC or 
MUTYH responsible for the polyposis phenotype in NMI patients.  Such variants 
may occur outside of the open reading frame (ORF) of the genes, in promoters, 
untranslated regions (UTRs) or introns, or they may be conventional mutations 
which occur at a low frequency within the patients (mosaicism).  They could 
underpin the pathogenesis of colorectal neoplasia through mechanisms such as 
abnormal gene transcription, reduced stability of mRNA and abnormal mRNA 
splicing.  I sought to identify variants and their mechanisms of action through a 
combination of approaches (Figure 3.1): 
 
 Quantitative PCR (qPCR) to interrogate APC and MUTYH transcription 
 gDNA/ cDNA sequencing to screen for allelic imbalance (AI) 
 cDNA sequencing of the coding sequences of APC and MUTYH to 
screen for splicing abnormalities 
 Ultradeep sequencing (UDS) of the whole of the APC and MUTYH 
genomic loci to identify variants outside of the ORF and low frequency 
variants, i.e. patients with generalised mosaicism 
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Figure 3.1 Flow chart of the studies employed in the interrogation of APC and MUTYH 
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3.2 Methods 
3.2.1 Quantitative PCR (qPCR): APC and MUTYH 
Transcription 
To determine whether any NMI polyposis patient had evidence of reduced 
transcription of APC or MUTYH compared to a cohort of healthy controls, RNA 
levels within a control cohort needed to be determined. To date, no study has 
characterised the normal range of APC and MUTYH RNA levels in RNA derived 
from venous blood samples from a healthy control cohort.   
 
High quality RNA was available for 40 healthy control samples (2.3.16) and 45 NMI 
patients (2.2.3.4).  3 affected FAP control patients and 4 affected MAP control 
patients were also included (Table 3.1).  FAPPol51 was used as a positive control 
for reduced APC transcription due to the confirmed presence by the NHS diagnostic 
service of an APC promoter deletion known to impair transcription.  The remaining 
FAP and MAP patients have mutations which are not predicted to affect 
transcription, so were used as negative controls.  Although some of these mutations 
may result in nonsense mediated decay (NMD) or could potentially affect transcript 
stability, the Taqman probes generate such short amplicons that it is highly likely 
they will be able to bind to fragmented RNA/ cDNA so that levels will appear to be 
within the normal range.  Unfortunately, MUTYH promoter mutations resulting in 
reduced gene transcription are thus far unreported in the literature, so no positive 
controls for reduced MUTYH transcription were available. 
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Sample  
Sample 
Group 
Mutation 
Expected Result for APC 
and MUTYH Gene 
Transcription 
Halo37 MAP 
Compound heterozygous 
for MUTYH c.536A>G & 
c.649C>T 
Normal 
Halo59 MAP 
MUTYH c.1187G>A 
homozygote 
Normal 
MAPPol71 MAP 
Compound heterozygous 
for MUTYH c.303G>T and 
c.312C>A 
Normal 
MAPPol90 MAP 
Compound heterozygous 
for MUTYH c.1187G>A 
and c.536A>G 
Normal 
FAPPol51 FAP APC promoter 1B deletion 
Reduced APC 
transcription 
FAPPol141 FAP 
APC exons 11 and 12 
deleted 
Normal 
Halo42 FAP 
APC c.1187 dup A, 
MUTYH c.536A>G 
Normal 
 
Table 3.1:  FAP and MAP controls used in gene transcription studies 
 
RNA was converted to cDNA following standard protocols (2.3.3.2).  cDNA 
underwent qPCR using standard reagents and reaction conditions (2.3.15) and 
Taqman assays for ACTB, GAPDH, APC and MUTYH (2.3.16.1, Table 2.3).  
Results were analysed using ThermoFisher Cloud software (2.3.16.1.1).  Any 
patient with an Rq </= 0.6 when compared to the healthy control cohort was 
identified for further characterisation.   
  
 99 
3.2.2 Karyotype Analysis 
Chromosomal rearrangements can affect gene expression through mechanisms 
such as disrupting genes or regulatory elements, producing fusion genes, placing 
genes in anomalous chromatin environments, placing genes near to telomeres and 
aberrant nuclear positioning (Harewood and Fraser 2014).  Karyotype analysis was 
performed by the AWMGS following their Standard Operating Procedure (SOP).   
 
3.2.3 Promoter Methylation Studies 
MSP was carried out to determine the methylation status of the APC 1A and 1B 
promoters (2.3.14).  MSP for the 1A promoter used primers described by Arnold et 
al (2004) (Appendix 3.1).  MSP for the 1B promoter used primers desribed by 
Esteller et al (2000) (Appendix 3.2).    
 
3.2.4 RNA Studies:  Allelic Imbalance (AI) and Splicing 
Abnormalities 
45 NMI patients and 4 unaffected relatives (Halo75, Halo76, Halo77 and Halo78) 
underwent studies on DNA and RNA to screen for APC +/- MUTYH RNA AI.  All of 
the work done with MUTYH was carried out by myself.  I carried out the APC AI 
work on 22 samples.  The remaining work was completed by Alice Davies and Alice 
Bolton, intercalating medical students (Davies A 2015, Bolton A 2016), and Julie 
Maynard, research assistant, Cardiff University.  
 
To screen for AI, common non-pathogenic exonic SNPs were identified in APC and 
MUTYH, using UCSC Genome Bioinformatics (http://genome.ucsc.edu/cgi-
bin/hgTracks?db=hg19&position=chr1%3A45794914-
45806142&hgsid=414232457_bzuux4uOZeA1wBLT5vBhLtb6YSg9) and NCBI 
dbSNP software (http://www.ncbi.nlm.nih.gov/projects/SNP/) (accessed 
26/11/2014).  The APC SNPs were rs2229992, rs351771, rs41115, rs42427, 
rs866006 and rs465899.  The MUTYH SNPs were rs3219489 and rs3219497 (full 
details in Appendix 3.3). 
 
Comparison was made of the sequence at each of these SNPs in the patient’s 
gDNA and their cDNA. If a patient was heterozygous for a common SNP in the 
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germline but was found to be hemizygous for either allele in cDNA, this was 
suggestive of allelic imbalance. 
 
3.2.4.1 gDNA analysis 
gDNA analysis was initially carried out by examining the UDS results (3.2.5).  Any 
heterozygous SNPs identified were validated with Sanger Sequencing.  One of the 
SNPs, rs465899, was not covered adequately through UDS, therefore Sanger 
sequencing was performed on all patients for this locus.  Sanger sequencing and 
sequence analysis were undertaken using standard reagents and reaction 
conditions (2.3.8.1, 2.3.8.5, 2.3.9-2.3.13).  Primers were those used by the AWMGS 
(Appendix 3.4).  Two samples required optimisation (Appendix 3.5). 
 
3.2.4.2 RNA Analysis 
RNA analysis involved reverse transcription to cDNA (2.3.3.2), PCR with gene 
specific primers (Appendix 3.6), and sequence analysis. Standard protocols and 
reaction conditions were used (2.3.8.1, 2.3.8.5, 2.3.9-2.3.13).  Only those SNPs 
which were confirmed to be heterozygous in the germline were examined in the 
RNA, as homozygous SNPs do not yield any discriminating information.  PCR 
conditions were optimised as shown in Appendices 3.7 (APC) and 3.8 (MUTYH). 
 
3.2.4.3 APC and MUTYH Splicing Abnormalities 
45 NMI patients underwent sequencing of APC +/- MUTYH cDNA to screen for 
splicing abnormalities.  All MUTYH sequencing was carried out by myself.  I carried 
out the APC cDNA sequencing for 17 samples.  The remaining work was completed 
by Alice Davies and Alice Bolton, intercalating medical students (Davies A 2015, 
Bolton A 2016), and Julie Maynard, research assistant, Cardiff University.  
 
3.2.4.3.1 APC cDNA Sequencing 
RNA was reverse transcribed (2.3.3.2) and cDNA underwent PCR with gene 
specific primers (Appendix 3.9). Standard reagents and reaction conditions were 
  
 101 
employed for PCR and sequencing (2.3.8.1, 2.3.8.5, 2.3.9-2.3.13).  The details for 
the samples which required optimisation are in Appendix 3.10. 
 
3.2.4.3.2 MUTYH cDNA Sequencing 
MAP is an autosomal recessive (AR) disease.  Even if abnormal splicing is found in 
one allele, there would need to be a pathogenic variant present in the other allele for 
manifestation of polyposis.  In view of this, a small study was initially performed on 9 
NMI polyposis patients, in order to optimise reaction conditions.  These were the 
first study participants that RNA was available for.  Subsequently, MUTYH cDNA 
sequencing was completed on all those patients who were known to have/ 
potentially have a pathogenic variant present affecting MUTYH: 
 
 Known monoallelic carriers of a MUTYH mutation 
o Halo40 
o Halo41 
 Potentially reduced expression of MUTYH (3.3.1) 
o Halo36 
o Halo63 
o Halo71 
 
RNA was reverse transcribed (2.3.3.2) and cDNA underwent PCR with gene 
specific primers (Appendix 3.11). Standard reagents and reaction conditions were 
employed for PCR and sequencing (2.3.8.1, 2.3.8.5, 2.3.9-2.3.13).  The details for 
the samples which required optimisation are in Appendix 3.12. 
 
3.2.5 APC and MUTYH Capture and Ultradeep Sequencing 
(UDS) 
UDS was performed for the whole genomic loci of APC and MUTYH 
(chr5:112042936-112186350, chr1:45794202-45807013) to identify mutations 
outside of the ORF and to identify APC mutations which occur at a low frequency 
within an individual.  It was carried out on DNA extracted from whole blood (2.3.2).  
Target sequence capture was achieved using the Haloplex assay (2.4.1).  
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Sequencing was performed by the Wales Gene Park (WGP) using the HiSeq 2500 
(2.4.2). 
82 individuals underwent UDS: 
 60 NMI polyposis patients (Table 2.1) 
 11 healthy controls (Tables 2.1 and 2.2): Halo02, Halo03, Halo09, Halo11, 
Halo73, Halo74, Halo75, Halo76, Halo77, Halo78, and Halo95 
 11 positive control samples (Table 2.2): 8 FAP patients (Halo01, 
F014_M_004_1, F014_M_005_1, F014_M_006_1, Halo10, Halo12, Halo16, 
Halo42 (also carries a monoallelic MUTYH mutation) and 3 MAP patients 
(Halo37, Halo39, Halo59) 
 
Bioinformatic analysis was performed by Dr. Peter Giles, WGP (2.4.3). 
 
3.2.5.1 Variant Analysis and Selection 
Variants of interest were selected using the following criteria: 
 
 Rare variants, with an allele frequency </= 1% according to dbSNP data or 
The 1000 Genomes Project data 
 Variants which were present in all affected family members 
 Synonymous variants were excluded  
 Variants which had been identified previously by the AWMGS diagnostic 
service and which were known to be non-pathogenic were excluded   
 Variants found in unaffected relatives/ healthy controls were excluded, taking 
into account the mode of inheritance (i.e. if a patient was found to be 
homozygous for a MUTYH variant, it was only excluded if it was also 
homozygous in an unaffected relative/ healthy control).  
 Exonic missense variants present in <2% of reads which were identified in 
multiple samples were excluded as they were likely to represent sequencing 
artefacts 
 
All shortlisted variants were then analysed using CADD software 
(http://cadd.gs.washington.edu/home) and were assessed using the Integrative 
Genomics Viewer (IGV) (https://www.broadinstitute.org/igv/).  Variants which had a 
CADD score >/= 15 were validated with Sanger sequencing.  
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3.2.5.2 Validation of Identified Variants 
Variants were validated with Sanger Sequencing, using standard reagents and 
reaction conditions (2.3.8.1, 2.3.8.5, 2.3.9-2.3.13).  Primers are listed in Appendix 
3.13. Variants present at a low frequency (<20%) were validated with COLD-PCR, 
using the full- or fast- standard protocol depending on the nature of the variant 
(2.3.8.3, 2.3.8.4, 2.3.8.6, 2.3.8.7). 
 
3.3 Results 
 
3.3.1 Quantitative PCR (qPCR): APC and MUTYH Expression 
A total of 92 samples underwent successful qPCR to determine levels of APC and 
MUTYH transcription:  40 healthy controls, 45 NMI polyposis patients, 3 FAP 
controls and 4 MAP controls (2.3.16, 2.2.3.5, Table 3.1). One of the FAP controls, 
FAPPol51, had an APC promoter deletion known to impair APC transcription.  The 
sample was used as a positive control to ensure that the assay was capable of 
detecting reduced APC transcription.  The remaining FAP and MAP controls all had 
genetic variants which did not affect gene transcription:  they were included as 
negative controls to confirm that the assay identified that APC and MUTYH RNA 
levels were within the normal range. 
 
The results for the control samples were largely as anticipated, although one of the 
FAP controls who also carries a monoallelic MUTYH mutation, Halo42, appeared to 
have reduced MUTYH transcription, although this was not statistically significant 
(Table 3.2). 
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The individual results for all the NMI patients are in Appendix 3.14 . 
Four patients were found to have APC Rq values below 0.6:  Halo46, APC Rq= 
0.563 (p=0.09); Halo52, APC Rq=0.368 (p=0.003); Halo53, APC Rq=0.545 
(p=0.07); Halo64, APC Rq=0.417 (p=0.01).  These results were confirmed by 
repeating the experiment from the initial reverse transcription reaction (Table 3.3).   
 
Three patients had MUTYH Rq values below 0.6.  Although these results are 
interesting, they do not have the same clinical implications as do the APC gene 
transcription results.  MAP is an AR disease, therefore reduced transcription of one 
allele alone would not explain a clinical phenotype.  In addition to this, a negative 
control was also observed to have an apparently reduced MUTYH Rq value 
(although this was not statistically significant), a positive control was not available, 
and only the Rq value for Halo36 reached statistical significance, with p=0.03.  The 
results were not repeated, but these patients were selected for further RNA studies 
(cDNA sequencing, 3.2.4.3.2) to determine whether they had any further potentially 
disease-causing genetic aberrations.  
 
The phenotype of those patients with an Rq value </= 0.6 is summarised in Table 
3.3: 
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Patient 
Identification 
APC/ MUTYH 
Rq Value 
Repeat Result Clinical Phenotype 
Halo46 APC Rq = 0.563  * 
44-year-old female who 
clinically has FAP and 
who has undergone a 
colectomy and 
proctectomy 
Halo52 APC Rq = 0.368 APC Rq = 0.400 
59-year-old male with 
>1000 adenomas   
Halo53 APC Rq = 0.545 APC Rq = 0.527 
51-year-old male with 
approximately 400 
adenomas and CRC at 
age 27   
Halo64 APC Rq = 0.417 APC Rq = 0.291 
54-year-old female with 
thousands of colorectal 
adenomas and a caecal 
carcinoma at age 23 
Halo36 
MUTYH  
Rq = 0.41 
 
67-year-old male with >10 
adenomas   
Halo63 
MUTYH Rq = 
0.509 
 
68-year-old male with at 
least 24 polyps  5 biopsies 
show 4 adenomas and 1 
HPP 
Halo71 
MUTYH Rq = 
0.508 
 
65-year-old female with 
14 adenomas 
 
Table 3.3:  Phenotypes of patients with evidence of reduced transcription of APC/ MUTYH   
 
*Repeat testing was not carried out for Halo46, as the causative mutation was identified 
(3.3.5.3). 
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3.3.2 Karyotype Analysis 
Karyotype analysis was performed on Halo52 and Halo53, both of whom appeared 
to have evidence of reduced APC expression.  Both had normal chromosome 
complements.  Unfortunately, patient Halo64 has been lost to follow up, so it was 
not possible to obtain a fresh blood sample.  Halo46 did not undergo karyotyping as 
a pathogenic mutation was identified (see section 3.3.5.3). 
 
3.3.3 Promoter Methylation Studies 
Methylation analysis of the APC 1A and 1B promoters was performed on 3 patients 
with reduced APC transcription (Halo52, Halo53 and Halo64) and the unaffected 
mother of Halo53.  It was not done for Halo46 as the pathogenic mutation was 
identified (section 3.3.5.3).  Methylation studies were also performed for NMI 
patients with any evidence of APC AI (section 3.3.4.1):  Halo08 and her affected 
son, Halo51 and her unaffected parents. 
 
There was no evidence of promoter methylation for either promoter: 
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                            M primers   U primers   M primers   U primers 
                     
 
Figure 3.2.  MSP for APC promoter 1A.  All samples, apart from the control methylated DNA 
(M DNA:  red arrow), produce a PCR product following MSP using primers specific for 
unmethylated DNA (U primers).  This is demonstrated by the high intensity of the bands.  
The only PCR product obtained when MSP was undertaken using primers specific for 
methylated-DNA (M primers) was that from the control methylated DNA sample (M DNA:  
yellow arrow), as shown by the high intensity band. 
 
M primers M primers     U primers     U primers 
 
 
Figure 3.3  MSP for APC promoter 1B.  All samples, apart from the control methylated DNA 
(M DNA:  yellow arrow), produce a PCR product following MSP using primers specific for 
unmethylated DNA (U primers) (there was a product for Halo52, although the PCR band was 
fainter than those obtained for the other samples).  The only PCR product obtained when 
MSP was undertaken using primers specific for methylated DNA (M primers) was that from 
the control methylated DNA sample (M DNA:  red arrow).  The bands which are smaller than 
the PCR products represent primer-dimers. 
Ladder                         Ladder 
1. Halo53  9.    Halo08 Son 
2. Halo53 Mother 10.  Control M DNA 
3. Halo52  11.  Control U DNA  
4. Halo64 
5. Halo51 
6. Halo51 Mother 
7. Halo51 Father 
8. Halo08 
   
 
Ladder 
1. Halo53 
 
2. Halo53 Mother 
 
3. Halo52 
 
4. Halo64 
 
5. Halo51 
 
6. Halo51 Mother 
 
7. Halo51 Father 
 
8. Halo08 
Ladder 
9. Halo08 Son 
 
10. Control M DNA 
 
11. Control U DNA 
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3.3.4 Allelic Imbalance Studies  
Allelic Imbalance (AI) studies were completed on 45 NMI patients and 4 unaffected 
relatives for whom high quality RNA samples were available (Halo75, Halo76, 
Halo77, Halo78). 
 
3.3.4.1 APC Allelic Imbalance 
Of the 45 patient samples, 22 had informative results, i.e. the presence of at least 
one heterozygous SNP in the germline.  A total of 4 patients displayed AI: 18% of 
the informative cohort, or 9% overall.  The patients were Halo08 and Halo51 (both 
had AI at the final SNP and visual inspection of the sequencing traces were 
suggestive of one allele having a weaker signal at some of the preceding SNPs), 
Halo52 (AI at first SNP only.  The subsequent SNPs were uninformative) and 
Halo53 (AI throughout). All of the individual patient results are in Appendix 3.15.  
The sequencing results for the SNPs exhibiting AI are in Appendix 3.16. 
 
Patients Halo52 and Halo53 had results which would be consistent with absent 
expression from one allele, which may result from a promoter lesion (Charames et 
al 2008).  This was concordant with their gene expression results (3.3.1).  It is noted 
that patient Halo53 did display tiny peaks of the alternate allele at SNPs rs41115 
and rs866006 (Appendix 3.16).  Whilst this may represent a sequencing artefact, it 
is possible that this allele was being expressed at such low levels that it was not 
reliably detected with Sanger sequencing. 
 
Patients Halo08 and Halo51 displayed complete loss of signal for one allele at the 
final SNP only.  This could possibly result from allele specific transcription 
termination or mRNA degradation, the presence of an allele specific alternate 
transcription start site (Wagner et al 2010) or it could represent a sequencing 
artefact.  There also appeared to be an abnormal allelic expression ratio at some of 
the preceding SNPs.  These findings were confirmed by repeating the experiments 
(Appendix 3.17).  The significance of these findings was not confirmed.   
 
The parents of Halo51 and Halo53 did not exhibit AI.  
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3.3.4.2 MUTYH Allelic Imbalance 
45 NMI polyposis patients underwent MUTYH AI studies.  16 had informative 
results.  There was no evidence of AI in any sample.  The full results are in 
Appendix 3.18. 
 
3.3.5 APC and MUTYH Splicing Abnormalities 
APC cDNA sequencing was completed on 45 patients.  There was no evidence of 
any splicing abnormalities.  
MUTYH cDNA sequencing was completed on 14 patients, including those with a 
monoallelic MUTYH mutation and those with potentially reduced MUTYH 
expression.  There was no evidence of any splicing abnormalities.   
 
3.3.5 APC and MUTYH Capture and Ultradeep Sequencing 
(UDS) 
The Haloplex assay was used for targeted capture of the whole of the APC and 
MUTYH genomic loci, followed by UDS using the HiSeq 2500 (Illumina) (Three 
samples had undergone sequencing using the MiSeq (Illumina) before the HiSeq 
2500 was being utilised: F014_M_004_1, F014_M_005_1, F014_M_006_1). 
 
3.3.5.1 Coverage of Ultradeep Sequencing 
The average depth of coverage of APC and MUTYH using the HiSeq 2500 was 
1665.5x and 2575.2x respectively.  The mean on-target coverage for APC was 
97.2% and for MUTYH it was 97.3%.  For APC, regions with consistently low 
coverage (<50 reads) occurred in exons 3 (65 bp), 5 (65 bp, 14bp), 6 (27 bp) and 15 
(9 bp, 11 bp, 15 bp, 14 bp, 65 bp, 23 bp).  There were 2 small areas with 
consistently no coverage: 16 bp of exon 5 and 52 bp of exon 15.  For MUTYH there 
were 9 bp of exon 12 with low coverage.  The detailed coverage for each individual 
patient is recorded in Appendices 3.19 (APC) and 3.20 (MUTYH). 
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3.3.5.2 Control Results 
The Haloplex assay followed by UDS identified all 15 known variants in APC or 
MUTYH.  This included 8 FAP controls, one of whom also carried a MUTYH variant 
(Halo42), 3 MAP controls, a previously confirmed APC variant in Halo33 and 
previously confirmed MUTYH variants in Halo40 and Halo41.  These variants and 
the coverage are described in Table 3.4: 
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Sample 
Identification 
Gene Variant  
Mean Coverage of 
Gene with Variant 
F014_M_004_1 APC c.2805C>A  2410 
F014_M_005_1 APC c.4393-4394delGA  3118 
F014_M_006_1 APC 
5% mosaic APC c.4393-
4394delGA  
2421 
Halo01 APC c.3631-3632delAT 723 
Halo10 APC c.3183-3187delACAAA 328 
Halo12 APC c.3927-3931delAAAGA 182 
Halo16 APC c.3408delA 236 
Halo33 APC c.6363-6365dupTGC 235 
Halo42 APC c.1133dupA 408 
Halo37 MUTYH 
Compound heterozygote: 
c.536A>G & c.649C>T  
3994 
Halo39 MUTYH 
Compound heterozygote: 
c.303G>T and c.312C>A  
638 
Halo40 MUTYH c.920G>A heterozygote 2443 
Halo41 MUTYH c.1187G>A heterozygote 7636 
Halo42 MUTYH c.536A>G heterozygote 604 
Halo59 MUTYH c.1187G>A homozygote 3387 
 
Table 3.4:  Control samples used for validating Haloplex capture and UDS 
3.3.5.3 Patient Results 
60 NMI polyposis patients underwent UDS of APC and MUTYH. 15 variants   
selected for validation/ further investigation are listed in Appendix 3.21.  Variants 
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present in >20% of reads were validated with standard Sanger sequencing following 
standard PCR protocols (Appendix 3.22).  Low frequency variants, present in <20% 
of reads, were amplified with COLD-PCR prior to Sanger sequencing (Appendix 
3.23).  Validation was not carried out if the variant had been previously identified by 
the AWMGS.   
 
Table 3.5 summarises the variants which were validated. 
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Sample 
ID 
Gene Position Variant Location Effect 
Additional 
Information 
CADD 
Score 
Halo23 APC 
5: 
112043492 
C>A 
5’UTR/ 
Exon 1  
N/A None 21.1 
Halo30 APC 
5: 
112102960 
C>T Exonic 
Misse
nse 
Validated by 
NHS 
34 
Halo35 APC 5:112104652 T>A Intronic N/A None 18.02 
Halo46 APC 
5: 
112043225 
G>A 5'UTR N/A None 22.4 
Halo51 APC 
5: 
112095775 
T>A Intronic N/A None 16.36 
Halo56 APC 
5: 
112043282 
C>CG 5’UTR N/A None 16.52 
Halo62 APC 
5: 
112162474 
C>T Intron N/A None 18.98 
Halo66 APC 
5: 
112163697 
A>C Exonic 
Misse
nse 
Validated by 
NHS 
25.4 
Halo71 APC 
5: 
112102960 
C>T Exonic 
Misse
nse 
Validated by 
NHS 
34 
Halo40 MUTYH 1: 45797851 C>T Exonic 
Misse
nse 
Validated by 
NHS.  Patient 
only has one 
pathogenic 
mutation 
20.4 
 
Table 3.5 Validated APC and MUTYH variants  
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All the variants which appeared to be approximately heterozygous were validated. 
None of the low frequency variants were definitely real, although one was uncertain, 
a missense exonic variant in sample Halo45, present in 4% of reads.  A truncating 
APC exonic variant in Halo63 was not validated with Sanger sequencing.  However, 
there was low coverage at this locus with NGS, with the variant being present in only 
2/11 reads, so it is likely to be an artefact.  The validated variants will be appraised in 
the Chapter Discussion (3.4.3.2). 
 
Table 3.6 summarises the key positive findings from Chapter 3: 
 
Unique 
Identifier 
 
qPCR: 
APC 
Rq 
Karyotype 
Analysis 
 
APC 
Promoter 
Methylation 
APC AI 
APC cDNA 
Sequencing 
APC UDS 
Halo46 0.563 N/A N/A Uninformative Normal 
Chr5: 
112043225 
G>A 
Halo52 0.368 Normal Normal 
AI at first 
SNP 
Normal Nil 
Halo53 0.545 Normal Normal AI throughout Normal Nil 
Halo64 0.417 Not done Normal Uninformative Normal Nil 
 
Table 3.6  Key positive results from all APC and MUTYH studies 
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3.4 Discussion 
This study involved investigating patients with multiple colorectal adenomas (>10) 
who had no mutation identified (NMI) in APC or MUTYH during routine clinical 
diagnosis.  The aim of this chapter was to identify missed or novel genetic variants 
in APC or MUTYH responsible for tumourigenesis.  I sought to identify such variants 
through a combination of: 
 
 Quantitative PCR (qPCR) to interrogate APC and MUTYH transcription 
 gDNA/ cDNA sequencing to screen for allelic imbalance (AI) 
 cDNA sequencing of the coding sequences of APC and MUTYH to 
screen for splicing abnormalities 
 Ultradeep sequencing (UDS) of the whole of the APC and MUTYH genes 
to identify variants outside of the ORF and APC low frequency variants 
 
DNA samples were available for all 60 patients, and RNA samples were available 
for 45 NMI polyposis patients.  
 
3.4.1 Gene Expression Studies and Allelic Imbalance 
RNA studies yielded interesting results for 7 patients:  4 appeared to have reduced 
APC transcription and 3 appeared to have reduced MUTYH transcription.  The 4 
patients with reduced APC transcription all had phenotypes in keeping with a clinical 
diagnosis of FAP.  The gene transcription results were concordant with the AI 
results in Halo52 and Halo53, while AI studies were uninformative in Halo46 and 
Halo64. 
The cause of the reduced APC expression was determined in Halo46.  UDS 
identified a 5’UTR variant (G>A at 5:112043225), at position c.-190G>A.  This 
variant is predicted to be pathogenic, with a CADD score of 22.4.  The patient has a 
strong family history of polyposis/ CRC, with the inheritance pattern suggestive of 
an autosomal dominant trait: 
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Figure 3.4 Family tree of Halo46.  Halo46 is marked with a black circle 
   
At the time this variant was identified in the index case, a paper was published 
which describes the exact same variant (Li et al 2016).  The variant occurred in a 
family with 5 affected patients, over 3 generations, with polyposis and/ or CRC.  The 
group performed electromobility shift assays (EMSA) to show that the mutation led 
to reduced protein binding, and that the protein likely to be affected was the 
transcription factor YY1.  Further work demonstrated that carriers of the mutation 
also showed AI of APC.  The work described by Li’s paper supports the 
pathogenicity of the variant identified in Halo46.  Furthermore, we were able to 
recruit the patient’s father and one cousin, both whom have clinical FAP.  Both were 
found to carry the same mutation. qPCR of APC cDNA levels was also performed:  
the Rq value was 0.55 when compared to the healthy control cohort for the father, 
and 0.63 for the cousin.  I tried to recruit further family members to further 
investigate whether the variant was segregating with the disease phenotype, but 
unfortunately was unable to do so during the time course of this project.  However, 
this research finding is being translated into clinical practice, and the AWMGS are 
establishing predictive genetic testing for this specific mutation in members of the 
extended family.  As far as we are aware, Halo46 does not have a gastric 
phenotype.  This is an interesting observation, as point mutations in the APC 1B 
promoter are reported to result in gastric neoplasia (Li et al 2016).  It is possible that 
Halo46 actually does have such a phenotype, but that we do not know about - for 
example if she has not attended upper gastrointestinal (UGI) endoscopic 
surveillance, or if she has attended UGI endoscopy but the associated endoscopic 
reports/ histopathological reports were not sent to the AWMGS for inclusion in the 
Key 
 
   Clinical FAP 
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genetics  notes.  Alternatively, she may lack gastric neoplasia if her gastric mucosa 
is 'protected' in some way.  The APC 1B transcript is usually more important than 
the 1A transcript in the stomach (reviewed in Li et al 2016) but it is possible that in 
this family, the 1A transcript plays a significant role.  Gastric protection could also be 
the result of environmental factors such as the biome.  It is also feasible that this 
specific mutation has a low/ incomplete penetrance in the stomach or has variable 
expressivity, mediated through the effects of modifier genes. 
 
I sought to determine the cause of the reduced gene transcription in the remaining 3 
samples.  Karyotype analysis was normal for Halo52 and Halo53, and there was no 
evidence of promoter methylation for any of the 3 patients.  If further evidence 
regarding the lack of promoter methylation was required, additonal techniques to 
confirm this would include pyrosequencing or qPCR.  UDS results did not identify 
any variants which could underpin abnormal transcription.  The cause of the 
reduced gene transcription was therefore not apparent.  There are several possible 
explanations for this phenomenon, including upstream/ enhancer variants which 
were not captured by the Haloplex assay, abnormalities in transcription factor(s), 
variants in further genes which are modulating gene expression and epigenetic 
effects.  All 3 patients underwent whole exome sequencing (Chapter 4) but further 
investigation into the reduced gene transcription was beyond the scope of this 
project.  We shall recommend that the patients undergo whole genome sequencing 
with the aim of searching for variants in the regions of the genome which have not 
yet been interrogated. 
 
Three patients appeared to have a reduction in MUTYH transcription (Halo36, 
Halo63 and Halo71), although only the result for Halo36 was statistically significant.  
All AI results were uninformative.  However, even if the reduced transcription is real, 
this alone would not explain the patients’ phenotypes, as MAP is an AR disease, 
and there would have to be a pathogenic change in the second allele:  in all three 
cases MUTYH cDNA sequencing showed no splicing abnormalities, and UDS did 
not reveal any pathogenic MUTYH variants.  Furthermore, reduced MUTYH 
transcription was also observed in a negative control sample, and it was not 
possible to identify a positive control, so the results are weak and are unlikely to be 
clinically significant. 
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To investigate transcription levels of APC and MUTYH it was necessary to 
determine the range of transcription of these genes in a healthy control cohort. 
Gene transcription studies were carried out on 40 unaffected individuals to generate 
this data.  To improve the reliability of the results, it would be necessary to increase 
the population size of healthy individuals.  If large-scale data were obtained, its 
validity would be more certain, and this could offer the possibility of gene 
transcription studies being performed in a diagnostic setting.  At the moment, it is 
cautiously suggested that gene transcription studies could be considered as a 
screening test in NMI patients, but that they need to be interpreted in the context of 
additional investigations such as AI studies and whole gene sequencing.   
 
Gene transcription studies were carried out using one probe for each gene.  For 
APC, the probe spanned the junction between exons 12 and 13 (HS01568269_m1) 
and for MUTYH the probe spanned exons 14 and 15 (HS01014856_m1).  For any 
clinical screening test, it is suggested that more than one probe would need to be 
used.  This was not possible during this project because of financial implications.  A 
cut-off value of Rq = 0.6 was chosen to try and identify patients with clinically 
significant reduced gene transcription.  It is important to be aware that this is an 
arbitrary value, and more accurate determination of a clinically significant threshold 
would need to be determined through large-scale studies.  
 
The AI studies identified APC AI in 4 samples:  18% of the informative cohort.  In 2 
patients, Halo52 and Halo53, it appeared to be across the whole allele.  In 2 
patients, Halo08 and Halo51, it was definite at the final SNP only.  When patients 
appeared to have lost a complete allele, this correlated with their gene expression 
results (Halo52 and Halo53).  However, there was no correlation for those patients 
who appeared to have lost the 3’ end of the allele.  The APC Rq values for patients 
Halo08 and Halo51 were 0.869 and 0.826 respectively, so even if there is a 
reduction in transcription from one allele, the overall amount of cDNA present 
appears to be within the normal range.  It is interesting to note that both Halo08 and 
Halo51 both have relatively strong phenotypes:  Halo08 has 629 adenomas and 
Halo51 has 208 adenomas.  In view of this, it might be expected that there could be 
reduced transcription from one allele, however the qPCR results did not support this 
finding, and the clinical implications of loss of the final SNP are uncertain.  
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3.4.2 Abnormal Splicing 
cDNA analysis did not identify any splicing abnormalities in APC or MUTYH.  
However, the sample size was relatively small (45 patients for APC and 14 for 
MUTYH) and the patients’ phenotypes were highly variable.  It has previously been 
reported that 8% of NMI polyposis patients have an aberrant APC transcript (Spier 
et al 2012). However, all of Spier’s index patients had at least 20 synchronous or 40 
metanchronous adenomas.  In the patient cohort for this study, it is not often clear 
from the patient notes whether the polyps were synchronous or metanchronous.  
The RNA samples obtained account for a maximum of 22 patients with at least 20 
adenomas, so the phenotype of this study cohort is weaker.  
  
cDNA sequencing for APC is a cheap technique to perform, so it is suggested that it 
forms part of the investigative protocol for NMI patients with an appropriate 
phenotype, for example those with at least 20 adenomas.  MUTYH cDNA 
sequencing proved difficult to optimise.  MAP is an AR disease, so even if any 
samples with abnormal MUTYH splicing had been identified, this alone would not be 
sufficient to explain the phenotype.  Whilst MUTYH cDNA sequencing may be a 
useful tool in patients who are already known to carry one pathogenic MUTYH 
variant, it is unlikely to be cost and time efficient if it were performed on all NMI 
polyposis patients. 
 
3.4.3 Ultradeep Sequencing 
A total of 15 variants were identified for further investigation/ validation, 14 in APC 
and 1 in MUTYH.  4 had been previously validated by the NHS, including the 
monoallelic MUTYH mutation, which is known to be pathogenic.   
Four of the APC variants were of very low frequency (present in <5% of reads), and 
one was at low frequency (present in 18% of reads).  None of the 5 low frequency 
reads were validated.  All of the variants which appeared to be approximately 
heterozygous were validated.   
 
3.4.3.1 Validation of Low Frequency Variants 
The Haloplex assay followed by UDS identified 5 very low/ low frequency variants.  
Whilst such variants may represent sequencing artefacts, they could also result 
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from the patient exhibiting generalised mosaicism.  This study sought to validate 
such variants using COLD-PCR, which is a technique that can be used to enrich 
samples for low-abundance DNA mutations (Milbury et al 2011).  The technique 
selectively amplifies low-abundance variants from mixtures of wild-type and mutant-
containing sequences by using a critical denaturation temperature.  A lower 
denaturation temperature allows the selective denaturation of amplicons which 
contain mutant/ wild type heteroduplexes or which contain Tm-reducing variants 
(Milbury et al 2011), so that they are preferentially amplified.  It is reported that 
COLD-PCR followed by Sanger sequencing can be used to identify mutant fractions 
down to 0.1%, but it is noted that enrichment potential is highly dependent upon the 
type of mutation being analysed, the initial mutation abundance, and the PCR 
platform utilised (Milbury et al 2011). 
 
None of the low frequency APC variants were definitely validated, although the 
result was ambiguous for sample Halo45. It is likely that they are sequencing 
artefacts from the UDS protocol, however it is also possible that the COLD-PCR 
reactions employed were not sufficiently sensitive to detect them.  Fortunately, most 
of the variants examined were missense changes.  Even if they had been real, such 
low frequency missense APC variants in an individual are unlikely to have a clinical 
impact (Cleary et al 2008).  There was a stop-gain variant present in Halo63 which 
was not validated.  However, it was only present in 2/11 reads and there was no 
evidence of it at all with Sanger sequencing, so it highly likely to be a sequencing 
artefact.  If more sensitive validation of low frequency variants was required, it would 
be necessary to consider an alternative technique such as digital droplet PCR. 
 
3.4.3.2 Validated Variants 
A total of 10 potentially pathogenic APC or MUTYH variants were identified by UDS 
and validated with Sanger sequencing (Table 3.5) .   
 
3.4.3.2.1 Validated Variants in APC 
All exonic variants occurring in APC had previously been identified by the NHS 
diagnostic service.  They were all putative missense variants which were of 
uncertain pathogenicity.  Pathogenic APC mutations are usually truncating 
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mutations, and there is currently minimal evidence that missense variants are 
clinically significant (Cleary et al 2008).  
 
Sample Halo23 has a variant in the untranslated region of exon 1.  She has no 
evidence of AI, gene expression studies were normal with APC Rq = 0.804 and 
there was no evidence of abnormal splicing.  Although the CADD score for this 
variant was 21.1, it has recently been classified as a benign variant on ClinVar 
(http://www.ncbi.nlm.nih.gov/clinvar/variation/133505/ accessed 3/5/16). 
 
Halo35 has an APC intronic variant.  Its CADD score is relatively low, at 18.02.  
There is no evidence of abnormal expression, with APC Rq = 0.894, and there was 
no evidence of abnormal splicing or allelic imbalance, so the variant is regarded as 
likely non-pathogenic. 
 
Sample Halo46 has a 5’UTR variant and evidence suggestive of reduced APC 
transcription.  She has been discussed above and this variant is believed to be 
pathogenic. 
 
Sample Halo51 has an intronic APC variant, rs4705624.  This has a CADD score of 
16.36, and there is one submission on ClinVar 
(http://www.ncbi.nlm.nih.gov/clinvar/variation/82836/ accessed 01/03/16) in which it 
is given a classification of ‘other’ in the context of familial colorectal cancer.  The 
patient exhibited loss of the final APC SNP, but there was no evidence of abnormal 
splicing.  DNA was initially only available for the patient’s mother:  the variant was 
not present.  However, once DNA was obtained for the patient’s unaffected father, 
the same variant was present, so the variant has been regarded as non-pathogenic. 
 
Sample Halo56 has an APC 5’UTR variant with a CADD score of 16.52.  There is 
no evidence of reduced APC expression, with APC Rq = 0.793. AI studies are 
uninformative.  Once the patient’s parents had been recruited to the study the 
variant was identified in the unaffected father, so it has been regarded as non-
pathogenic.  
 
Sample Halo62 has an intronic variant with a CADD score of 18.98.  There is no 
evidence of reduced APC expression, with APC Rq = 0.766, and AI studies show no 
evidence of AI.  There is no abnormal splicing.  Taking into account these findings, 
the variant has been assumed to be non-pathogenic. 
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3.4.3.2.2 Validated Variants in MUTYH 
The final variant was identified in MUTYH in sample Halo40.  This is one of the 
recurrent MUTYH mutations known to cause MAP, p.Gly396Asp.  The patient is a 
carrier of a monoallelic mutation, so this by itself cannot explain the polyposis 
phenotype.  The patient had no evidence of MUTYH AI, reduced gene expression or 
abnormal splicing. 
 
3.4.3.3 Summary of Gene Capture and Ultradeep 
Sequencing 
The Haloplex assay followed by UDS was used to look for variants throughout the 
whole of the APC and MUTYH genomic loci, and to identify any patients who might 
exhibit mosaicism. There are several other available techniques for targeted gene 
capture, including long-range PCR (LR-PCR).  LR-PCR was initially trialled for use 
in this project.  However, it failed to amplify the known mutant alleles from two FAP 
control patients.  Despite carrying out a series of investigations to determine why 
this had occurred, the explanation was not clear.  It is possible that certain 
mutations alter the structure of the DNA in such a way that the polymerase cannot 
replicate the mutant strand.  Instead of LR-PCR, the Haloplex Assay was employed.  
The assay costs approximately £100 per patient sample, which is not prohibitive for 
use in a diagnostic setting.  60 patients underwent UDS of APC and MUTYH.  All 
exonic variants which we filtered for had previously been identified by the NHS, so 
this study did not identify any mutations which had been ‘missed’ in the diagnostic 
setting.  There were 6 variants outside of the ORF which were validated, one of 
which is believed to be pathogenic (the APC 5’UTR variant in Halo46).  The 
remaining variants are regarded as unlikely to be clinically significant once the gene 
expression results, cDNA sequencing and AI studies are taken into consideration.  
This highlights the importance of using a range of investigative techniques, so that 
results are never viewed in isolation.   
 
None of the patients had evidence of APC mosaicism.  The depth of coverage was 
excellent with UDS, so if there were any true cases, it is unlikely to have been 
missed.  It is reported that somatic mosaicism can occur in 10-20% of sporadic 
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cases of FAP (reviewed in Rohlin et al 2009; Hes et al 2008; Aretz et al 2007).  28 
of the patients included in this study are thought to be sporadic polyposis cases, but 
the actual figure may differ from this as the family histories obtained are often 
vague/ missing.   
It is also important to note that analysis has been performed in DNA extracted from 
whole blood.  It is clear from the literature that some patients have mosaic mutations 
which are only present in colonic tissue (Jansen et al 2017), so we would not have 
identified these. 
 
NGS inevitably generates large amounts of data, and a challenge is to identify what 
is clinically significant.  In this thesis, CADD scoring was used as a tool to predict 
pathogenicity.  CADD scoring gives a standardised genome-wide, variant scoring 
metric that incorporates the weighted results of widely used in silico pathogenicity 
prediction tools, such as SIFT and PolyPhen, and of genomic annotation sources 
like ENCODE (reviewed in van der Velde et al 2015). The resulting CADD scores 
are expressed as a measure of deleteriousness (selection pressure bias) for single-
nucleotide variants (SNVs) and small indels (van der Velde et al 2015).  Although 
CADD scores are useful in assisting the prioritisation of identified variants (van der 
Velde et al 2015), it is important to be aware that their sensitivity and specificity will 
never be 100%.  CADD scores should be used in combination with other available 
data such as family segregation studies, functional analysis and literature reviews 
(Schiemann and Stowell 2016) and must not be regarded as the gold standard of 
variant appraisal. 
  
3.4.4 Chapter Conclusions   
60 NMI polyposis patients underwent interrogation of APC and MUTYH to try and 
determine the cause of their genetically unexplained phenotype.  The study 
employed qPCR, AI screening, cDNA sequencing, karyotype analysis, MSP and 
UDS as research tools.  Whilst the gene transcription and AI studies gave 
interesting results suggestive of reduced APC transcription for 4 patients, Halo46, 
Halo52, Halo53 and Halo64, the underlying cause for this was only determined for 
Halo46:  UDS identified a 5’UTR variant in APC. 
 
Although pathogenic variants/ molecular mechanisms of disease were not identified 
for the majority of the patients, the techniques used as part of this study are all 
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relatively cost-effective and could be considered for use in future diagnostic 
protocols for NMI polyposis patients, although further validation in clinical cohorts 
would be necessary. 
 
In Chapter 4 of this thesis, all 60 patients who underwent UDS of APC and MUTYH 
will be subject to UDS of a further 15 genes possibly implicated in the pathogenesis 
of colorectal neoplasia to further investigate the cause of their phenotype.  A subset 
of 24 patients will undergo whole exome sequencing (WES). 
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Chapter 4 Exome Sequencing in 
Polyposis Patients using Targeted 
and Whole Exome Approaches 
4.1 Introduction 
After a detailed examination of APC and MUTYH, the next phase of this study 
focused on exome sequencing.  The initial strategy was to use a targeted approach.  
Targeted exome sequencing of 15 genes associated with colorectal/ intestinal 
neoplasia was performed.  Subsequently, whole exome sequencing (WES) was 
undertaken for a subset of patients. 
 
60 NMI patient samples and 11 relatives/ healthy controls underwent targeted 
exome sequencing of 15 genes:  AXIN2, BMPR1A, CDH1, CHEK2, EPCAM, MLH1, 
MSH2, MSH6, PMS2, POLD1, POLE, PTEN, SMAD4, STK11 and TP53.  The 
relatives/ healthy controls were included to assess whether variants identified in 
NMI patients were occurring de novo and to allow variants to be assigned as likely 
non-pathogenic if they were found in a healthy control, once the mode of inheritance 
was taken into consideration.  Gene capture was achieved using the Haloplex 
Assay and sequencing was performed using the HiSeq 2500 (Illumina).  The 
patients were also screened for recurrent pathogenic NTHL1 mutation, c.268A>T , 
p.Gln90* (Weren et al 2015).  NTHL1 had not been included in the Haloplex assay 
as the assay been designed prior to the publication of Weren’s paper.  Putatively 
pathogenic variants were validated with Sanger Sequencing and confirmed to be 
present in cDNA. 
 
WES was performed on 24 patients.  These were selected based on their 
phenotype, the availability of family members and the results of previous 
investigations completed as part of this study.  Putatively pathogenic variants were 
validated with Sanger sequencing.   
 
4.2 Targeted Exome Screening and Sequencing 
Targeted exome sequencing used the Haloplex Assay for gene capture. The assay 
was designed in 2014, and was based on one of the commercially available CRC 
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gene panels available at the time, produced by AmbryGen: the Colonext NGS panel 
(http://www.ambrygen.com/tests/colonext accessed 20/4/16).  14 of the genes 
included on the study plate were present on the Colonext NGS plate (BMPR1A, 
CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, PMS2, POLD1, POLE, PTEN, 
SMAD4, STK11, TP53). AXIN2 was added based on current evidence that it may 
have a role in the pathogenesis of colorectal neoplasia (Lammi et al 2004; Marvin et 
al 2011; Rivera et al 2014).  The rationale for all of the genes investigated as part of 
this chapter is described below.  
 
4.2.1.1 NTHL1 
NTHL1 is mutated in NTHL1-associated polyposis/ CRC as described in Chapter 1 
(1.5.1.4). 
 
4.2.1.2 BMPR1A and SMAD4 
Bone morphogenetic proteins (BMPs) are part of the TGFβ family.  They bind to 
their receptors, triggering receptor activation, which proceeds to phosphorylate a 
receptor-associated SMAD protein.  This then complexes with SMAD4, which 
translocates to the nucleus to regulate gene transcription (reviewed in Hardwick et 
al 2008) and plays a role in growth inhibition (reviewed in Fleming et al 2013).  The 
BMPR1A gene encodes the BMP-receptor 1A, and SMAD4 encodes the SMAD4 
protein described above.  Germline mutations in both genes are associated with 
impaired growth inhibition and are found in patients with Juvenile Polyposis 
Syndrome (JPS), in which patients develop intestinal hamartomas and have an 
increased risk of CRC (reviewed in Hardwick et al 2008).  Germline BMPR1A 
mutations have also been identified in a 58-year old male patient with ‘multiple’ (8) 
colorectal adenomas (Lipton et al 2003b) and in families with microsatellite stable 
hereditary non-polyposis CRC (Nieminen et al 2011).   
 
4.2.1.3 CDH1 
The CDH1 gene codes for E-cadherin, a member of the cadherin family of cell 
surface glycoproteins (reviewed in Kim et al 2000).  It has roles in embryogenesis, 
polarisation, differentiation and cell migration in inflamed tissue (reviewed in Kim et 
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al 2000).  Importantly, it is also known to be involved in intestinal cancer:  loss of E-
cadherin function is associated with invasiveness, lymph node metastasis and 
distant metastasis (reviewed in Kim et al 2000).  It is well-established that germline 
mutations in CDH1 result in an increased risk of developing hereditary diffuse 
gastric cancer (HDGC) and breast cancer (Pharoah et al 2001).  It has also been 
suggested that inherited CDH1 mutations might increase the risk of an individual 
developing CRC (Richards et al 1999; Kim et al 2000). 
 
4.2.1.4 CHEK2  
The protein product of the CHEK2 gene acts as a checkpoint kinase (reviewed in 
Cybulski et al 2004).  Activation of CHEK2 in response to DNA damage prevents 
the cell from undergoing mitosis (reviewed in Cybulski et al 2004).  It is clear that 
CHEK2 variants can play a role in the pathogenesis of breast cancer (Walsh et al 
2006; Cybulski et al 2004), and there is evidence that CHEK2 variants may also be 
associated with malignancies in multiple other organ systems, including the thyroid 
gland, prostate, colorectum and kidney (Cybulski et al 2004).  In 2007, Cybulski et al 
(Cybulski et al 2007) reported that carriers of a CHEK2 missense variant, 
p.Ile157Thr, had an increased risk of CRC compared to a control cohort (OR = 1.5, 
p = 0.002), and that this specific variant might be responsible for 3% of all CRC in 
Poland.  Very similar results regarding increased CRC risk have also been reported 
in more recent papers investigating Russian populations (Yanus et al 2018), Polish 
populations (Suchy et al 2010) and in Finnish populations (Kilpivaara et al 2006). 
 
4.2.1.5 EPCAM and the MMR Genes:  MLH1, MSH2, MSH6, 
PMS2  
The MMR system involves 7 key genes: MSH2, MSH6, MSH3, MLH1, PMS1, PMS2 
and MLH3.  The role of five of these genes in polyposis, CRC and Lynch Syndrome 
has been described in Chapter 1 (1.3 and 1.5.1.5 ).  
EPCAM is not a MMR gene, rather it is a cell adhesion molecule.  However, it too 
plays an important role in the pathogenesis of Lynch Syndrome.  Patients with 
germline deletions at the 3’ end of the EPCAM gene experience epigenetic silencing 
of MSH2, which is 17kb downstream of EPCAM (reviewed in Tutlewska et al 2013).   
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4.2.1.6 POLE and POLD1 
POLE and POLD1 are mutated in PPAP and have been described in Chapter 1 
(1.5.1.3). 
 
4.2.1.7 PTEN 
PTEN is a tumour suppressor gene: its product is a phosphatase which negatively 
regulates the phosphatidylinositol 3-kinase-AKT and mammalian target of 
rapamycin (mTOR) signalling pathways, which are involved in cell proliferation, cell 
cycle progression and apoptosis (reviewed in Lam-Himlin et al 2014).  PTEN 
mutations are involved in the pathogenesis of several carcinomas, including breast, 
endometrial, thyroid, large bowel and kidney (reviewed in Lam-Himlin et al 2014).  
PTEN mutations are identified in 80% of patients with Cowden’s Syndrome 
(reviewed in Omunsden and Lam 2012), described in Chapter 1 (1.5.3.3). 
 
4.2.1.8 STK11 
The LKB1/ STK11 gene is a nuclear serine threonine kinase which regulates cell 
polarisation, growth and metabolism. Mutations in the gene account for 
approximately 50% of cases of PJS (reviewed in Omunsden and Lam 2012), 
described in Chapter 1 (1.5.3.1).   
 
4.2.1.9 TP53 
The p53 protein is a transcription factor which has a vital role in maintaining 
genomic stability (reviewed in Sarasqueta et al 2013).  Following DNA damage, p53 
activation causes arrest of the cell cycle to allow DNA repair (reviewed in 
Sarasqueta et al 2013).  If the damage is too extensive, p53 can drive a cell towards 
senescence or apoptosis (reviewed in Sarasqueta et al 2013; reviewed in 
Vogelstein and Kinzler 2004).  Somatic p53 mutations are a key event in the 
development of CRC (reviewed in Iacopetta 2003; Vogelstein et al 1988).  Germline 
p53 mutations give rise to Li Fraumeni Syndrome, a highly penetrant cancer 
predisposition syndrome, in which patients develop a variety of early onset tumours, 
including sarcomas, carcinomas, haematological malignancies and brain tumours 
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(reviewed in Gonzalez et al 2009).  CRC is observed in 2.8% of patients with 
germline p53 variants (Gonzalez et al 2009). 
 
4.2.1.10 AXIN2 
It is well established that the majority of CRC are characterised by activation of the 
Wnt signalling pathway.  As described in the previous chapters, nuclear β-catenin 
complexes with DNA-binding proteins of the TCF/ LEF family, which leads to 
enhanced expression of oncogenes involved in tumour progression (reviewed in Wu 
et al 2012).  AXIN2 is a scaffold protein which is involved in regulating Wnt 
signalling.  It forms part of the ‘destruction complex’ which targets β-catenin for 
degradation: AXIN2 supports the GSK3β-dependent phosphorylation of β-catenin, 
which marks the protein for ubiquitination and subsequent proteosomal degradation 
(reviewed in Wu et al 2012).  AXIN2 is a transcriptional target of β-catenin 
dependent Wnt signalling, and AXIN2 levels are elevated in cancers with Wnt 
activating mutations, therefore potentially negatively regulating Wnt signalling 
(reviewed in Mazzoni and Fearon 2014).  There is some evidence that AXIN2 
mutations may have a role in colorectal neoplasia:  this will be described in detail in 
Chapter 5.    
 
4.2.2 Aims and Objectives:  Targeted Exome Sequencing 
The aim of the first part of this chapter was to identify novel genetic variants in 
genes thought to be/ known to be associated with intestinal neoplasia in NMI 
patients with multiple colorectal polyps.  This involved screening for the known 
pathogenic mutation in NTHL1 using Sanger sequencing and examining the exons 
of 15 genes using NGS technologies. 
 
The polyposis patients included in this study are the same 60 patients that 
underwent UDS of APC and MUTYH described in Chapter 3, as are the 11 
unaffected controls (3.2.5). 
 
4.2.3 Methods 
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4.2.3.1 Screening NTHL1 
DNA was extracted from whole blood of 60 NMI patients using standard protocols 
(2.3.2).  PCR and Sanger sequencing was performed using standard reagents and 
reaction conditions (2.3.8.1, 2.3.8.5, 2.3.9-2.3.13) to screen for the recurrent 
polyposis-associated mutation in NTHL1, c.268A>T, p.Gln90*.  The primers were 
designed by Dr. Laura Thomas (Appendix 4.1) who carried out the PCR reactions 
and sequencing. 
 
4.2.3.2 Haloplex Assay and Sequencing 
 
4.2.3.2.1 Targeted Exome Capture, Sequencing and Data 
Analysis 
Targeted exome capture was achieved using the Haloplex assay (Agilent).  The 
probes for the Haloplex assay were designed using Agilent’s Sure Design software 
(https://earray.chem.agilent.com/suredesign/home.htm).  DNA extracted from blood 
samples underwent UDS using the HiSeq 2500, as described in Chapter 2 (2.4.2).  
Bioinformatic analysis followed the protocol detailed in Chapter 3 (2.4.3).  
 
The data was filtered to select for variants which were: 
 
 rare, with an allele frequency </= 1% based on data from The 1000 
Genomes Project 
 not synonymous 
 not known to be benign when investigated using 4 public databases 
(dbSNP, HGMD, InSiGHT and LOVD) 
 present in all affected relatives 
 not present in unaffected relatives (where family members were available 
for analysis)/ not present in healthy controls (the pattern of inheritance was 
taken into account.  For example, when modelling dominant traits, variants 
which were present in a healthy control were excluded; when modelling 
autosomal recessive traits, variants identified in polyposis patients were only 
excluded if they were also homozygous in a healthy control)  
 present in </= 3 samples 
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Variants were then analysed using CADD software 
(http://cadd.gs.washington.edu/home).  Variants which had a CADD score >/= 15 
were validated with Sanger sequencing provided they appeared real when observed 
using Integrative Genomics Viewer (IGV) (https://www.broadinstitute.org/igv/). 
 
4.2.3.3 Validation of Identified Variants 
Variants identified were validated with Sanger Sequencing, using standard reagents 
and reaction conditions (2.3.8.1, 2.3.8.5, 2.3.9-2.3.13). Variants present at a low 
frequency (<20%) were validated with COLD-PCR, using standard protocols 
(2.3.8.3, 2.3.8.4, 2.3.8.6, 2.3.8.7). 
The primers were designed by Marc Naven (Cardiff University) using a combination 
of his own scripts, samtools and primer3 software, and by myself using primer3 
software.  They were supplied by Eurofins (Appendix 4.2). 
 
4.2.3.4 Confirmation of the Variants in cDNA 
RNA was converted to cDNA following standard protocols (2.3.3.2).  DNA 
underwent PCR and Sanger sequencing as per the standard protocol (2.3.8.1, 
2.3.8.5, 2.3.9-2.3.13).  The primers used are listed in Appendix 4.3.  
 
4.2.4 Results 
 
4.2.4.1 Screening for the common mutations in NTHL1 
60 patients were screened for the known pathogenic NTHL1 mutation, c.268A>T, 
p.Gln90*.  This was not identified in any of the patient samples. 
 
4.2.4.2 Haloplex Assay and Sequencing 
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4.2.4.2.1 Metrics of UDS 
The mean depth of coverage was 2900 reads across all 15 genes.  The mean on-
target coverage across all the genes was 98.1%.  The details for each gene are 
listed in Table 4.1: 
Gene Mean Depth of Coverage 
(number of reads) 
Mean On-Target Coverage 
(%) 
AXIN2 2928 100 
BMPR1A 3010 99.6 
CDH1 3627 99.7 
CHEK2 2232 89.3 
EPCAM 2343 100 
MLH1 2876 94.8 
MSH2 2290 97.2 
MHS6 3523 100 
PMS2 2605 98.1 
POLD1 3526 99.9 
POLE 3910 99.8 
PTEN 1834 97.6 
SMAD4 2649 99.9 
STK11 3112 99.8 
TP53 3039 95.5 
 
Table 4.1 Coverage of the 15 genes on the Haloplex assay 
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4.2.4.2.2 Variants Selected for Validation 
60 NMI patients underwent targeted exome capture and UDS.  A total of 33 different 
variants were selected for validation across 32 patients (Table 4.2).  The validation 
sequencing traces are in Appendix 4.4. 
  
1
3
6
 
 
Sample Gene Location Variant Frequency 
CADD 
Score 
Amino Acid Change  
Genomic 
Annotation 
Validated 
Halo05 CHEK2 22: 29091740 C>G 
1335/3023 
(44%) 
26.9 p.Arg406Pro 
nonsynonymous 
SNV 
Yes 
Halo06 
POLD1 19: 50918229 G>A 
1716/3706 
(46.4%) 
22.4 p.Arg849His 
nonsynonymous 
SNV 
Yes 
MSH2 2:47639637 T>A 3/3 (100%) 24.5 p.Leu244Met 
nonsynonymous 
SNV 
No 
Halo07 SMAD4 18:48603114 C>A 
9/890 
(1.01%) 
24.7 p.Pro472Gln 
nonsynonymous 
SNV 
No 
Halo14 CHEK2 22:29107974 C>T 
277/632 
(43.8%) 
24.8 p.Glu239Lys 
nonsynonymous 
SNV 
Yes 
Halo15 POLE 12:133249812 T>C 
22813/45964 
(49.6%) 
24.4 p.Met471Val 
nonsynonymous 
SNV 
Yes 
Halo17 TP53 17:7577117 A>T 
55/3547 
(1.56%) 
29.8 p.Val274Asp 
nonsynonymous 
SNV 
No 
Halo18 POLE 12:133202816 C>T 
310/609 
(50.9%) 
23.8 p.Glu2140Lys 
nonsynonymous 
SNV 
Yes 
Halo20 MSH6 2:48026861 C>T 
7/669 
(1.05%) 
32 p.Ser580Leu 
nonsynonymous 
SNV 
No 
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Sample Gene Location Variant Frequency 
CADD 
Score 
Amino Acid Change  
Genomic 
Annotation 
Validated 
Halo25 CDH1 16:68867388 G>A 
1856/3910 
(47.5%) 
27.8 p.Gly879Ser 
nonsynonymous 
SNV 
Yes 
Halo26 MSH2 2:47630458 A>G 
439/858 
(51.2%) 
26.2 p.Tyr43Cys 
nonsynonymous 
SNV 
Yes 
Halo27 POLD1 19:50919693 C>T 
1081/2232 
(48.5%) 
34 p.Thr954Met 
nonsynonymous 
SNV 
Yes 
Halo28 
AXIN2 17:63534353 T>C 
1147/3499 
(32.8%) 
15.42 p.Ser390Gly 
nonsynonymous 
SNV 
Yes 
MSH2 2:47639633 C>A 
8/767 
(1.04%) 
25 p.Asn242Lys 
nonsynonymous 
SNV 
No 
Halo29 PTEN 10:89720870 T>G 
264/2436 
(10.84%) 
27.9 p.Phe341Val 
nonsynonymous 
SNV 
No 
Halo31 POLE 12:133245032 A>T 
2428/4862 
(49.9%) 
23 p.Phe695Ile 
nonsynonymous 
SNV 
Yes 
Halo35 CHEK2 22:29121042 G>A 
152/3145 
(4.83%) 
16.85 p.Thr215Ile 
nonsynonymous 
SNV 
No 
Halo43 PTEN 10:89720678 A>T 
12/848 
(1.41%) 
25.1 p.Thr277Ser 
nonsynonymous 
SNV 
No 
Halo45 MSH6 2:48026228 C>T 
580/1532 
(37.9%) 
29.5 p.Thr369Ile 
nonsynonymous 
SNV 
Yes 
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Sample Gene Location Variant Frequency 
CADD 
Score 
Amino Acid ChanGlye  
Genomic 
Annotation 
Validated 
Halo46 MLH1 3:37067140 G>T 
7/619 
(1.13%) 
39 p.Gly351* stopgain No 
Halo47 AXIN2 17:63533512 C>A 
357/742 
(48.2%) 
37 p.Gly548* stopgain Yes 
Halo49 MSH6 2:48010592 G>T 8/734 (1%) 36 p.Gly74* stopgain No 
Halo51 PMS2 7:6045634 T>C 
936/2788 
(34%) 
25.6 p.Ile18Val 
nonsynonymous 
SNV 
No 
Halo54  CHEK2 22:29090061 G>A 
71/4620 
(1.5%) 
34 p.Arg474Cys 
nonsynonymous 
SNV 
Yes 
Halo58 MSH6 2:48030603 C>T 
44/4148 
(1%) 
23.8 p.Pro1073Ser 
nonsynonymous 
SNV 
No 
Halo61 POLE  12:133245452 T>C 
3617/6785 
(53%) 
26.0 p.Tyr623Cys 
nonsynonymous 
SNV 
Yes 
Halo62 
CDH1 16:68855966 G>A 
609/1192 
(51%) 
23.9 p.Ala592Thr 
nonsynonymous 
SNV 
Yes 
EPCAM 2:47612347 G>A 
267/922 
(29%) 
29.1 p.Glu301Lys 
nonsynonymous 
SNV 
Yes 
Halo64 BMPR1A 10:88677029 T>G 
19/1240 
(1.5%) 
29.7 p.Phe272Val 
nonsynonymous 
SNV 
No 
  
1
3
9
 
Sample Gene Location Variant Frequency 
CADD 
Score 
Amino Acid ChanGlye  
Genomic 
Annotation 
Validated 
Halo68 AXIN2 17:63533512 C>A 
1176/2351 
(50%) 
37 p.Glylu548* stopgain Yes 
Halo69 POLE  12:133253974 C>T 
1611/3091 
(52%) 
24.4 p.Arg259His 
nonsynonymous 
SNV 
Yes 
Halo70 MSH6 2:48030669 C>T 
398/997 
(40%) 
35 p.Arg1095Cys 
nonsynonymous 
SNV 
Yes 
Halo72 TP53 17:7578245 G>A 
763/1656 
(46%) 
16.71 p.Arg202Cys 
nonsynonymous 
SNV 
Yes 
Halo80 TP53 17:7578388 C>T 
56/162 
(35%) 
28.5 p.Arg181His 
nonsynonymous 
SNV 
Yes 
Halo81 POLE  12:133253974 C>T 
1851/3784 
(48.9%) 
24.4 p.Arg259His 
nonsynonymous 
SNV 
Yes 
 
Table 4.2 Variants selected for validation following targeted exome capture 
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4.2.4.2.3 Confirmation of the Variants in cDNA 
At the time of the experiments, RNA was available for 14 patients with variants 
validated in DNA.  All the variants which were identified in DNA were confirmed to 
be present in cDNA (Appendix 4.5).  
 
4.2.5 Further Assessment of Validated Variants 
Validated variants were checked in dbSNP 
(https://www.ncbi.nlm.nih.gov/projects/SNP/), HGMD (https://portal.biobase-
international.com/hgmd/pro/start.php), InSiGHT (https://www.InSiGHT-
group.org/variants/databases/) and LOVD (http://lovd.nl/3.0/home).  International 
experts who specialise in specific genes were contacted to determine whether they 
had any further information regarding the clinical significance of the confirmed 
variants.  I also liaised with AmbryGen, a company which provides a clinical 
genetics testing and diagnostic service in the United States of America.   
 
Several of the variants identified using the Haloplex assay followed by UDS have 
been deemed to be pathogenic, but in clinical situations other than colorectal 
polyposis.  For example, the CHEK2 mutation found in Halo14 
(c.715G>A:p.Gln239Lys) is assigned to be DM (pathological) in prostate cancer 
(CM030421:  inherited variant) on HGMD and the TP53 mutation in Halo072 
(c.604C>T:p.Arg202Cys) is reported as DM in adrenocortical carcinoma 
(CM121764:  inherited variant).   
 
With regards to the CDH1 variants, I contacted Professor Seruca’s research group 
in Portugal.  One of the CDH1 variants which had been found in Halo62, 
c.1774G>A:p.Ala592Thr, has been classified as non-pathogenic.  The group had 
already evaluated its significance in vivo and demonstrated that cells expressing the 
variant are not invasive (Keller et al 2004).  The second variant identified in Halo25, 
c.2635G>A:p.Gly879Ser, had been reported in an 81-year old Caucasian woman 
with lobular breast cancer, but its functional relevance remains to be evaluated. 
Professor Seruca noted that although CRC can occur as part of the tumour 
spectrum in Hereditary Diffuse Gastric Cancer, which can develop as a 
consequence of germline mutations in CDH1, it is specifically of signet ring cell type.  
She reported that there is no evidence to suggest that CDH1 mutations increase the 
risk of CRC associated with colorectal polyposis (personal communication 
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10/10/2016).  In light of this, the CDH1 mutations were not pursued as part of this 
project. 
 
AmbryGen provided their classification, if available, of the validated variants (VLB: 
variant likely benign, Poly: polymorphism, VUS: variant of unknown significance, 
VLP: variant likely pathogenic).  This is listed in Table 4.3: 
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Based on this information, the following conclusions were drawn: 
4.2.5.1 CHEK2 
It is possible that CHEK2 variants may have a role in colorectal neoplasia.  Three 
different variants were validated in this cohort of NMI patients:  
c.1217G>C:p.Arg406Pro in Halo05, c.715G>A:p.Glu239Lys in Halo14 and 
c.1420C>T:p.Arg474Cys in Halo54.  However, during the time course of this project 
it was not possible to recruit additional family members for de novo/ segregation 
analysis.  Therefore these variants have not been pursued in the short-term.    
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4.2.5.2 POLE and POLD1 
The VUS/ unreported POLE variants were selected for additional studies in Chapter 
5 of this thesis.  One of the POLD1 variants, c.2546G>A:p.Arg849His, is recorded 
as a polymorphism by AmbryGen, and has recently been classified as benign in 
dbSNP (https://www.ncbi.nlm.nih.gov/clinvar/variation/220865/ accessed 
08/05/2018) so was not pursued.  The second POLD1 variant, 
c.2861C>T:p.Thr954Met, is not previously reported.  It was taken forward for further 
work described in Chapter 5. 
 
4.2.5.3 CDH1 
These variants were not investigated following Professor Seruca’s advice that they 
are unlikely to be pathogenic in the context of polyposis.  This was also consistent 
with AmbryGen’s classification of the variants identified as VLB/ Poly. 
 
4.2.5.4 MSH2, MSH6, MSH6, MLH1, EPCAM 
Variants in the MMR genes were selected for further work.  Although the AmbryGen 
classification was taken into consideration, the gold standard classification is that 
provided by the InSiGHT consortium (https://www.InSiGHT-
group.org/syndromes/lynch-syndrome/), so this was given the greatest weight.  The 
only variant which wasn’t pursued was the EPCAM missense variant.  Only 
deletions of EPCAM that inactivate the adjacent MSH2 gene in Lynch syndrome are 
considered pathogenic, (Tutlewska et al 2013) rather than missense changes. 
 
4.2.5.5 AXIN2 
Neither of the variants identified had been reported by AmbryGen.  We were unable 
to recruit further relatives for Halo28, and the variant was a missense change, so is 
less likely to be pathogenic.  Therefore, the c.1168A>G:p.Ser390Gly variant was not 
taken forward.  The variant found in Halo47 and Halo68, c.1642G>T:p.Glu548*, was 
extensively investigated as reported in Chapter 5 of this thesis. 
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4.2.5.6 TP53 
One of the variants has been discussed above.  TP53 c.604C>T:p.Arg202Cys was 
identified in Halo72, and is thought to have a role in adrenocortical carcinoma.  
Halo72 had an interesting family history, including several family members in the 
preceding generation having CRC/ lung cancer/ cancer of unknown origin.  
However, we were unable to recruit any further family members, so the variant has 
not been pursued at the present time.  The second variant, c.542G>A:p.Arg181His, 
is recorded as likely pathogenic by AmbryGen, who have 12 cases of patients 
carrying this variant.  11/12 had breast cancer, and the remaining patient had a 
family history of breast cancer.  Although most of the families had histories of further 
malignancies, they did not fulfil Li Fraumeni diagnostic criteria, and there were no 
cases of polyposis.  In light of this, the variant was not investigated further. 
 
The variants which were selected for further investigations were therefore those 
whose significance was unknown/ which were unreported and for which basic 
functional/ in silico work could be carried out and/ or those which were identified in 
patients in whom relatives were available to be recruited for genetic analysis to 
determine de novo status or segregation. 
 
The genes I selected to focus on were the MMR genes, POLE, POLD1 and AXIN2.  
This work is described in Chapter 5 of this thesis.  
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4.3 Whole Exome Sequencing 
The next phase of this project involved whole exome sequencing (WES) of 24 
patients, plus 5 relatives.  The relatives were included to assess whether variants 
identified in NMI patients were occurring de novo and to allow variants to be 
assigned as likely non-pathogenic if they were found in a healthy control, once the 
mode of inheritance was taken into consideration.  Although most of the patients 
included in this thesis will ultimately undergo WES and/ or whole genome 
sequencing, this cohort was selected based on a phenotype of early onset or 
profuse polyposis and/ or the availability of relatives and/ or those patients in whom 
a novel putative polyposis-causing variant had already been identified, to help 
exclude the presence of an additional previously undetected polyposis-associated 
variant. 
 
The patients and relatives included are recorded in Table 4.4 below: 
 
Unique 
Identifier 
Demographic 
Details 
Clinical 
Phenotype 
Relative Available 
Halo05 
46-year-old 
female 
Aged 39 had multiple 
adenomas (at least 
19): one polyp 
contained Duke's pT1 
CRC 
 
Halo08 
70-year-old 
female 
629 adenomas  
Halo15 84-year-old male 12 adenomas  
Halo17 66-year-old male 
25 mixed polyps: 
adenomas and 
hyperplastic lesions 
(exact numbers of 
each is not clear). 2 
CRC aged 63 
(pT2,pT3) 
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Halo18 72-year-old male 
Referred from 
screening programme.  
27 polyps: adenomas 
with 4 HPPs   
 
Halo19 
62-year-old 
female 
>10 adenomas and 
CRC (no further 
information available 
about the CRC) 
 
Halo27 
67-year-old 
female 
17 adenomas  
Halo28 61-year-old male 
1990: sigmoid 
colectomy for a 
probable diverticular 
perforation.  Multiple 
'benign metaplastic 
polyps' were noted 
?number.  2012: 
subtotal colectomy for 
>30 polyps.  The 
majority of the polyps 
were TA; 2 were 
serrated adenomas 
with LG dysplasia. 
 
Halo40 
70-year-old 
female 
18 adenomas, 3 HPPs  
Halo45 77-year-old man 27 adenomas, 7 HPP  
Halo46 
44-year-old 
female 
Clinical FAP – has had 
a colectomy and 
proctectomy 
 
Halo47 
51-year-old 
female 
Colonoscopy found in 
excess of 50 sessile 
polyps throughout the 
colon.  2 of these were 
biopsied: TVA.  Px had 
Halo68 (Sister) 3 TVA with 
LGD, 10 TA with LGD and 7 
HPPs.  
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a subtotal colectomy - 
?4 polyps were 
sampled: 2 TA, 2 
’serrated adenomas’.  
The patient 
subsequently had a 
completion colectomy 
– she was found to 
have a rectal 
carcinoma (pT4N2Mx) 
Sister of Halo68 
Halo48 71-year-old male 
Referred from 
screening. 30 polyps: 4 
have been biopsied:  
all adenoma.  
Subsequent colectomy. 
 
Halo49 
57-year-old 
female 
Rectal 
adenocarcinoma age 
32 (?stage), 
ameloblastoma age 38. 
22 polyps: mixture of 
adenomas and 
hyperplastic lesions 
 
Halo51 
43-year-old 
female 
208 adenomas 
Halo77 (mother): 
unaffected 
Halo78 (father): 
unaffected 
Halo52 59-year-old male Over 1000 adenomas  
Halo53 51-year-old male 
Approximately 400 
adenomas, carcinoma 
age 27 (Duke’s C) 
Halo75 (mother): 
unaffected 
Halo76 (father): 
unaffected 
Halo55 54-year-old male 
18 polyps: 9 
adenomas, 9 serrated 
lesions 
F_Halo55 (father): 
unaffected 
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Halo61 
60-year-old 
female 
60-year-old female with 
11 polyps:  2 serrated 
adenomas, 7 TA, 1 
TVA, and 1 HPP 
 
Halo63 68-year-old male 
At least 24 polyps.  5 
biopsies show 4 
adenomas and 1 HPP 
 
Halo64 
54-year-old 
female 
Thousands of 
colorectal polyps, 
those which have been 
biopsied showed 
adenomas.  Caecal 
carcinoma aged 23 
(?stage) 
 
Halo65 33-year-old male 117 adenomas   
Halo66 70-year-old male 23 adenomas, 4 HPPs  
 
Table 4.4: Patients and relatives undergoing WES 
 
4.3.1 Methods 
DNA was extracted from whole blood by the AWMGS (2.3.2).  The concentration of 
the DNA samples to be examined were determined using the Invitrogen Qubit kit 
following the manufacturer’s protocol.  The DNA was diluted to a concentration of 
5ng/μl.   
 
4.3.1.1 Sequencing 
Sequencing was carried out by Sarah Edkins, Wales Gene Park, using the Nextera 
Rapid Capture Enrichment Library Preparation and Sequencing Protocols (2.4.4).  
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4.3.1.2 Sequence Analysis 
Bioinformatic analysis was performed by Dr. Kevin Ashelford (Cardiff University) 
(2.4.5).   
4.3.1.3 Variant Analysis and Selection 
A candidate gene approach was initially adopted, and the data was filtered for 
genes which were: 
1) present in an in-house list of 1177 candidate CRC genes (Smith et al Appendix 
4.6) or  
2) were established cancer predisposition genes (Rahman 2014) or  
3) were genes which are differentially expressed in solid tumours (Digital Differential 
Display (DDD) genes, Scheurle et al 2000)  
 
Novel genes outside of this list were being investigated by Beth Bradford as her 
professional training year (PTY) project (Bradford, B (2017) Use of Whole Exome 
Sequencing for the Identification of Novel Genetic Mechanisms in Colorectal 
Polyposis).  Any patient not investigated by Bradford was subject to interrogation by 
myself, to ensure that all patient samples had been examined in the same way.  I 
therefore examined samples Halo05, Halo15, Halo27, Halo28, Halo47, Halo61 and 
Halo68. 
 
The complete protocol for shortlisting variants of interest is outlined in Figure 4.1. 
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Figure 4.1 WES variant analysis and selection 
Candidate Gene 
Approach
Variants are shortlisted to inclue those 
which are present in an in-house list of 
candidate CRC genes or which are 
established cancer predispostion genes 
or which are differentially expressed in 
solid tumours (4.3.1.3)
Variants are further filtered, selecting 
for heterozygous/ homozygous/ 
compound heterozygous variants which: 
pass the bioinformatic quality control, 
have an allele frequency <0.5% 
(according to data from The 1000 
Genomes Project), are present in >20% 
of reads, are present in <50% of 
samples (to exclude sequencing 
artefacts), are frameshift/ non-
synonymous/ are at a splice site/ stop 
gain, which are not present in a healthy 
control (taking into consideration the 
mode of inheritance).   Non-coding 
variants are excluded unless they are at 
a splice site  
CADD Score >20
Perform a literature review for each 
variant and select those for validation
Novel Gene Approach
Variants are filtered, selecting for 
heterozygous/ homozygous/ compound 
heterozygous variants which: pass the 
bioinformatic quality control, have an 
allele frequency <0.5% (according to 
data from The 1000 Genomes Project), 
are present in >20% of reads, are 
present in <50% of samples (to exclude 
sequencing artefacts), are frameshift/ 
non-synonymous/ are at a splice site/ 
stop gain/ non frameshift deletions/ 
non frameshift insertions/ stoploss, 
which are not present in a healthy 
control (taking into consideration the 
mode of inheritance)
Exclude variants which are present in an 
in-house list of candidate CRC genes or 
which are established cancer 
predispostion genes or which are 
differentially expressed in solid tumours 
(4.3.1.3)
CADD Score >20
Prioritise variants using ToppGene 
software 
(https://toppgene.cchmc.org/prioritizati
on.jsp accessed August 2017).  Smith’s 
CRC candidate gene list was used as the 
training set.  Patients’ filtered genes 
were compared according to the 
following rules:  similar molecular 
function/ involvement in similar 
biological processes/ similar cellular 
component/ involvement in similar 
human and mouse phenotypes/ 
involvement in the same molecular 
pathways/ PubMed similarity/ similar 
interactions/ similar transcription factor 
binding sites/ involvement in similar 
diseases
Perform a literature review for variants 
with a CADD score >/= 30 and the top 10 
hits in ToppGene and any truncating 
variants.  Select those for validation
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4.3.1.4 Validation of Identified Variants 
Variants were validated with Sanger sequencing, using standard reagents and 
reaction conditions (2.3.8.1, 2.3.8.5, 2.3.9-2.3.13).  Primers were designed by Dr. 
Marc Naven (Cardiff University) using a combination of his own scripts, samtools 
and primer3 software, and by myself using primer3 software.  They are listed in 
Appendix 4.7. 
 
4.3.2 Results 
 
4.3.2.1 Coverage 
The mean depth of coverage across the 29 patients/ relatives was 61.99 reads.  
The details for each patient, including the percentage of target region covered at 
different depths, are recorded in Table 4.5: 
 
 Percentage of target region covered at the following 
coverage depths: 
Sample Mean Reads 1x 4x 10x 20x 30x 40x 50x 
Halo05  88.82 97.20 95.24 92.51 87.21 81.18 74.76 68.09 
Halo08 50.36 97.26 92.08 81.69 67.66 56.34 46.60 38.23 
Halo15 123.42 98.47 95.99 91.60 84.90 79.14 74.13 69.61 
Halo17 49.62 97.88 93.33 83.02 67.78 55.27 44.74 36.01 
Halo18 49.11 97.95 93.48 83.17 69.90 55.46 44.85 36.02 
Halo19 44.73 97.36 91.86 80.32 64.60 52.03 41.55 33.01 
Halo27 85.95 97.97 95.01 89.39 80.82 73.54 67.13 61.17 
Halo28 64.59 97.26 94.97 91.20 83.39 74.30 64.67 55.17 
Halo40 60.54 98.01 97.73 86.87 73.69 62.23 52.22 43.53 
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Halo45 40.69 97.42 91.46 79.15 64.40 49.11 38.20 29.52 
Halo46 76.93 98.24 95.63 89.59 79.02 69.69 61.43 53.92 
Halo47 73.33 97.93 95.68 92.77 86.91 79.50 71.04 62.15 
Halo61 139.76 98.66 96.73 93.43 87.76 82.43 77.62 73.23 
Halo68 74.90 97.25 95.11 91.90 85.40 77.84 69.70 61.41 
Halo48 36.24 98.07 93.33 79.35 57.19 41.45 30.65 22.99 
Halo49 64.64 98.26 95.19 87.78 75.11 64.14 54.52 46.03 
Halo51 52.73 98.06 94.47 85.40 70.66 58.30 47.70 38.79 
Halo77 51.57 97.70 93.77 84.16 69.62 57.62 47.27 38.49 
Halo78 61.28 98.04 93.93 84.21 69.45 57.28 46.81 37.98 
Halo52 62.20 98.26 95.27 87.78 74.86 63.69 53.94 45.40 
Halo53 62.15 98.22 95.10 87.52 74.69 63.58 53.85 45.30 
Halo75 38.16 96.85 90.30 77.47 60.55 46.94 35.84 27.21 
Halo76 62.76 97.56 92.81 83.67 71.53 61.88 53.57 46.27 
Halo55 45.34 97.56 92.19 80.85 65.29 52.89 42.50 33.87 
Halo55 
Father 
56.64 98.90 94.08 85.05 71.50 60.30 50.63 42.21 
Halo63 54.32 98.14 94.38 85.26 70.92 59.00 48.77 40.03 
Halo64 58.35 98.05 94.42 85.95 72.61 61.50 51.83 43.31 
Halo65 54.59 97.95 94.01 84.97 71.07 59.38 49.24 40.47 
Halo66 14.02 93.60 76.76 50.51 24.75 12.15 5.83 2.71 
 
Table 4.5:  Patient-specific depth of coverage for WES 
 
  153 
4.3.2.2 Variants Selected for Validation 
106 variants were selected for validation across the 24 patients. The details and 
results of validation are in Table 4.6.  The validation sequencing traces are in 
Appendix 4.8. 
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Patient ID Gene Chr. Location Variant 
CADD 
Score 
Validated 
Genomic 
Annotation 
Notes 
Halo05 LZTS1 8 20107358 G>A 34 Yes Missense  
Halo05  ERCC6 10 50690821 G>A 34 No Missense 
There was a synonymous variant 
adjacent to the called variant 
Halo05  LRP4 11 46918516 G>A 29.3 Yes  Missense  
Halo05  ATM 11 108114679 G>T 24.4 No 
Splice site 
acceptor 
Only present in 2/5 reads (NGS) 
Halo05  ATM 11 108114684 G>T 23.3 No Missense Only present in 2/7 reads (NGS) 
Halo05  ATM 11 108114689 C>T 23.4 No Missense Only present in 2/10 reads (NGS) 
Halo05  ATM 11 108196797 G>A 34 Yes Missense  
Halo05  PALB2 16 23635370 C>T 26.6 Yes Missense  
Halo05  LIG1 19 48620943 C>A 29 Yes Missense  
  
1
5
5
 
Patient ID Gene Chr. Location Variant 
CADD 
Score 
Validated 
Genomic 
Annotation 
Notes 
Halo05  FZD5 2 208633009 C>T 22.5 Yes Missense  
Halo05  ATR 3 142272170 A>G 20.5 Yes Missense  
Halo05  MCPH1 8 6479113 C>T 24.6 Yes Missense  
Halo08  EYA4 6 133789765 C>T 24.8 Yes Missense  
Halo08  BCLAF1 6 136599544 G>A 36 Yes Stopgain  
Halo08  BMP1 8 22049596 G>A 33 Yes Missense  
Halo15 SFN 1 27190196 A>T 26.1 Yes Missense  
Halo15 CELSR2 1 109812092 G>A 22 Yes Missense  
Halo15 CAPN9 1 230907799 C>T 35 Yes  Missense  
Halo15 ATR 3 142272170 A>G 20.5 Yes Missense  
  
1
5
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Patient ID Gene Chr. Location Variant 
CADD 
Score 
Validated 
Genomic 
Annotation 
Notes 
Halo15 
ZKSCAN
4 
6 28219686 
CGGTC
A>C 
24.4 No Frameshift 
There was low coverage at this locus.  
The variant was called in 2/3 reads 
(NGS) 
Halo15 DAAM2 6 39864686 C>T 34 Yes Missense  
Halo15 EGFR 7 55273086 G>A 35 Yes Missense  
Halo15 ST18 8 53030923 G>T 31 Yes Missense  
Halo15 NCOR2 12 124824869 G>A 24.3 Yes Missense  
Halo15 NCOR2 12 124911260 C>T 24.6 Yes Missense  
Halo15 HDAC5 17 42171169 G>A 25.6 Yes Missense  
Halo17  BMPR2 2 203407059 G>A 23.1 Yes Missense  
Halo17  BMPER 7 34125622 C>T 34 Yes Missense  
  
1
5
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Patient ID Gene Chr. Location Variant 
CADD 
Score 
Validated 
Genomic 
Annotation 
Notes 
Halo17  TTI2 8 33361016 C>T 24.6 Yes Missense  
Halo17  CBL 11 119169085 G>A 21.6 Yes Missense  
Halo17  DSC3 18 28605748 C>T 35 Yes Missense  
Halo17  DSC2 18 28647999 T>TTC 35 Yes Frameshift  
Halo18  CNKSR1 1 26515380 G>A 33 Yes Missense  
Halo18  POLQ 3 121207509 
CAATAG
TA>C 
34 Yes Frameshift 
 
Halo18  CBL 11 119148958 T>C 23.9 Yes Missense  
Halo18  RAD51B 14 68353893 A>G 27.2 Yes Missense  
Halo19  THRAP3 1 36757052 G>A 24.3 Yes Missense  
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Patient ID Gene Chr. Location Variant 
CADD 
Score 
Validated 
Genomic 
Annotation 
Notes 
Halo19  RB1 13 49047524 G>A 28 Yes Missense  
Halo19  MGA 15 42028820 A>G 22.2 Yes Missense  
Halo19  WNT9B 17 44953675 G>A 31 Yes Missense  
Halo19  MED12 X 70342603 G>A 33 Yes Missense  
Halo27 PLK3 1 45267346 G>T 33 Yes Missense  
Halo27 RBM5 3 50155887 TGA>T 35 No Frameshift 
There was relatively low coverage at this 
locus and the variant was only called in 
5/22 reads (NGS) 
Halo27 TRRAP 7 98591187 G>C 21.6 Yes Missense  
Halo27 KAT5 11 65482096 G>A 28.1 Yes Missense  
Halo27 PTPRH 19 55697712 G>A 36 Yes Stopgain  
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Patient ID Gene Chr. Location Variant 
CADD 
Score 
Validated 
Genomic 
Annotation 
Notes 
Halo28  PIK3C2A 11 17140810 A>G 23.5 Yes Missense  
Halo28 CD82 11 44626709 G>A 33 Yes Missense  
Halo28 RBMS2 12 56982155 C>T 21.3 Yes Missense  
Halo28  
PPP1R1
3B 
14 104205127 T>C 23.1 Yes Missense 
 
Halo28  MGA 15 42058553 G>C 22 Yes Missense  
Halo28 DCC 18 50961517 G>A 28.2 Yes Missense  
Halo28  BIRC6 2 32706513 G>T 32 Yes Missense  
Halo28  EYA4 6 133789765 C>T 24.8 Yes Missense  
Halo28  AKAP9 7 91623985 G>C 26 Yes Missense  
  
1
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Patient ID Gene Chr. Location Variant 
CADD 
Score 
Validated 
Genomic 
Annotation 
Notes 
Halo28  MET 7 116381047 A>G 23.1 Yes Missense  
Halo40  GDF7 2 20870532 C>A 23.6 Yes Missense  
Halo40  
PDCD6I
P 
3 33883492 G>A 30 Yes Missense 
 
Halo40  LRP5 11 68183958 G>A 23.9 Yes Missense  
Halo40  DSC2 18 28672114 C>T 21.7 Yes Missense  
Halo45  EIF3I 1 32688188 A>G 28.2 Yes Missense  
Halo45  HELQ 4 84374567 C>T 25.5 Yes Missense  
Halo45  RPLP2 11 810305 A>G 22.6 Yes Missense  
Halo46  MSH4 1 76345823 A>G 28.6 Yes Missense  
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Patient ID Gene Chr. Location Variant 
CADD 
Score 
Validated 
Genomic 
Annotation 
Notes 
Halo47  
PPP1R1
3B 
14 104245134 C>T 23.5 Yes Missense 
 
Halo47  XAB2 19 7694391 G>C 23.5 Yes Missense  
Halo47  ENG 9 130588091 C>T 23.9 Yes Missense  
Halo48  ADAM17 2 9633092 C>T 34 Yes Missense  
Halo48  FZD3 8 28420428 G>A 23 Yes  Missense  
Halo49  BMPR1B 4 96070060 G>C 33 Yes Missense  
Halo49  MSH3 5 80063899 G>C 23.7 Yes Missense  
Halo49  EPHB4 7 100421340 C>T 25.2 Yes Missense  
Halo49  ID1 20 30193351 C>T 29 Yes Missense  
  
1
6
2
 
Patient ID Gene Chr. Location Variant 
CADD 
Score 
Validated 
Genomic 
Annotation 
Notes 
Halo52  EP400 12 132471141 C>T 15.34 Yes Missense  
Halo52  
TSC22D
1 
13 45008887 G>T 24.6 Yes Missense 
 
Halo52 FOXC2 16 86602293 G>C 28.3 Yes Missense  
Halo52 PHF12 17 27239701 T>G 18.87 Yes Missense  
Halo55  DVL1 1 1273404 G>A 22.8 Yes Missense  
Halo55  BMP8B 1 40228846 G>T 39 Yes Stopgain  
Halo55  TLE1 9 84228372 G>A 29.5 Yes Missense  
Halo61 PARP1 1 226564855 G>A 26.2 Yes Missense  
Halo61 ANAPC2 9 140069828 C>T 31 Yes Missense  
  
1
6
3
 
Patient ID Gene Chr. Location Variant 
CADD 
Score 
Validated 
Genomic 
Annotation 
Notes 
Halo61 RECQL 12 21623219 G>C 38 Yes Stopgain  
Halo61 INHBE 12 57850383 G>A 33 Yes Missense  
Halo61 POSTN 13 38156538 C>T 34 Yes Missense  
Halo61 EEF2K 16 22269048 C>T 26.8 Yes Missense  
Halo61 ZFP14 19 36831616 T>A 25.9 Yes Missense  
Halo63  BIRC6 2 32726929 A>C 22.3 Yes Missense  
Halo63  XRCC5 2 217026733 G>A 24.1 Yes Missense  
Halo63  WNT10A 2 219754822 G>A 24 Yes Missense  
Halo63  CHD7 8 61734439 G>A 25.7 Yes Missense  
Halo63  WISP1 8 134232908 C>T 24.3 Yes Missense  
  
1
6
4
 
Patient ID Gene Chr. Location Variant 
CADD 
Score 
Validated 
Genomic 
Annotation 
Notes 
Halo63  ARID2 12 46233172 C>T 26.4 Yes Missense  
Halo64  MTHFR 1 11854085 T>A 23.3 Yes Missense  
Halo64  WAPAL 10 88259879 T>C 25 Yes Missense  
Halo65  POLQ 3 121207520 G>A 24.2 Yes Missense  
Halo65  ERCC8 5 60194107 G>T 24.4 Yes Missense  
Halo65  NUDT1 7 2284301 G>A 23.7 Yes Missense  
Halo65  ATM 11 108186610 G>A 31 Yes Missense  
Halo65  TMBIM6 12 50146761 C>T 24.7 Yes Missense  
Halo66  MSH3 5 80063896 C>T 22.8 Yes Missense  
Halo66  MMS19 10 99218456 C>T 32 Yes Missense  
  
1
6
5
 
Patient ID Gene Chr. Location Variant 
CADD 
Score 
Validated 
Genomic 
Annotation 
Notes 
Halo66  XAB2 19 7694391 G>C 23.5 Yes Missense  
Halo68  
PPP1R1
3B 
14 104245134 C>T 23.5 Yes Missense 
 
Halo68  XAB2 19 7694391 G>C 23.5 Yes Missense  
Halo68  ENG 9 130588091 C>T 23.9 Yes Missense  
 
Table 4.6:  WES validation
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All of the validated variants were subsequently investigated using multiple 
databases to determine whether there was any additional information available 
about their likely pathogenicity:  dbSNP, Exac, Ensembl, HGMD, LOVD, COSMIC, 
CBioPortal, ClinVar, CanVar (Databases accessed May/ June 2017, 
http://exac.broadinstitute.org/, http://grch37.ensembl.org/index.html, 
https://portal.biobase-international.com/hgmd/pro/start.php, 
http://www.lovd.nl/3.0/home, http://grch37-cancer.sanger.ac.uk/cosmic, 
http://www.cbioportal.org/index.do, https://www.ncbi.nlm.nih.gov/clinvar/, 
https://canvar.icr.ac.uk/, https://genome.ucsc.edu/cgi-
bin/hgTracks?db=hg19&lastVirtModeType=default&lastVirtModeExtraState=&virtMo
deType=default&virtMode=0&nonVirtPosition=&position=chr11%3A108186595-
108186625&hgsid=594778521_y7cxR9MaVPipen9AAAExDrahzrKP).   
The results are summarised in Appendix 4.9.  Particular attention was paid to the 
clinical situations in which specific inherited variants had been identified in, and 
whether or not the variants had been described as a somatic change in different 
cancer types.   
 
Relatives were available for Halo51, Halo53 and Halo55.  For both Halo51 and 
Halo53, no putative pathogenic de novo variants were identified.  For Halo55 only 2 
were found:  missense changes in TLE1 and BRIC6.  A third variant identified in 
Halo55 was a stopgain in BMP8B.  At a relatively late stage in the project, DNA 
became available for the patient’s unaffected mother, in whom the BMP8B variant 
was also identified, so it is unlikely to be clinically significant.
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4.4 Discussion  
 
4.4.1 Targeted Exome Sequencing 
The Haloplex assay was used for targeted exome capture of 15 candidate polyposis 
genes, followed by UDS using the HiSeq 2500 (Illumina). 33 different variants 
across 32 patients were selected for validation (a total of 35 variants as 2 different 
variants were identified in 2 sets of different patients).  21 variants which appeared 
to be heterozygous changes were validated.  A possible MHS2 homozygous variant 
observed in patient Halo06 was not validated.  There were only 3 reads with UDS, 
so this is highly likely to be an artefact.  A PMS2 variant identified in Halo51 in 34% 
of reads was not validated.  There are known to be multiple pseudogenes of PMS2 
(Vaughn et al 2010), so it is likely that UDS had identified a variant in such a 
pseudogene.  
 
Twelve low frequency variants underwent COLD-PCR protocols followed by Sanger 
sequencing.  In 2 samples, Halo17 and Halo49, the COLD-PCR protocols used did 
not successfully amplify the desired amplicon, and the required melting temperature 
was 95⁰C as in standard PCR.   For sample Halo64 the full COLD PCR protocol 
appeared to work at denaturation temperatures as low as 68°C.  However, this 
would be extremely unlikely, if not impossible.  It is most probable that the 
hybridisation step did not work, therefore the effective denaturation temperature 
would have been 95°C.   
 
11/12 low frequency variants were not validated, so the UDS results are likely to be 
artefacts.  However, it is possible that the COLD-PCR was not sufficiently sensitive 
to detect them. COLD-PCR has been discussed in Chapter 3 (3.4.3.1).  The one low 
frequency variant which was validated was identified in sample Halo54: CHEK2 
22:29090061 G>A.  The UDS results indicated a variant fraction of 1.5% (71/4620 
reads).  However, the trace obtained with the Sanger sequencing validation 
revealed that the patient was approximately heterozygous rather than a very-low 
frequency mosaic (Appendix 4.4), suggesting that there had been preferential 
amplification of the wild-type allele with UDS.   
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The aim of this part of the project was to identify novel/ rare variants in genes 
already known to have/ potentially have a role in colorectal neoplasia.  A key issue 
encountered was the lack of availability of relatives for many of the probands for 
determination of the variant’s de novo status or assessment of whether it was 
segregating with the disease.  Without such evidence, it is often not sensible to 
commence functional studies.  The variants that have been selected for further work 
in this thesis are a novel truncating AXIN2 mutation (c.1642G>T:p.Glu548*), which 
has been identified in 2 affected siblings, and variants in POLE, POLD1 and the 
MMR genes.  Although relatives were not always available for the patients found to 
carry variants in the latter group of genes, their established roles in inherited 
predisposition to colorectal tumours and availability of basic functional studies made 
it reasonable to investigate the pathogenicity of the variants. 
 
The work in this part of the project required database interrogation to aid in 
appraising identified variants, and also communication with international experts.  
This highlights the importance of communication and collaboration in clinical 
research.  It is apparent that genetic variants identified through clinical research 
projects are often not recorded in publicly accessible databases.  This is a great 
shame.  It would be excellent if all variants were recorded in a centralised 
repository, such as LOVD, as this would allow improved understanding of disease 
pathogenesis and therefore improved patient care.  With the advent of the 100 000 
Genomes Project it is hoped that there will be improved understanding of the role of 
the genome in health and disease.  The project aims to sequence 100 000 genomes 
of individuals with cancer/ rare diseases/ infectious diseases.  Genomes will be 
sequenced, annotated and analysed in the context of the individual’s medical 
history.  The project seeks to enhance the clinical interpretation of the data and 
derive new findings from the data (https://www.genomicsengland.co.uk/faqs-about-
gecip/ accessed 10/5/2018).  The Human Variome Project has a similar ethos.  It is 
an international non-governmental organisation which functions to ensure that all 
information on genetic variation and its effects on human health can be collected, 
crated, interpreted and shared freely and openly 
(http://www.humanvariomeproject.org/about/about-the-human-variome-project.html 
accessed 10/05/18).  The project itself doesn’t physically store the data, but it 
develops standards and approaches so that data from different sources can be 
shared in an appropriate manner.  LOVD is one example of a database which now 
functions under the auspices of the Human Variome Project. 
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4.4.2 Whole Exome Sequencing 
24 patients underwent WES to try and identify further genes which may be 
implicated in colorectal neoplasia.  Two approaches were taken:  a candidate gene 
approach and a novel gene approach (Bradford 2017).  Using the candidate gene 
approach, 106 variants were selected for validation:  only 6 of these were not 
validated.  In one of these cases, ERCC6 in Halo05, there was a synonymous 
change at the base adjacent to that called, so it is likely that the bioinformatic 
analysis was miscalling the actual change.  In 3 cases also occurring in Halo05, in 
the ATM gene, there was poor coverage at the loci, so the variants called are likely 
to be artefactual.  In Halo15, a ZKSCAN4 variant was not validated, but again there 
was low coverage at this locus, and the variant was called in only 2/3 reads.  The 
final variant which was not validated was an RBM5 frameshift in Halo27.  The 
variant was only called in 5/22 reads, and it was at a region where there were 
numerous AC dinucleotide repeats, so the call was likely to be an artefact. 
 
There are several important points to note about the WES results using the 
candidate gene approach: 
 
 There were no obvious mutations which could explain the reduced APC 
expression for samples Halo52, Halo53 and Halo64. 
 There was not a ‘second hit’ in a gene involved in BER for Halo40, who is a 
monoallelic carrier of a pathogenic MUTYH mutation. 
 There were no mutations for Halo46 which were more likely to be 
pathogenic than her previously-identified APC mutation. 
 In Halo47 and Halo68 there were no mutations in genes involved in the 
pathogenesis of oligodontia/ ectodermal dysplasia (CXORF5, DLX1, DLX2, 
EDA, EDAR, EDARADD, FGFR1, GLI2, GLI3, LEF1, LTBP3, MSX1, 
NEMO, PAX9PITX2, P68, Wnt10a.  Chhabra et al 2014; Deshmukh et al 
2012) (See Chapter 5). 
 Of the truncating mutations, which are generally more likely to be clinically 
significant than missense changes: 
o The BCLAF1 variant identified in Halo08 was not present in her 
affected son, whose DNA became available at a late stage in the 
project. 
o The DSC2 variant in Halo17 may be implicated in a clinical 
phenotype other than colorectal neoplasia (cardiomyopathy) and no 
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relatives were available for screening, so it was not followed up in 
the short term as part of this project. 
o A frameshift POLQ variant was identified in Halo18.  I liaised with 
AmbryGen about this variant, and they commented that ‘the 
subpopulation frequencies in 1K Genomes for 
POLQ c.4262_4268delTACTATT are high indicating that this would 
probably be likely benign based on our current classification scheme’ 
(Felicia Hernandez personal communication 09/03/2017).  
Furthermore, relatives were not available for screening as the patient 
sadly passed away during the course of the project, so familial follow 
up was not possible. 
o The PTPRH variant found in Halo27 may be involved in the 
pathogenesis of Parkinson’s Disease (Appendix 4.9) and colorectal 
neoplasia is not typically part of the phenotypic spectrum, so it was 
not followed up in the short term as part of this project. 
o The RBMS2 variant in Halo28 had been mis-described in the 
bioinformatic analysis of the exome sequencing:  it was actually a 
synonymous change rather than a stop-gain. 
o The BMP8B variant in Halo55 was subsequently identified in his 
unaffected mother, as described above. 
o The RECQL variant in Halo61 is interesting as RECQL is involved in 
DNA repair.  Unfortunately, during the time course of this project it 
was not possible to recruit any relatives, but this variant will be 
pursued by the Inherited Tumour Syndromes Research Group, 
Cardiff University.  Halo61 also carries a POLE mutation, which is 
being followed up in Chapter 5 of this thesis. 
 The remaining variants, although all potentially interesting, were not 
followed up in the short term due to at least one of the following reasons: 
o No relatives available. 
o Variant more likely to be involved in a phenotype other than 
colorectal neoplasia. 
o Too common. 
o Insufficient evidence of a role in colorectal neoplasia to prioritise 
further study. 
 
The second strategy in data analysis involved searching for novel polyposis genes 
(Bradford 2017).  Bradford found one interesting variant.  In Halo53, a novel de 
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novo stopgain in MAP3K11 (p.Arg561*) was identified. MAP3K11 is a mitogen 
activated protein kinase that is involved in the regulation of the c-Jun N-terminal 
kinase (JNK) pathway (Mishra et al 2007).  There is some evidence that it may have 
a role in tumourigenesis:  in HER+ breast cancer tissue, there is reduced function of 
MAP3K11 kinase activity (Das et al 2015).  Furthermore, HER2-directed drugs such 
as trastuzumab and lapatinib, as well as depletion of HER2/ HER3, stimulate 
MAP3K11 kinase activity in HER2+ breast cancer cell lines (Das et al 2015). 
MAP3K11 has known pro-apoptotic effects and stable knockdown of MAP3K11 in 
the HER2+ cell line blunted the pro-apoptotic effects of trastuzumab and lapatinib. 
These findings suggest that HER2 activation inhibits the pro-apoptotic function of 
MAP3K11, which plays a mechanistic role in mediating anti-tumour activities of 
HER2-directed therapies (Das et al 2015).  If the apoptotic effects of MAP3K11 are 
reduced, as may be the case with the p.Arg561* variant identified in Halo53, there 
may be enhanced tumour cell survival (Bradford 2017).  Interestingly, there may be 
interactions between MAP3K11 and the Wnt-pathway.  Although MAP3K11 can 
stabilise -catenin, it has also been shown to inhibit conventional -catenin/ TCF 
transcriptional activation (Thylur et al 2011).  Therefore, MAP3K11 mutations might 
be expected to lead to enhanced expression of Wnt-target genes.  The MAP3K11 
variant is being further investigated by the Inherited Tumour Syndromes Research 
Group. 
  
In this study, the most important factors limiting progress in the search for novel 
variants associated with polyposis were the lack of additional family members and 
the size of the study cohort.  Other studies have been more successful because 
they were larger or prioritised the study of familial cases (Adam et al 2016; Weren et 
al 2015) with availability of samples from multiple affected relatives. 
 
Although the mean depth of coverage across the 29 patients/ relatives who 
underwent WES was 61.99 reads, the percentage of the target region covered at 
50x depth was only 43.9%.  The coverage was also variable between patients, 
ranging from a mean of only 14.02 reads (Halo66) to a mean of 139.76 reads 
(Halo61).  When apparent variants were not validated with Sanger sequencing, 
these tended to have occurred in regions of low coverage. 
 
WES generates enormous amounts of data.  Although a predetermined pipeline 
was used to analyse the data, the potential for human error remained.  A literature 
search was performed for all the shortlisted variants to try and inform decisions 
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about which ones to pursue further, but the process remained subjective.  This 
inevitably introduces bias into the process of data analysis.  All the data is in the 
process of being re-analysed by a second, independent reviewer, Dr. Hannah West, 
but the scope for missing potentially significant variants will always remain.  When 
analysing the results using the novel-gene approach, the volume of data potentially 
for literature review was significantly larger than when using the candidate-gene 
approach.  In view of this, even more stringent criteria had to be applied before 
carrying out the literature search.  Again, this introduces another layer of bias into 
data analysis.  It is important to be aware that all pipelines used for WES data 
analysis included the criteria that the variant must have an allele frequency <0.5% in 
the general population.  This would allow the identification of rare, dominant 
variants, but it means that recessive/ compound heterozygous diseases would only 
have been identified if they were very rare. This threshold was employed as it is 
comparable to the minor allele frequencies of pathogenic mutations identified in the 
recently identified autosomal recessive polyposis syndromes.  In NTHL1-associated 
polyposis the mutant NTHL1 variant has an allele frequency of 0.0036 in the control 
population (Weren et al 2015).  In Adam’s paper describing MSH3-associated 
polyposis the group had used a minor allele frequency of 1% as part of their filtering 
criteria for recessive variants, but the actual allele frequencies of the pathogenic 
mutations identified were 0.008%/ 0.0016%/ unreported (Adams et al 2016). 
 
As anticipated, exome sequencing using both targeted and WES approaches 
identified many variants.  These had to be prioritised in the short term, so variants 
were selected in genes which have an established role in inherited predisposition to 
colorectal tumours (POLE, POLD1 and the MMR genes) or variants which were 
identified in families in which multiple family members were available for analysis 
(AXIN2).  Assessment of variants using knowledge from databases is improving 
continuously. For example, in the 100 000 Genomes Project, different contributing 
centres may identify just 1 variant in a gene possibly associated with a particular 
phenotype.  Once the data from all centres is collated, these variants can be linked 
so that an informative pattern emerges.  Therefore review of the variants I have 
identified will be possible in the future, and may be helpful in highlighting further 
variants implicated in inherited polyposis. 
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4.5 Summary 
This chapter utilised exome sequencing to try and identify novel genetic variants 
responsible for tumourigenesis in the cohort of NMI polyposis patients.  Initially a 
targeted approach was used:  60 patients underwent deep sequencing of 15 genes 
known to be/ possibly involved in the pathogenesis of colorectal neoplasia.  A 
subset of the cohort then had WES performed on germline DNA.  A large number of 
variants were identified, from which variants in AXIN2, POLE, POLD1 and the MMR 
genes were selected for further follow up in Chapter 5 of this thesis. 
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Chapter 5 Functional 
Characterisation of Variants 
Identified in the Mismatch Repair 
Genes, POLE, POLD1 and AXIN2 
5.1 Introduction 
The final part of this thesis involved the genetic and functional characterisation of 
variants identified in Chapter 4.  Mutations of interest were found in 3 genes/ groups 
of functionally similar genes: the MMR genes, two of the pol genes: POLE and 
POLD1, and AXIN2.  This chapter is therefore divided into 3 sections, each 
addressing one of these genes/ groups. 
 
5.2 The Mismatch Repair (MMR) Genes  
 
5.2.1 Introduction 
The human MMR system involves 7 key genes: MSH2, MSH6, MSH3, MLH1, 
PMS1, PMS2 and MLH3.  The role of five of these genes in CRC and Lynch 
Syndrome has been described in Chapter 1 (1.3 and 1.5.1.5 ).  
As a result of targeted exome sequencing, three patients were found to carry 
potentially pathogenic variants in the MMR genes.  They are summarised in Table 
5.1: 
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All three variants were investigated using a combination of database interrogation, 
MMR IHC and microsatellite instability testing. 
5.2.2 Database Interrogation 
The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) is an 
international organisation which seeks to improve the quality of care for those 
individuals with any hereditary condition resulting in gastrointestinal tumours 
(https://www.InSiGHT-group.org/ accessed 31/08/2017).  Part of their work includes 
the curation of a database which records variants in the MMR genes, along with a 
classification of the likelihood of pathogenicity.  This database is recognised by 
clinicians as the ‘gold standard’ for the interpretation of such variants and is widely 
used in the clinical genetic diagnostic and research settings.  There is also a French 
database, the Universal Mutation Database, UMD-MMR, which records variants in 
MLH1, MSH2 and MSH6 which have been reported in French laboratories in 
patients with CRC/ endometrial carcinoma (http://www.umd.be/ accessed 
31/08/2017).  It is also possible to calculate the prior probability of pathogenicity of 
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MMR gene variants, based on sequence conservation and position (Thompson et al 
2013). 
All these tools were employed in the investigation of the MMR variants which had 
been identified in NMI patients. 
 
5.2.3 MMR Immunohistochemistry (IHC) 
It is well established that mutations in the MMR genes, MLH1, MSH2, MSH6 and 
PMS2 lead to Lynch Syndrome (LS), which accounts for around 5% of cases of 
CRC (reviewed in Mishra and Hall 2012).  LS-related cancers are characterised by 
the absence of MMR protein expression (reviewed in South et al 2009), and MMR 
IHC is a fundamental component of the molecular diagnosis of LS.  Previous 
authors have reported that colorectal polyps which develop in carriers of known LS 
mutations show loss of MMR staining:  this was observed in 79% of adenomas and 
27% of serrated lesions (Walsh et al 2012). 
 
I hypothesised that if the MMR mutations identified in NMI patients were pathogenic, 
the majority of adenomas in the patients would show loss of MMR protein staining.    
 
5.2.4 Microsatellite Instability (MSI) Testing 
Microsatellite instability (MSI) refers to a hypermutable phenotype caused by 
defective MMR activity (Boland and Goel 2010).  It is the characteristic genetic 
signature identified in cancers associated with LS.  It has previously been shown 
that 80% of adenomas from patients with LS show evidence of MSI (Iino et al 2000).  
 
I hypothesised that if the MMR variants identified in the NMI patients were 
pathogenic, their adenomas would show evidence of MSI. 
 
5.2.5 Methods 
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5.2.5.1 Database Interrogation 
All variants were investigated to determine what their InSiGHT and UMD 
classifications were, and what their prior probability of pathogenicity was (Thompson 
et al 2013).  The databases accessed are available at: 
 
1. http://www.InSiGHT-database.org/genes  
2. http://www.umd.be/MSH2/ 
3. http://www.umd.be/MSH6/ 
4. http://hci-
lovd.hci.utah.edu/variants.php?select_db=MSH2_priors&action=search_all&
search_Variant%2FDNA=c.128A%3EG, http://hci-
lovd.hci.utah.edu/variants.php?select_db=MSH6_priors&action=search_uniq
ue&order=Variant%2FDNA%2CASC&hide_col=&show_col=&limit=100&sear
ch_Variant%2FExon=&search_Variant%2FDNA=&search_Variant%2FRNA=
&search_Variant%2FProtein=p.T369I&search_Variant%2FCustom_PP2_sc
ore=&search_Variant%2FMAPP_score=&search_Variant%2FMAPP%2FPP
2_Prior=&search_Variant%2FReference=&search_Variant%2FDetection%2
FTemplate=&search_Variant%2FDetection%2FTechnique=&search_Variant
%2FDBID= 
5. http://hci-
lovd.hci.utah.edu/variants.php?select_db=MSH6_priors&action=search_uniq
ue&order=Variant%2FDNA%2CASC&hide_col=&show_col=&limit=100&sear
ch_Variant%2FExon=&search_Variant%2FDNA=&search_Variant%2FRNA=
&search_Variant%2FProtein=p.R1095C&search_Variant%2FCustom_PP2_
score=&search_Variant%2FMAPP_score=&search_Variant%2FMAPP%2FP
P2_Prior=&search_Variant%2FReference=&search_Variant%2FDetection%
2FTemplate=&search_Variant%2FDetection%2FTechnique=&search_Varia
nt%2FDBID=    
 
(accessed 26/06/2017)   
 
5.2.5.2 MMR IHC 
FFPE tissue (multiple adenomas and HPPs) was available for all 3 patients in whom 
we had identified MMR gene variants:  Halo26 (6 x TVA LGD, 7 x TA LGD, 1 x VA 
LGD), Halo45 (13 x TVA LGD, 2 x HPP) and Halo70 (2 x TVA LGD, 13 x TA LGD, 1 
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x HPP).  All FFPE tissue blocks underwent IHC analysis of MLH1, MSH2, MSH6 
and PMS2 at the Cellular Pathology Department, University Hospital of Wales. The 
EnVision FLEX System (Agilent) was used, following the manufacturer’s protocol, 
and the primary antibodies MLH1 Flex RTU, MSH2 FE11, MSH6 EP49 and DAKO 
PMS2 1/80.  I reviewed the slides using an Olympus BX43 light microscope. 
 
5.2.5.3 MSI Testing 
DNA was extracted from FFPE polyps by the AWMGS using the Maxwell Promega 
LEV FFPE kit.  MSI testing was carried out by the AWMGS following the protocol 
given in Appendix 5.1. 
 
5.2.6 Results 
5.2.6.1 Database Interrogation 
The results from the database interrogation are summarised in Table 5.2 (InSiGHT 
class 3: uncertain; UV: uncertain variant): 
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The MSH2 variant, c.128A>G:p.Tyr43Cys, has an InSiGHT classification of 3, 
meaning that its pathogenicity is uncertain.  The prior probability of pathogenicity is 
0.8980, in concordance with its InSiGHT classification.  The MSH6 variant, 
c.1106C>T:p.Thr369Ile, has not previously been recorded in the InSiGHT/ UMD 
databases.  However, it has a low prior probability of pathogenicity score:  0.0462.  
This would put it in the InSiGHT class 2 category (https://www.InSiGHT-
group.org/criteria/) i.e. likely not pathogenic.  The variant in Halo70, MSH6 
c.3283C>T:p.Arg1095Cys, had not previously been reported in the InSiGHT 
database.  There were 5 reports on UMD, and it was recorded as a UV.  It had a 
relatively high prior probability of pathogenicity score:  0.9342.  This would place it in 
the InSiGHT class 3 category (https://www.InSiGHT-group.org/criteria/).   
 
5.2.6.2 MMR IHC 
Attempted IHC staining of the MMR proteins was performed on all tumours from the 
3 patients.  One TA LGD from Halo45 had cut out, so there was no tissue available 
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for MMR IHC, and there was insufficient tissue available for complete MMR IHC for 
one HPP from Halo45, so results for MLH1 were not available. 
 
For the tumours with successful MMR IHC, there was no evidence of loss of MMR 
staining in any of the lesions and the staining pattern was normal. 
A representative image of the MMR IHC is shown in Figure 5.1: 
 
A 
 
B 
 
C 
 
D 
 
E
 
 
 
Figure 5.1:  Halo70 TA LGD. A: H&E, B:  MLH1 IHC, C: MSH2 IHC, D: MSH6, E: PMS2 
 
5.2.6.3  MSI Testing 
A subset of 20 tumours underwent MSI testing (Appendix 5.2).  The remaining 
tumour samples did not undergo screening due to significant diathermy artefact/ the 
lesion cutting out/ a small number of dysplastic glands being present amongst 
normal glands/ the specimen being too small.   
 
There was no evidence of MSI in any of the tumours tested. 
 
5.2.7 Conclusions of MMR Gene Investigations 
Database interrogation, MMR IHC and MSI testing was performed for the patients in 
whom variants in the MMR genes had been identified through targeted exome 
sequencing.  Database interrogation showed that all three variants were likely to be 
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of uncertain pathogenicity (MSH2 c.128A>G:p.Tyr43Cys and MSH6 
c.3283C>T:p.Arg1095Cys) or were likely not pathogenic (c.1106C>T:p.Thr369Ile). 
Tumour samples from the carriers of these variants showed normal MMR IHC and 
no evidence of microsatellite instability.  Although relatively small numbers of 
tumours underwent testing, it is unlikely that any of the identified mutations are 
clinically significant.     
 
There were no relatives available for any of the patients to be screened.  
 
In summary, 3 patients were identified as carrying variants in the MMR genes.  
Although polyposis is not the typical phenotype seen in heterozygous carriers of 
MMR gene mutations, these variants were investigated to gain a greater 
understanding of whether they might have significant functional effects.  It is unlikely 
that any of the variants are clinically significant, in view of the normal MMR IHC and 
microsatellite stability of the tumours.   
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5.3 POLE and POLD1 
 
5.3.1 Introduction 
Mutations in the proofreading domains of the human polymerase enzymes, POLE 
and POLD1, have been shown to have a role in the pathogenesis of colorectal 
neoplasia, as described in Chapter 1 (1.5.1.3).  As a result of the targeted exome 
sequencing, four patients were found to carry missense variants in POLE/ POLD1.  
They are summarised in Table 5.3, along with the patients’ phenotypes and the 
location of the resultant amino acid change in the protein:
   
1
8
4
 
Patient 
ID 
Gene Posn. Variant 
CADD 
Score 
Amino Acid 
Change 
Location of Amino Acid Change 
AmbryGe
n Class 
Patient Phenotype 
Halo15 POLE 
12:1332
49812 
T>C 24.4 p.Met471Val 
In ribonuclease H-like domain, DNA directed 
DNA polymerase Family B exonuclease domain 
Not 
reported 
84-year-old male with 13 
TA LGD 
Halo18 POLE 
12:1332
02816 
C>T 23.8 p.Glu2140Lys No domain VUS 
72-year-old male with 27 
polyps,  majority TAs 
Halo27 POLD1 
19:5091
9693 
C>T 34 p.Thr954Met  
In DNA directed DNA polymerase family B 
multifunctional domain 
Not 
reported 
67-year-old female with 17 
adenomas 
Halo61 POLE  
12:1332
45452 
T>C 26 p.Tyr623Cys 
In DNA directed DNA polymerase family B 
multifunctional domain 
VUS 
60-year-old female with 11 
polyps:   2 SAs, 7 TA, 1 
TVA, 1 HPP 
 
Table 5.3:  Variants in the pol genes identified through targeted exome sequencing.  The amino acid location was determined using  
http://www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi?INPUT_TYPE=live&SEQUENCE=NP_006222.2 (accessed 09/03/16)
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Only one of the variants was located in the exonuclease domain of the protein, 
POLE p.Met471Val in Halo15.  All of the pathogenic variants that have been 
reported in the literature thus far are also located within the exonuclease domain of 
POLE/ POLD1 (Palles et al 2013).  However, I hypothesised that a variant may be 
pathogenic, even if it lies outside of the exonuclease domain, if it can alter the ability 
of the exonuclease domain to elicit its functional effects, for example through 
altering the movement of DNA through the active site of the polymerase.   
 
In Palles’ paper (Palles et al 2013), the group examined 39 tumours from 
11 POLE p.Leu424Val carriers for somatic mutations.  Second hits by LOH involving 
the germline wildtype allele were found in some tumours and all tumours were 
microsatellite stable.  Most tumours were screened for KRAS and BRAF driver 
mutations, and a sub-set of tumours were screened for known pathogenic mutations 
in APC, CTNNB1, PIK3CA and FBXW7.  Mutations were all base substitutions.  
This was especially interesting for APC, as ~60% of mutations seen in sporadic 
tumours are frameshifts (reviewed in Palles et al 2013). In addition to this, certain 
sites not commonly mutated in sporadic colorectal tumours seemed to be mutation 
hotspots, for example codons 1114 and 1338 of APC and codon 146 of KRAS. In 
view of this, I hypothesised that the same ‘hot spot’ locations may be mutated in 
tumours obtained from the patients we identified as harbouring germline POLE 
variants, if the variants were pathogenic.  I also hypothesised that the tumours 
should be microsatellite stable, in keeping with Palle’s results.  
 
Palle’s group is currently carrying out work to determine whether tumours 
developing in patients carrying pathogenic mutations in the pol genes have a 
characteristic mutational signature.  We collaborated with their group to examine the 
somatic mutations in tumours occurring in the patients we identified as carrying pol 
gene variants. 
 
The genetic variants identified were therefore investigated through a combination of: 
 
 Modelling the mutant proteins to investigate whether the amino acid 
changes could theoretically affect movement of DNA through the 
exonuclease domains of the polymerases.  This work was carried out in 
collaboration with Dr. Pierre Rizkallah, Cardiff University 
 Somatic mutation screening, to identify ‘hotspot’ mutations as described by 
Palles et al (2013) 
  186 
 MMR IHC and MSI testing to determine whether tumours were microsatellite 
stable 
 Segregation/ de novo analysis in families, where family members were 
available for testing 
 Investigation of the mutation signature of the tumours.  This work was 
carried in collaboration with Professor Ian Tomlinson and Dr. Claire Palles 
(Oxford University/ Birmingham University) 
 
5.3.2 Methods 
 
5.3.2.1 In Silico Modelling of Pol Variants 
Thank you to Dr. Pierre Rizkallah for his expert help with this part of the project. 
 
The Protein Databank (PDB) (http://www.rcsb.org) server’s BLAST based sequence 
alignment algorithm was used to match the human POLD1 sequence with the 
sequence of many POLD1 entries represented in the structural database. The top 
hit was 3IAY (Swan et al 2009), with the alignment shown in Appendix 5.3a. The 
sequence of the human POLE had the top hit 4M8O (http://www.rcsb.org, Hogg et 
al 2014).  The alignment is shown in Appendix 5.3b.  These models were then used 
to analyse the effect of variants on a per residue basis. The program 
Crystallographic Object-Oriented Toolkit (COOT) (Emsley and Cowtan 2004) 
introduced the identified mutations and regularised the geometry in the immediate 
neighbourhood. PyMOL (Delano 2002) was used to produce graphical images to 
visualise the results of the predictions. 
 
5.3.2.2 Somatic ‘Hot Spot’ Mutation Screening in APC and 
KRAS 
At the time of the experiments, a total of 15 FFPE tumours were available for 
Halo15 and Halo61 (Halo15:  11 x TA LGD; Halo61: 4 x TA LGD) (Appendix 5.4).  A 
further 45 tumours were obtained from patients with variants in POLE that were 
assumed to be non-pathogenic, due to their AmbryGen classification (4.1.4.2.4) 
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(Halo31:  10 x TA LGD, 2 x HPP; Halo69:  6 x TA LGD, 10 x HPP, 1 x CRC; Halo81:  
3 x TA LGD, 3 x TVA LGD, 9 x HPP, 1 x TVA arising in a SSL) (Appendix 5.4).  
These were included in the study protocol to ensure that somatic ‘hotspot’ mutations 
were not present: if such mutations had been identified it would suggest that the 
designation of the variants as benign may not be correct.  DNA was extracted from 
the tumours using the GeneRead DNA FFPE Kit (Qiagen) following the standard 
protocol (2.3.4).  DNA underwent PCR and Sanger sequencing using standard 
reagents and reaction conditions for DNA extracted from FFPE tissue (2.3.8.2, 
2.3.8.5, 2.3.9-2.3.13).  Tumours were screened at the ‘hotspot’ mutation locations in 
APC and KRAS described by Palles et al (2013): APC codons 1114 and 1338 and 
KRAS codon 146.   Primers were designed using primer3 software and were 
supplied by Eurofins (Appendix 5.5).  
 
5.3.2.3 MMR IHC and Microsatellite Stability of Tumours 
in Carriers of Pol Gene Variants 
34 FFPE tumours from Halo15, Halo27 and Halo61 were available (Halo15:  11 x 
TA LGD; Halo27: 17 x TA LGD, 1 x SSL; Halo61: 5 x TA LGD (Appendix 5.6). 
All FFPE tumours underwent IHC analysis of MLH1, MSH2, MSH6 and PMS2 at the 
Cellular Pathology Department, University Hospital of Wales. The EnVision FLEX 
System (Agilent) was used, following the manufacturer’s protocol, and the primary 
antibodies MLH1 Flex RTU, MSH2 FE11, MSH6 EP49 and DAKO PMS2 1/80. 
A subset of 28 tumours underwent DNA extraction.  This was done by the AWMGS 
service using the Maxwell Promega LEV FFPE kit.  MSI testing was carried out 
following the protocol given in Appendix 5.1.  The remaining tumours did not 
undergo MSI testing due to the dysplastic glands being too scanty to warrant DNA 
extraction or there being significant diathermy artefact. 
 
5.3.2.4 Segregation Analysis 
I sought to recruit relatives of the patients in whom we had identified germline 
variants in POLE and POLD1 to try and determine whether the variants were 
occurring de novo in the index cases or whether they were segregating with disease 
if multiple family members were affected.  
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Halo15 was an only child and there was no family history of colorectal neoplasia.  
Halo18’s mother and maternal aunt had a possible history of CRC, reported by the 
family.  Halo18 has two siblings who are thought to be unaffected.  Halo27 has 3 
siblings with colorectal polyposis and her father had CRC.  Halo61 has one sibling 
with colorectal polyposis and 2 unaffected siblings.  She had a son who died of CRC 
at the age of 23.  The son’s tumour IHC was suggestive of a MMR defect, but there 
was insufficient DNA for MSI testing.  Halo61 also has a daughter who had 
developed a single colorectal polyp at the age of 28.  There was, in addition, a 
history of CRC on her husband’s side of the family. 
 
The only relatives that were successfully recruited to the study were both children of 
Halo15.  The daughter of Halo15 was a 43-year old female.  She had a colonoscopy 
at age 30 for rectal bleeding:  it showed colonic endometriosis but no polyps.  The 
son was a 42-year old male who has never had a colonoscopy.  Germline DNA was 
extracted from whole blood by the AWMGS (2.3.2).  RNA was extracted from whole 
blood following the standard protocol (2.3.3).  RNA was reverse transcribed to 
cDNA (2.3.3.2).  DNA and RNA underwent PCR and Sanger sequencing to screen 
for the POLE mutation, c.1411A>G:p.Met471Val.  Standard reagents and reaction 
conditions were used (2.3.8.1, 2.3.8.5, 2.3.9-2.3.13).  DNA  primers were those 
used for Haloplex validation (Appendix 4.2). cDNA primers are listed in Appendix 
5.7. 
 
5.3.2.5 Investigation into the Mutation Signature of 
Tumours 
This work was carried out with Professor Ian Tomlinson’s group at the Wellcome 
Trust Centre for Human Genetics, Oxford University.  I am extremely grateful for 
their help and involvement. 
 
The mutation signature of tumours occurring in patients with germline POLE/ 
POLD1 variants was determined by examining 30 genes.  For some genes, the full 
coding regions, with 10 bp flanking region were interrogated.  For others, hotspots 
or domains were selected.  The genes interrogated were: ACVR2A, APC, ARID1A, 
ATM, B2M, BCL9L, BMPR2, BRAF, CTNNB1, ELF3, FBXW7, GNAS, KRAS, MLH1, 
MSH2, MSH6, NRAS, PIK3CA, POLD1, POLE, PTEN, RNF43, RPL22, SMAD2, 
SMAD4, SOX9, TCF7L2, TGIF1, TP53, ZFP36L2.  
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The genes which didn’t have the full coding region examined were: APC (codons 1-
1600), POLD1 (chr19:50905938-50910304), POLE (chr12:133249809-133253238), 
GNAS (codon 200), BRAF (exons 11 and 15: chr7: 140453074-140453193, 
chr7:140481375-140481493), CTNNB1 (hotspots chr3:41266444-41266698, 
chr3:41267150-41267352, chr3:41274831-41274935, chr3:41275019-41275358, 
chr3:41277214-41277334, chr3:41266016-41266244), PIK3CA (hotspots 
chr3:178916613-178916965, chr3:178935997-178936122, chr3:178951881-
178952152). 
 
Gene capture was achieved using single molecule molecular inversion probes 
(smMIPs), which were designed by Dr. Palles using MIPgen software and were 
supplied by Integrated DNA Technologies.  A total of 300 smMIPs were used to 
target 63.1kb.  The smMIPs capture ~1800 sites which are commonly mutated 
when there is impaired POLD1/ POLE proofreading due to a functional mutation in 
the exonuclease domain (Palles personal communication). 
 
I travelled to Oxford to assist with the smMIP gene capture.  The protocol for the 
capture and subsequent sequencing is described in Chapter 2 (2.4.6). 
 
5.3.3 Results 
 
5.3.3.1 Modelling of Pol Variants 
The 3-dimensional location of the variants is described and shown, along with their 
potential functional effects, in Table 5.4:  
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5.3.3.2 Somatic ‘Hot Spot’ Mutation Screening in APC and 
KRAS 
60 tumours from patients carrying presumed benign or putatively pathogenic Pol 
gene variants were screened for mutations at APC codons 1114 and 1338, and 
KRAS codon 146.  No mutations were identified. 
 
5.3.3.3 MMR IHC and Microsatellite Stability of Tumours 
in Carriers of Pol Gene Variants 
34 tumours from patients carrying putatively pathogenic variants in POLE/ POLD1 
were screened using MMR IHC +/- MSI testing.  There was no evidence of loss of 
MMR protein staining or MSI in any of the samples (Appendix 5.8). 
 
5.3.3.4 Segregation Analysis 
The son and daughter of Halo15 both underwent screening for the POLE  variant, 
c.1411A>G:p.Met471Val.  The variant was present in the daughter only, in both 
DNA and cDNA (sequencing traces in Appendix 5.9). 
 
5.3.3.5 Investigation into the Mutation Signature of 
Tumours 
A total of 2 tumour samples from Halo15 have thus far undergone successful 
smMIP gene capture and sequencing.  Both lesions were TA LGD. Tumour samples 
from Halo27 are currently being analysed: DNA from 7 x TA LGD has been 
submitted.  The tumour DNA (one TA LGD) from Halo61 failed quality control and 
no results are available.  
 
At the time of writing, the high quality raw results for somatic mutation sequencing 
for Halo15 were available (Appendix 5.10).  However, these were being further 
analysed by the bioinformatics team at Birmingham University, to determine 
whether they are consistent with a hypermutated signature observed in tumours 
occurring in carriers of known pathogenic mutations in the pol genes. 
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5.3.4 Conclusions of POLE/ POLD1 Gene Interrogation 
Four patients were found to carry potentially pathogenic germline mutations in 
POLD1 or POLE.  All variants were missense changes.  The variants were 
investigated using a combination of database interrogation, modelling the variants 
using in silico structural modelling, MMR IHC and MSI testing, somatic mutation 
analysis and family segregation studies. 
 
Based on in silico modelling, two of the variants were thought most likely to be 
disease-causing.  One was a POLD1 variant in Halo27, p.Thr954Met, which was 
predicted to distort the structure of the active site of the enzyme.  It had a very high 
CADD score of 34. The second variant was identified in Halo15, p.Met471Val.  This 
is a novel variant which is located in the exonuclease domain of the protein. 
 
The remaining two variants included a POLE variant in Halo18, p.Glu2140Lys, and 
a POLE variant in Halo61, p.Thr623Cys.  POLE p.Glu2140Lys is reported as benign 
on dbSNP.  It does not lie within any of the POLE functional domains and was not in 
the protein model used as part of this project.  The variant is considered very 
unlikely to be clinically significant.   
 
POLE p.Thr623Cys was suggested to possibly have pathogenic effects that could 
be mediated through an alteration in the protein structure in the proximity of DNA as 
it moves through the active site of the enzyme (Dr. Pierre Rizkallah, personal 
communication).  It has a CADD score of 26 and is classified as a VUS by 
AmbryGen.  Tumour DNA from Halo61 did not have any evidence of ‘hot spot’ 
mutations in APC or KRAS, although only 4 lesions were available for analysis.  
Unfortunately, tumour DNA was not successfully sequenced following smMIP gene 
capture, so its mutation signature remains uncertain.  Therefore, at the present time, 
there is insufficient evidence to support or refute a pathogenic effect of this mutation 
and it remains a VUS. 
 
Tumours from Halo15 and Halo61 underwent testing for somatic ‘hotspot mutations’ 
described by Palles et al (2013).   No such mutations were identified, however this 
is not surprising:  in Palles’ paper, the mutations were present at the following 
frequencies: 
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Variant 
Prevalence in 
Adenomas 
Prevalence in 
Carcinomas 
APC p.Arg1114* (C>T) 1/36 (3%) 1/3 (33%) 
APC p.Gln1338* (C>T) 3/36 (8%) 1/3 (33%) 
KRAS p.Ala146Thr 
(A>C) 
1/36 (3%) 1/3 (33%) 
 
There were 11 tumours available for Halo15/ p.Met471Val and 4 for Halo61/ 
p.Tyr623Cys.  This study was therefore underpowered to identify mutations at the 
hotspot locations, as we had insufficient numbers of tumours.  Additionally the 
dysplastic epithelial component of the lesions was highly variable – ranging from 
10%-100%.  For the lesions with a small dysplastic component, even if a hotspot 
mutation was present it may not have been observed with Sanger sequencing.   
 
Tumour material for Halo27 only became available at a late stage of the project.  
Tumour DNA did not undergo screening for the ‘hot spot’ variants but is undergoing 
mutation signature analysis, which potentially has a greater power to support or 
refute the pathogenicity of the POLD1 variant. 
 
All of the tumours from Halo15, Halo27 and Halo61 which underwent MSI testing 
were found to be microsatellite stable.   
 
The only relatives available for family studies were the son and daughter of Halo15.  
The daughter was found to carry the same variant as her affected father, and this 
was confirmed to be present in both DNA and cDNA.  However, her phenotype is 
not accurately known, as she has not had a recent colonoscopy.  The genetic 
finding has been fed back to her clinician, who has arranged surveillance 
colonoscopy.  
 
SmMIP gene capture is being performed on tumour DNA from Halo15 and Halo27, 
in collaboration with Professor Ian Tomlinson’s group at Oxford University/ 
Birmingham University.  The aim of this work is to determine whether the tumours 
from these patients have a hypermutated genetic signature, in keeping with that 
observed in the tumours which occur in carriers of known pathogenic mutations in 
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the pol genes.  Although the raw results are available for 2 TA LGD from Halo15, 
bioinformatic analysis is still pending.  There was a seven-month delay between 
carrying out the sample preparation and obtaining the raw data, due to factors 
outside of our control.  It is anticipated that the complete analysis will be finalised 
within the next several months.  Therefore, at present, the variants identified in 
Halo15 and Halo27, c.1411A>G:p.Met471Val  and c.2861C>T:p.Thr954Met 
respectively, remain as VUS.  
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5.4 AXIN2 and AXIN2-Associated Polyposis (AxAP) 
 
5.4.1 Introduction 
The role of the Wnt-pathway in colorectal neoplasia has been described in the 
previous chapters of this thesis.  AXIN2 is a scaffold protein which is involved in 
regulating Wnt signalling.  It forms part of the ‘destruction complex’ which targets β-
catenin for degradation: AXIN2 supports the GSK3β-dependent phosphorylation of 
β-catenin, which marks the protein for ubiquitination and subsequent proteosomal 
degradation (reviewed in Wu et al 2012).  The AXIN2 protein has several domains, 
including a Tankyrase binding domain which regulates protein stability, an RGS 
domain which mediates binding to APC, a β-catenin binding domain and a DIX 
dimerization domain (reviewed in Mazzoni and Fearon 2014).  AXIN2 is a 
transcriptional target of β-catenin dependent Wnt signalling, and its levels are 
elevated in cancers with Wnt activating mutations, therefore potentially negatively 
regulating Wnt signalling (reviewed in Mazzoni and Fearon 2014). 
 
In view of its effects on Wnt signalling, it is possible that germline AXIN2 mutations 
might be associated with an increased risk of colorectal neoplasia.  In 2004, Lammi 
et al described a Finnish family with oligodontia (Lammi et al 2004).  The family 
exhibited oligodontia segregating as an AD trait across 4-generations.  Two patients 
from the oldest generation were known to have a history of colorectal neoplasia 
(one had metastatic CRC and the other had 68 adenomas) and 10 further family 
members underwent a colonoscopy/ sigmoidoscopy:  7 with oligodontia and 3 
healthy individuals.  Colorectal neoplasia was identified in 6 individuals with 
oligodontia, but not in the unaffected individuals.  The colorectal phenotype was 
highly variable, ranging from a single HPP to 10-20 HPP plus 2 adenomas.  Family 
members were screened for AXIN2 mutations in coding regions/ flanking intronic 
sequences, and a c.1966C>T transition in exon 7 of was identified. This results in a 
p.Arg656* codon and premature termination of translation.  The mutation was 
present in 11 individuals with oligodontia, but in none of 6 healthy family members. 
The group also identified a further AXIN2 truncating mutation in a 13-year-old boy 
with oligodontia.  They describe a 1bp G insertion after nucleotide 1994 in exon 7, 
which results in re-coding of the amino acids starting at p.Asn666 and a stop codon, 
40 codons later.  The same mutation had previously been identified as a somatic 
mutation in CRC (reviewed in Lammi et al 2004).  
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Lammi et al concluded that their results provide strong evidence that familial 
colorectal cancer can be caused by mutations in AXIN2. 
 
In 2011, Marvin et al reported the identification of a novel AXIN2 mutation, 
c.1989G>A, in a family with a history of oligodontia, absent eyebrows, sparse hair, 
colonic polyps, early onset CRC and early onset breast cancer (Marvin et al 2011).  
The colorectal phenotype included an individual with >100 adenomas and an 
individual with 2 metanchronous CRC plus 5 adenomas.  The mutation introduces a 
stop codon at amino acid 663, p.Tyr663*, in exon 7 (Marvin et al 2011).  It was 
identified in 3 individuals with a phenotype of oligodontia and colorectal neoplasia, 
and was absent in 2 unaffected family members.  Subsequent in vitro transcription 
and translation of a c.1989G>A construct and expression of the construct in 
HEK293T cells produced a truncated AXIN2 product (Marvin et al 2011).  The group 
commented that their findings provided further evidence of an AD multisystem 
ectodermal and neoplastic phenotype associated with a germline AXIN2 mutation.  
They noted that the truncated protein would lack its DIX dimerization domain, which 
they predicted would impair the inhibitory action of AXIN2 on WNT signalling. 
 
Functional studies subsequently carried out on the mutation identified by Marvin et 
al (2011), AXIN2 c.1989G>A, revealed that the mutation did not result in nonsense 
mediated decay (NMD), and that it could cause activation of the Wnt pathway, 
although this was context dependent (Mazzoni et al 2015).  The group transiently 
transfected HEK293T cells with wild-type and mutant-containing plasmids.  They 
showed that truncated AXIN2 protein was more abundant than wild-type (WT) 
protein, despite equivalent transcript levels. Interestingly, despite lacking the 
dimerization domain, truncated AXIN2 was still found to interact with both WT-
AXIN2 and truncated AXIN2.  It was suggested that such interactions may not be 
direct but might be mediated by another protein in the destruction complex, such as 
APC, which contains AXIN binding sites.  Although truncated AXIN2 was able to 
interact with AXIN2, its ability to bind to AXIN1 was impaired.  An important point to 
note is that when overexpressed, truncated AXIN2 was able to inhibit SW480 CRC 
cell colony formation and was able to inhibit β-catenin/ T cell factor- dependent 
reporter gene activity, as would be expected with WT protein.  However, when 
stably expressed in rat intestinal IEC-6 cells, truncated AXIN2 did not match WT 
AXIN2’s ability to inhibit Wnt-mediated expression of Wnt-regulated target genes 
(Mazzoni et al 2015).  It was suggested that when AXIN2 levels are low, such as in 
the absence of Wnt-stimulation, the mutation may have a loss-of-function effect.  
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When there is elevated AXIN2 expression, the truncated protein may have gain-of-
function effects.   
 
In 2014, Rivera et al identified a further novel variant in AXIN2 in a 3-generation 
family with a phenotype of multiple colorectal adenomas and/ or CRC, but without 
any signs of ectodermal dysplasia/ oligodontia.  The missense variant, c.1387C>T, 
p.Arg463Cys is located in exon 5 within the β-catenin binding domain.  However, its 
pathogenicity is questionable, as the mutant allele was apparently lost in polyps 
from the proband and his sister (Mazzoni and Fearon 2014), and the mutation was 
found to be present in an unaffected relative (Rivera et al 2014). 
 
Although these three papers have identified potentially pathogenic germline AXIN2 
mutations in patients with colorectal polyposis/ CRC, there are also several studies 
which have failed to identify pathogenic variants, although the study cohorts were 
small (Mongin et al 2012; Lejeune et al 2006).  Mongin et al (2012) did not identify 
any mutations in the coding sequence of AXIN2 in a cohort of 38 NMI patients with 
>40 adenomas or >20 polyps, and Lejeune et al (2006) failed to identify pathogenic 
variants in AXIN2 in a cohort of 31 patients with multiple colorectal adenomas (18 
individuals), one of whom also had tooth agenesis, or microsatellite stable CRC (13 
individuals).  However, in the latter paper, the patients had only undergone APC 
screening to define their NMI status, and when MUTYH was analysed as part of the 
study protocol, 32% of the patients were found to have MAP. 
 
Chapter 4 described the targeted exome capture and UDS of genes which might be 
implicated in polyposis/ CRC.  A sibling pair was found to carry a truncating 
mutation in AXIN2:  c.1642G>T:p.Glu548* (Halo47 and Halo68, Family A).  This 
section of Chapter 5 will focus on this mutation and approaches to investigate its 
possible pathogenicity.   
 
5.4.2 Halo47 and Halo68:  Family History and Clinical 
information 
Halo47 was a 51-year-old female when she was recruited to the study.  In 2013, at 
the age of 50, she had removal of 2 TVAs with LGD and 3 TAs with LGD. A 
subsequent colonoscopy found >50 sessile polyps, up to 10mm, throughout the 
colon.  She underwent a subtotal colectomy, and approximately 40 sessile polyps 
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were identified macroscopically.  Four blocks were taken of polyps: the majority 
were TA LGD, but 2 were serrated adenomas (it is not clear exactly how many 
polyps were sampled).  The patient was due to have a completion colectomy, but at 
the time of surgery she was found to have a large rectal cancer.  She underwent 
sigmoidectomy/ proctectomy/ abdominoperineal resection and the cancer was 
reported as being pT4bN2MX, Duke's C1.  Unfortunately, she developed liver and 
lung metastases and she passed away during the course of this project. 
 
Her sister, Halo68, had a colectomy for colorectal polyposis at the age of 50.  She 
had 14 TA with LGD and 6 HPPs. 
 
Both Halo47 and Halo68 had been diagnosed with colorectal neoplasia following 
symptomatic presentation. 
 
There is a family history of intestinal neoplasia.  Their mother (1.2) had CRC 
(moderately differentiated Duke’s A adenocarcinoma), and her medical records 
described a VA with LGD and ‘three small metaplastic polyps’ identified 
macroscopically, one of which was confirmed microscopically to be a HPP.  When 
all available specimens were reviewed for this research, she was found to have had 
at least one VA LGD, CRC arising in a VA, one HPP and one TA LGD. 
 
The sisters Halo47 and Halo68 had a maternal aunt (1.1) with pT3N2MX CRC and 
8 polyps (5 were sampled and were found to be TA with LGD) and a maternal aunt 
with ‘stomach cancer’ reported by the family (it was not possible to access her 
medical records). 
 
The family tree is illustrated in Figure 5.2 and the family is hereafter referred to as 
Family A: 
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Figure 5.2:  Family tree of Family A  
 
Both sisters and their mother allegedly lacked all adult teeth.  This was confirmed in 
Halo68 by a formal dental assessment at the University Hospital of Wales dental 
department.  Halo68 was reviewed in clinic and was found to have sparse hair on 
the outer third of her eyebrows, thin hair on her head, and she was born with a 
malformation of the nail on her left index finger.   
 
One of the daughters of Halo68 also has sparse hair on the outer third of her 
eyebrows, but her head hair and teeth are normal.  Family photos of Halo47 and 
Individual 1.2 are suggestive of scanty eyebrow hair.  See Figure 5.3. 
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Figure 5.3:  Phenotype of Halo68 (A-G) and her daughters (H-M).  Halo68:  note sparse 
eyebrows and thin hair (A-D), malformation of finger nail (E, F), and absence of teeth on an 
orthopantogram (G).  One daughter has sparse eyebrows (H, I) but her hair (J), nails and 
teeth are normal.  The second daughter is phenotypically normal (K-M).  N and O:  Halo47 
wearing false teeth (N) and Individual 1.2 (O):  both appear to have scanty eyebrow hair 
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5.4.3 AXIN2: c.1642G>T:p.Glu548*  
The germline mutation identified in the affected siblings Halo47 and Halo68 is 
AXIN2 c.1642G>T:p.Glu548* in exon 5.  The mutation was confirmed to be present 
in the cDNA of Halo47 (4.1.4.2.3).  If a truncated protein results from this mutation it 
is predicted to lose its DIX dimerization domain 
(http://www.uniprot.org/uniprot/Q9Y2T1#showFeaturesViewer accessed 
04/05/2017).   
 
5.4.4 Studies to Investigate the Mutation 
The further studies performed to determine the pathogenicity of AXIN2 
c.1642G>T:p.Glu548* are described below. 
 
5.4.4.1 Family Segregation Studies 
There is a family history of colorectal neoplasia (Figure 5.2).  It is important to 
ascertain whether the mutation is segregating with the disease phenotype.  It is also 
important to try to determine which of the additional clinical features observed in the 
family, i.e. sparse eyebrows/ thin hair/ nail abnormalities/ oligodontia, are a part of 
the disease spectrum. 
 
5.4.4.2 Protein Analysis to Confirm that the AXIN2 
Mutation Produces a Truncated Protein 
It has already been shown that the mutation is present in DNA and is transcribed to 
RNA.  This is interesting, as the location of the mutation is predicted to trigger NMD.  
NMD refers to the process in which mRNA harbouring premature termination 
codons (PTCs) is destroyed (Wen and Brogna 2008).  It is a surveillance 
mechanism which prevents the accumulation of aberrant mRNA, and therefore 
potentially toxic truncated peptides (Wen and Brogna 2008).  AXIN2 c.1642G>T is 
predicted to result in NMD (http://www.mutationtaster.org/cgi-
bin/MutationTaster/MutationTaster69.cgi accessed 31/08/2016) and yet it remains 
present in RNA, similar to the findings of Marvin et al (2011) for the reportedly 
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pathogenic mutation p.Tyr663*.  The next logical step is to confirm that the mutation 
produces a truncated protein.  
 
5.4.4.3 β-catenin IHC on FFPE Tumours to Assess 
Somatic Activation of the Wnt Pathway 
APC mutations allow the accumulation and nuclear translocation of β-catenin.  
Histologically normal colorectal epithelia exhibit a membranous location of β-
catenin, as observed with IHC (Wong et al 2004; Iwamoto et al 2000; Hao et al 
1997; Valizadeh et al 1997).  Colorectal adenomas, which are typically 
characterised by APC mutations, may display membranous and nuclear staining 
(Wong et al 2004; Iwamoto et al 2000; Hao et al 1997; Valizadeh et al 1997), but 
nuclear staining is not always observed (Kobayashi et al 2000).  It is likely that 
nuclear staining increases with increasing degrees of dysplasia (Wong et al 2004; 
Iwamoto et al 2000; Kobayashi et al 2000; Hao et al 1997; Valizadeh et al 1997).  β-
catenin nuclear staining seems to occur in the majority of CRC (Wong et al 2004; 
Iwamoto et al 2000; Hao et al 1997), although not all papers report the same 
finding: Kobayashi et al (2000) observed that 55% of sporadic CRC exhibited 
negative/ scattered nuclear β-catenin expression.  Different results could be 
attributed to differences in the protocols used for immunostaining, and differences in 
histological interpretation of neoplastic lesions (Wong et al 2004). 
 
AXIN2 is a further component of the β-catenin ‘destruction complex’.  I therefore 
hypothesised that pathogenic AXIN2 mutations might result in a similar pattern of β-
catenin immunostaining as is observed in adenomas/ CRC with APC mutations.  I 
sought to determine the subcellular location of β-catenin in adenomas/ CRC from 
patients with inherited variants in AXIN2 using IHC.  The results from this work are 
to be interpreted alongside the results from the somatic APC gene mutation 
screening in the same tumours. 
 
5.4.4.4 Somatic APC Screening 
The APC mutations which play a role in the pathogenesis of colorectal neoplasia 
are not random: ‘typical’ patterns are identified.  Approximately a third of germline 
mutations in FAP patients occur at codons 1061 and 1309, and the reminder occur 
 204 
 
largely uniformly between codons 1200 and 1600 (Fearnhead et al 2001).  As 
described in the introduction chapter (1.5.1.1) of this thesis, in FAP the nature of the 
first mutation determines the type of second hit to APC.  If the germline mutation 
occurs between codons 1194 and 1392, there is selection for allelic loss of APC as 
the second hit, whereas if the germline mutation lies outside of this region, the 
second hit is most likely to be a truncating mutation in the MCR (Fearnhead et al 
2001).  In sporadic tumours, over 60% of somatic mutations occur between codons 
1286 and 1513, the MCR, which accounts for <10% of the coding sequence of APC 
(Fearnhead et al 2001).  Within the MCR, there are further hotspots for mutations at 
codons 1309 and 1450 (reviewed in Fearnhead et al 2001) and codon 1554 (Rowan 
et al 2000). 
 
APC mutations partially mediate their effects through enhanced Wnt-signalling.  
AXIN2 mutations are hypothesised to have a similar effect.  If this is true, then the 
tumours which occur in patients with inherited AXIN2 mutations might not need to 
acquire APC mutations, so the ‘typical’ APC mutations observed in colorectal 
tumourigenesis might be absent.  However, if typical APC mutations are identified in 
patients with germline AXIN2 variants this could suggest that AXIN2 variants are not 
pathogenic or alternatively that they are exerting tumourigenic effects through a 
mechanism other than through the Wnt-pathway. 
 
To further elucidate the mechanism(s) by which AXIN2 mutations may exert 
pathological effects, DNA was extracted from FFPE tumours originating in patients 
with inherited AXIN2 variants.  DNA was screened to determine whether ‘typical’ 
APC mutations were present.  
 
5.4.4.5 AXIN2 Loss of Heterozygosity (LOH) Analysis 
LOH describes the situation whereby one allele of a gene is ‘lost’ somatically.  It is a 
common genetic event in many cancers.  It may develop through copy neutral 
mechanisms, in which there is a homologous recombination event or because a 
retained chromosome was duplicated, or it may be observed with copy loss, in 
which all/ part of the chromosome is lost (Ryland et al 2015).  LOH is strongly 
associated with the loss of the wild-type allele in the tumours of individuals with 
inherited cancer predisposition syndromes who carry a germline mutation in a 
tumour suppressor gene (Ryland et al 2015). 
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Of the three papers which suggest that germline AXIN2 mutations may predispose 
an individual to the development of polyposis +/- CRC (Lammi et al 2004; Marvin et 
al 2011; Rivera et al 2014), only one sought to investigate AXIN2 LOH (Rivera et al 
2014).  Paradoxically it was the mutant allele which was lost in the tumours which 
were sampled.  Two adenomas from the proband and four polyps (two adenomas, 
one HPP and one mixed polyp) from a sister were examined:  LOH of the mutant 
allele was identified in one polyp from the proband, and in an adenoma and the 
mixed polyp from the sister.  The authors also noted that the ‘other adenoma 
(with low-grade dysplasia) had reduced amplification of one allele, and therefore 
incipient LOH, but not sufficiently so to confirm LOH per se’. 
 
If AXIN2 is acting as a typical tumour suppressor gene, and inherited mutations 
result in an increased risk of neoplasia, it would be expected that there might be 
loss of the wild type allele in tumours.  This was investigated in DNA extracted from 
FFPE tumours. 
 
5.4.4.6 Functional Characterisation of AXIN2 
c.1642G>T:p.Glu548* 
Pathogenic mutations in AXIN2 are proposed to result in increased activation of the 
Wnt-pathway, in a similar manner to APC mutations.  To determine whether the 
variant identified in this study impacts Wnt-signalling, HEK293 TCF-Luc reporter 
cells were transfected with WT-AXIN2, the AXIN2 mutation identified by Marvin et al 
(2011) (c.1989G>A, p.Tyr663* referred to hereafter as Fearon-AXIN2.  See 
5.3.2.7.1) or with the variant identified during this study (c.1642G>T:p.Glu548*,  
Short-AXIN2).  Wnt-pathway activation was assessed using luciferase assays. 
 
5.4.5 Methods 
 
5.4.5.1 Family Segregation Studies 
In addition to Halo47 and Halo68, a further 6 family members were recruited to the 
study.  The details of these individuals are in Figure 5.4 and Table 5.5 below: 
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Figure 5.4:  Family tree of Family A illustrating recruited individuals.  The yellow circles 
indicate recruited family members. 
 
 
Family 
Member 
Demographic 
Details 
Phenotype 
Material 
Available for 
Analysis 
Individual 
1.1 
 
Deceased 
female 
Moderately differentiated CRC 
pT3N2Mx. 8 polyps identified 
macroscopically:  5 sampled: TA 
with LGD.  Hemicolectomy 
performed when the patient was 
79-years-old  
FFPE material: 
tumour and 
normal mucosa 
(4 x TA LGD, 1 
x CRC) 
Individual 
1.2 
 
Deceased 
female 
Moderately differentiated Duke’s 
A CRC, a VA with LGD and 
‘three small metaplastic polyps’, 
one of which was confirmed 
microscopically to be a HPP.  
FFPE material: 
tumour and 
normal mucosa 
(1 x TA LGD, 1 
x VA LGD, 1 x 
VA LGD that 
Halo68 Halo47 
1.1 1.2 
2.1 
3.3 3.2 3.1 
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CRC diagnosed when the patient 
was 59-years-old. 
Allegedly did not develop adult 
teeth 
CRC has arisen 
in, 1 x CRC, 1 x 
HPP) 
Individual 
2.1 
48-year-old 
male 
Clear colonoscopy in 2016 
Normal teeth 
DNA from 
whole blood 
Individual 
3.1 
 
35-year-old 
female 
Clear colonoscopy as a 
teenager, no recent colorectal 
examination 
Normal teeth 
DNA from 
whole blood 
Individual 
3.2 
 
27-year-old 
female 
Never had a colonoscopy 
Normal teeth 
DNA from 
whole blood 
Individual 
3.3 
 
24-year-old 
female 
Never had a colonoscopy 
Allegedly lacks 2 adult teeth 
DNA from 
whole blood 
 
Table 5.5: Demographic details and clinical phenotypes of recruited family members 
 
For the individuals in whom blood was available, DNA was extracted from whole 
blood by the AWMGS (2.3.2).  DNA was screened for the familial AXIN2 mutation 
with PCR and Sanger sequencing using standard reagents and reaction conditions 
(2.3.8.1, 2.3.8.5, 2.3.9-2.3.14).  The primers were those used for Haloplex validation 
(Appendix 4.2). 
 
For the individuals in whom FFPE tissue was available, DNA was extracted from 
normal mucosa by the AWMGS using the Maxwell Promega LEV FFPE kit.  DNA 
underwent PCR using reagents as per the protocol for PCR for DNA extracted from 
FFPE tissue (2.3.8.2, 2.3.8.5, 2.3.10).  The primers were those used for Haloplex 
validation (Appendix 4.2), and the products were sequenced from reactions using 
Tas of 55.1 and 63.4⁰C, which were the Tas resulting in successful PCR 
amplification.  6.25 µl of PCR product was used in the Big Dye reaction, which 
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followed standard conditions (2.3.11).  Subsequent steps in the sequencing protocol 
followed the standard conditions (2.3.12, 2.3.13).  
 
For any individual not found to carry the AXIN2 mutation, the PCR and sequencing 
reactions were repeated with a second set of primers (Appendix 5.11). 
 
5.4.5.2 Protein Analysis: Confirmation of a Truncated 
Protein 
The familial AXIN2 mutation, c.1642G>T:p.Glu548*, had been shown to be present 
in cDNA.  To confirm that it produces a truncated protein, HEK293 TCF-Luc cells 
were transfected with WT-AXIN2 plasmid, Short-AXIN2 plasmid or empty plasmid.  
The Short-AXIN2 plasmid had been generated through SDM of WT-AXIN2 
(5.3.2.6.1, 5.3.2.6.2). The same protocols and plasmid dilutions were followed as for 
the Luciferase assays (5.3.2.7, 2.5.7-2.5.10).  A 24-well plate was used so the 
reaction volumes were adjusted accordingly.  48-hours after transfection, the cells 
were lysed and protein extracted (2.5.13).  Protein was quantified using a BCA 
assay (2.5.14), and equivalent amounts of protein underwent Western Blotting, 
using anti-myc primary antibodies, and anti-mouse secondary antibodies (2.5.15).   
To ensure that equal amounts of protein had been loaded onto the electrophoresis 
gel, the membrane was stripped using Restore Plus Stripping Buffer (2.5.16) and 
was re-probed using primary antibodies against -actin and anti-mouse secondary 
antibodies (2.5.15). 
5.4.5.3 β-Catenin Immunohistochemistry (IHC) 
FFPE tumours were available for Halo47 (CRC, TA LGD x 3, SA x 2) and Halo68 
(TA LGD x 14, HPP x 6), their mother (Individual 1.2.  CRC, the VA LGD that the 
CRC had arisen from, TA LGD x 1, VA LGD x 1, HPP x 1) and their aunt (Individual 
1.1.  CRC, TA LGD x 4).  
 
IHC was also performed on a known FAP patient (germline mutation APC 
c.2940_2941 delA) as a positive control (CRC, TA LGD x 8, TA HGD x 1, mixed 
TVA/ HPP x1, biopsy of HGD/ CRC). 
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The Cellular Pathology Department, Cardiff and Vale NHS Trust, carried out β-
catenin IHC using the EnVision FLEX System (Agilent) following the manufacturer’s 
protocol and primary antibody Beta-Catenin Flex RTU. 
 
5.4.5.4 Somatic APC Mutations in Colorectal Neoplasms 
FFPE tumours were available for Halo47, Halo68, Individual 1.1 and Individual 1.2 
as described in 5.4.5.3.  DNA was extracted by the AWMGS using the Maxwell 
Promega LEV FFPE kit. 
Due to a limited supply of poor quality DNA, APC MCR screening was performed, 
rather than the whole of the coding sequence. Codons 1181-1648 were sequenced. 
Work was carried out by the AWMGS following the protocol described in Appendix 
5.12.   
  
5.4.5.5 AXIN2 Loss of heterozygosity Analysis (LOH) 
FFPE tumours were available for Halo47, Halo68, Individual 1.1 and Individual 1.2 
as described in 5.4.5.3.  DNA was extracted by the AWMGS using the Maxwell 
Promega LEV FFPE kit. 
LOH analysis was carried out by testing for heterozygosity at the site of the germline 
mutation.  Standard reagents and reaction conditions were employed (2.3.8.2, 
2.3.8.5, 2.3.9-2.3.13).  The primers used are listed in Appendices 4.2 and 5.11.  
LOH analysis was performed for all the DNA samples which remained after somatic 
APC screening:  several of the samples had been used to exhaustion. 
 
5.4.5.6 Functional Characterisation of the AXIN2 Variant 
5.4.5.6.1 AXIN2-Containing Plasmids 
Plasmids containing the human AXIN2 coding sequence were very kindly supplied 
by Professor Eric Fearon, University of Michigan Medical School.  The plasmid used 
during this study was N-terminal 6xmyc-tagged AXIN2 in pCS2+MT.  Both wild-type 
AXIN2 was provided, and mutant AXIN2 containing the c.1989G>A variant 
described by Marvin et al (Marvin et al 2011), Fearon-AXIN2. 
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Plasmids were retrieved from filter paper (2.5.1) and used to transform XL-1 Blue 
Competent cells (2.5.4).  Plasmid DNA was extracted using the MiniPrep kit 
(Qiagen) (2.5.5.) and the identity of the AXIN2 coding sequence was confirmed with 
sequencing (2.5.5). 
 
5.4.5.6.2 Site Directed Mutagenesis (SDM) 
Site directed mutagenesis and bacterial transformation were employed to generate 
plasmids containing the AXIN2 mutation identified as part of this study, 
c.1642G>T:p.Glu548* (2.5.6), Short-AXIN2.  Primers are described in Appendix 
5.13.  Plasmid DNA was extracted using the MiniPrep kit (Qiagen) (2.5.5).   
To confirm the presence of the desired mutation, sequencing was carried out by 
Dundee Sequencing.  Primers are described in Appendix 5.14.   
 
5.4.5.6.3 The Luciferase Reporter Assay in HEK293 TCF-
Luc Cells  
HEK293 TCF-Luc cells were kindly supplied by Professor Jeremy Nathans, John 
Hopkins University.  They were kept at -80˚C.  Once defrosted (2.5.7) they were 
seeded onto a 96-well Assay plate (2.5.9) prior to transfection with varying amounts 
of WT-AXIN2, Fearon-AXIN2, Short-AXIN2 or WT/ Short-AXIN2 plasmids (2.5.10).   
Following transfection, cells were stimulated with exogenous Human Wnt3a and 
Human R-Spondin-1 (2.5.11).  WIST was subsequently added, before measuring 
WIST and luciferase activity (2.5.12). 
 
5.4.6 Results 
 
5.4.6.1 Family Segregation Studies 
Six further family members were screened for the familial AXIN2 mutation, 
c.1642G>T:p.Glu548*.  The mutation was identified in Individuals 1.1 and 1.2, who 
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had a history of colorectal neoplasia.  It was not present in the family members who 
were unaffected, Individuals 2.1, 3.1, 3.2, 3.3 (sequencing traces in Appendix 5.15)  
5.4.6.2 Protein Analysis 
HEK293 TCF-Luc cells were transfected with a series of dilutions of WT-AXIN2, 
Short-AXIN2 or empty plasmid.  Protein was extracted and analysed using Western 
Blotting. 
 
Results showed that Myc-tagged-WT-AXIN2 was detected in the cells transfected 
with WT-AXIN2 plasmid, and a truncated AXIN2 protein, approximately 30 KDa 
smaller than the WT protein, was detected in the cells transfected with Short-AXIN2 
plasmid.  Protein was only detectable at the highest two concentrations of plasmid 
used for transfection.  No AXIN2 protein was detected in the cells transfected with 
empty vector. 
-actin protein was detected with approximately equal intensity in all samples of 
protein lysate, confirming that the same amounts of protein had been loaded in each 
well. 
The mutant AXIN2 was detected at greater intensity than WT protein, suggesting 
that it may possibly be a more stable protein.  The protein ran at a larger size than 
predicted, by approximately 30 KDa, but this is commonly observed with AXIN2 (Dr. 
Anika Offergeld, personal communication).  Possible reasons include it interacting 
with other proteins or the way in which it was interacting with the gel.  See Figure 
5.5.  
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Figure 5.5.  A:  Western blot probing for AXIN2. L: ladder.  Decreasing concentrations of 
AXIN2 plasmid used for cell transfection (1.  90 ng/25 µl, 2.  30 ng/25 µl, 3.  10 ng/25 µl, 4.  
3.33 ng/25 µl, 5.  1.11 ng/25 µl, 6.  0.37 ng/25 µl, 7.  0.12 ng/25 µl, 8.  ng/25 µl).  B:  Western 
blot probing for β –actin. L: ladder. 
 
5.4.6.3 β-Catenin Immunohistochemistry (IHC) 
Immunostaining was interpreted by myself and Professor Geraint Williams, and I am 
extremely grateful for his help and advice. 
 
Results from the FAP positive control patient showed that β-catenin IHC in the 
adenomas exhibited largely membranous staining, but in most of the lesions, there 
were occasional cells with nuclear positivity.  However, this did not seem to 
correlate with the degree of dysplasia, i.e. membranous staining was observed in 
both low-grade and high-grade regions, and the focal nuclear positivity present 
occurred in regions of low-grade dysplasia.  However, LGD was by far the 
predominant morphology, so it is feasible that there wasn’t sufficient HGD present to 
observe nuclear staining.  The CRC exhibited mainly membranous staining of β-
 
 
L 
L L 
L 
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catenin.  There were occasional cells with nuclear positivity, and these tended to 
occur at the invasive margin of the tumour.  See Figure 5.6. 
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A1 
 
A2 
 
A3 
 
B1 
 
B2 
 
C1 
 
C2 
 
C3 
 
 
Figure 5.6: -catenin IHC of colorectal adenomas and CRC from a patient with confirmed 
FAP, germline mutation APC c.2940_2941delA.  A1:   TA LGD H&E.  A2:  -catenin IHC is 
largely membranous but there are scattered cells with nuclear staining as seen in A3 (red 
arrows).  B1: Region of HGD H&E.  Note membranous staining in B2.  C1:  CRC H&E. -
catenin IHC is predominantly membranous, C2,  but there are occasional cells with nuclear 
positivity, C3 (red arrows).  Scale bars in the bottom right corner of each image. 
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There was no evidence of nuclear β-catenin in any of the serrated/ hyperplastic 
lesions from patients carrying the AXIN2 mutation (Figure 5.7): 
 
A1 
 
A2 
 
B1  
 
 
B2 
 
C1 
 
C2 
 
 
  
Figure 5.7:   A1:  Halo47 SA LGD H&E, A2. Halo47 SA LGD β-catenin IHC; B1:  Halo68 
HPP H&E, B2:  Halo68 HPP β-catenin IHC; C1:  Individual 1.2 HPP H&E, C2:  Individual 1.2 
HPP β-catenin IHC 
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All of the tubular adenomas from patients carrying the AXIN2 mutation were low 
grade lesions.  The prominent staining pattern was membranous.  The only patient 
to exhibit any β-catenin nuclear positivity was Individual 1.1:  in two adenomas there 
was an occasional cell with nuclear staining (Figure 5.8): 
 
A1 
 
A2 
 
B1 
 
B2 
 
C1
 
C2
 
D1 
 
D2 
 
E1
 
E2 
 
 
 
 
 
Figure 5.8: A1:  Halo47 TA LGD H&E, A2 Halo47 TA LGD β-catenin IHC; B1:  Halo68 TA 
LGD H&E, B2:  Halo68 TA LGD β-catenin IHC; C1:  1.2 TA LGD H&E, C2:  1.2 TA LGD β-
catenin IHC; D1:  1.1 TA LGD H&E, D2 TA LGD β-catenin IHC.  Note focal nuclear staining 
(red arrow); E1:  1.1 TA LGD H&E, E2:  TA LGD β-catenin IHC.  Note focal nuclear staining 
(red arrow) 
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The only villous adenomata present were in Individual 1.2.  Both the solitary VA and 
the VA which had progressed to carcinoma showed focal evidence of nuclear β-
catenin staining.  There was weak membranous staining of the carcinoma, but no 
evidence of nuclear β-catenin, although overall the staining pattern was very weak 
(Figure 5.9): 
A1 
 
A2 
 
B1 
 
B2 
 
C1 
 
C2 
 
C3 
 
 
 
Figure 5.9: Individual 1.2 A1:  Solitary VA H&E.  A2:  Solitary VA β-catenin IHC.  Note focal 
nuclear staining (red arrows). B1:  VA that has progressed to CRC H&E, B2:  VA that has 
progressed to CRC β-catenin IHC.  Note focal nuclear staining (red arrows). C1:  CRC H&E. 
C2:  CRC β-catenin IHC. C3:  Contrast between the intensity of the staining of β-catenin 
between the villous adenoma (blue arrow) and the CRC (green arrow) 
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For Halo47, IHC staining of the adenocarcinoma showed different patterns:  most of 
the tumour was moderately differentiated, but there were regions of poor 
differentiation. In the moderately differentiated regions, there were cells with 
prominent nuclear β-catenin staining, but this was not universal.  In the poorly 
differentiated area, nuclear β-catenin was ubiquitous (Figure 5.10): 
 
A1 
 
A2
 
B1 
 
B2 
 
 
Figure 5.10: Halo47: A1:  Moderately differentiated CRC H&E. A2:  Moderately differentiated 
CRC β-catenin IHC.  Note nuclear staining (red arrows) B1:  Poorly differentiated CRC H&E. 
B2:  Poorly differentiated CRC β-catenin IHC 
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The CRC in Individual 1.1 again showed predominantly membranous staining of -
catenin, but there were occasional cells with nuclear positivity (Figure 5.11). 
 
A1 
 
A2
 
A3 
 
A4 
 
 
Figure 5.11:  Individual 1.1: A1:  Moderately differentiated CRC H&E; A2-A4:  Moderately 
differentiated CRC β-catenin IHC.  Focal nuclear staining is present (red arrows)   
5.4.6.4 Somatic APC mutations in colorectal neoplasms 
Several DNA samples extracted from FFPE tissue were of very low concentration, 
and PCR amplification followed by sequencing was not always successful.  The 
successful PCR and sequencing reactions are described in Table 5.6.  A pathogenic 
APC mutation refers to stop gains and frameshift mutations, it does not include 
silent or missense changes. 
  
 220 
 
 
 
 221 
 
 222 
 
It was therefore seen that only a minority of tumours were identified as having a 
somatic APC mutation present.  
5.4.6.4.1 Correlation between β-Catenin 
Immunohistochemistry (IHC) and Somatic APC Mutations 
Only a small proportion of lesions exhibited evidence of nuclear -catenin or were 
identified as having a somatic APC mutation.  The correlation between these 
findings is described in Table 5.7. 
 
Patient 
Sample 
Morphology 
Nuclear -
Catenin 
Somatic APC Mutation 
Halo47 CRC Yes 
Uncertain (11/12 fragments 
sequenced) 
1.1 TA LGD Yes 
Uncertain (7/12 fragments 
sequenced) 
1.1 TA LGD Yes 
Yes 
c.3870_3877delTCAGACGA 
1.1 CRC Yes Yes c.3667delT 
1.2 VA Yes 
Uncertain (3/12 fragments 
sequenced) 
1.2 
VA progressed 
to CRC 
Yes Yes c.3856 G>T 
 
Table 5.7:  Correlation between nuclear -catenin IHC and the presence of a somatic APC 
mutation 
5.4.6.5 AXIN2 Loss of Heterozygosity Analysis (LOH) 
Successful LOH screening was achieved for a total of 12 tumours/ tumour regions.  
There was no evidence of LOH of the WT AXIN2 allele in any of the tumours 
sampled (sequencing traces in Appendix 5.16).   
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5.4.6.6 Functional Characterisation of the AXIN2 Variant 
In order to further characterise the effects of the AXIN2 c.1642G>T:p.Glu548* 
variant, studies were performed in HEK293 TCF-Luc cell lines.  Luciferase assays 
were used to determine the effects of the mutation on Wnt-pathway activation. 
 
Cultured cells transfected with empty plasmids were stimulated with exogenous 
Wnt3a and R-Spondin.  This lead to an approximately 67-fold increase in the 
normalised luciferase score, compared to unstimulated cells. 
 
Cells were transfected with a series of dilutions of AXIN2 plasmid:  WT-AXIN2, 
Fearon-AXIN2, Short-AXIN2 or a WT/ Short mix. At all concentrations of plasmid, 
mutant AXIN2, both Fearon and Short, was less able to inhibit reporter gene activity 
than WT-AXIN2 (Figure 5.12A).  Interestingly, it was the WT/ Short mix which had 
the least effect on Wnt-pathway inhibition.  
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Figure 5.12A:  Graph to show the different effects of AXIN2 mutations on Wnt-pathway 
inhibition.  Mutant AXIN2 is less able to inhibit Wnt-pathway activation than WT-AXIN2; 
5.12B:  Standard deviations shown for each separate plasmid used for transfection.  
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Statistical analysis was carried out with the help of Dr. Matthew Mort.  A 2-way 
ANOVA analysis and Tukey multiple pairwise analysis was performed to determine 
whether the difference in Wnt-pathway inhibition was statistically significant between 
the WT-AXIN2 and the mutant plasmids.  Statistical significance was reached when 
WT-AXIN2 was compared to the Short/ WT- AXIN2 mix, with a p-value of 0.00155.  
Statistical significance was not reached for Fearon-AXIN2 (p=0.1021872) or Short-
AXIN2 (p=0.1274879) compared to WT-AXIN2.  This could be due to the small 
sample size. 
 
5.4.7 Conclusions of Studies into AXIN2 c.1642G>T:p.Glu548* 
The AXIN2 c.1642G>T:p.Glu548* mutation was initially identified in the sibling pair 
Halo47 and Halo68, both of whom had been recruited to the study due to their 
phenotype of colorectal polyposis.  The same variant was subsequently identified in 
their mother and maternal aunt.  Both had colorectal neoplasia:  they had a history 
of CRC, but their polyp counts were below 10.  The variant was not present in a 
brother, who had recently had a clear colonoscopy, and in the daughters and niece 
of Halo68. 
 
Both sisters and their mother allegedly lacked all adult teeth.  This was confirmed by 
dental X-rays in Halo68.  We were unable to get any information about the dental 
history of the aunt.  Halo68 also exhibited clinical signs of ectodermal dysplasia – 
she had sparse hair on the outer half of her eyebrows, thin hair on her head and a 
nail malformation.  We were unable to do a clinical assessment of the remaining 
variant-carriers in the family as they had all passed away, but family photos of 
Halo47 and her mother were suggestive of sparse eyebrow hair.  Whether these 
features are part of the phenotypic spectrum associated with AXIN2 mutations 
remains to be determined. In both Lammi’s (Lammi et al 2014) and Marvin’s (Marvin 
et al 2011) papers, AXIN2 mutant-carriers had oligodontia, and in the family 
reported in Marvin’s paper, signs of ectodermal dysplasia were also present.  In this 
study, a daughter of Halo68 had sparse eyebrows and no other signs of ectodermal 
dysplasia, but did not carry the familial mutation.  It seems that oligodontia 
segregates with the colorectal phenotype, but further studies in AXIN2-mutant 
families are required to better characterise the clinical features.   
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Western blotting confirmed that cell lines transfected with Short-AXIN2 plasmids 
produce a protein approximately 30 KDa smaller than cells transfected with WT-
AXIN2 plasmids.  The truncated protein may possibly be more stable than WT 
protein.  This would need to be confirmed by a technique such as a pulse chase 
experiment.  Increased stability of mutant AXIN2 had previously been reported for 
the truncated protein investigated by Mazzoni et al and may be due to the loss of a 
destabilising phosphorylation site (Mazzoni et al 2015). 
 
It is possible that the mutation may have further effects in addition to being a 
nonsense change.  Analysis using MutPred Splice 
(http://www.mutdb.org/mutpredsplice/about.htm accessed 06/03/2018) suggests 
that the mutation is a splice neutral variant with a score of 0.37.  However, in silico 
analysis using Human Splicing Finder (http://www.umd.be/HSF3/ accessed 
06/03/2018) suggests that the mutation could possibly add an exon splicing silencer 
and remove an exonic splicing enhancer.  In theory, this could lead to skipping of 
Exon 5.  Analysis with Mutalyzer (https://mutalyzer.nl accessed 06/03/2018) 
confirmed that the loss of Exon 5 would produce a truncated protein, but that the 
transcript would be in-frame.  The truncated product would be approximately 88 
KDa.  Exon 5 is partially responsible for encoding the domain of AXIN2 which 
interacts with GSK3β (http://www.uniprot.org/uniprot/Q9Y2T1#showFeaturesViewer 
accessed 06/03/018) so if it was absent from the protein, this could have functional 
consequences.  To further investigate this, techniques such as mass spectrometry 
could be used. 
 
-catenin IHC was initially performed on tumour samples from a known FAP patient.  
Throughout all adenomas and CRC, the staining pattern was predominantly 
membranous, with occasional cells exhibiting nuclear positivity.  For the patients 
carrying the familial AXIN2 mutation, Halo47, Halo68, Individual 1.1 and Individual 
1.2, there was no nuclear staining in any of the hyperplastic lesions.  This is as 
expected, as such lesions do not typically exhibit activation of the Wnt-pathway.  Of 
all the tubular adenomas present, only two had any focal nuclear -catenin staining.  
It was anticipated that if the adenomas had similar levels of Wnt-pathway activation 
as do APC-mutant tumours, there should have been more evidence of nuclear 
positivity.  Interestingly, the villous adenomata, which are more likely to progress to 
cancer than tubular lesions did show evidence of nuclear β-catenin staining.  
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There were three CRC present – in Halo47, Individual 1.1 and Individual 1.2.  The 
cancer in Halo47 showed different patterns of -catenin staining:  most of the 
tumour was moderately differentiated, but there were regions of poor differentiation. 
In the moderately differentiated regions, there were cells with prominent nuclear β-
catenin, but this was not universal.  In the poorly differentiated area, nuclear β-
catenin was ubiquitous.  In Individual 1.1, the cancer again showed predominantly 
membranous staining of -catenin, but there were occasional cells with nuclear 
positivity.  In Individual 1.2, the cancer had arisen in a VA.  There was weak 
membranous staining of the carcinoma, but no evidence of nuclear β-catenin.  
However, the staining of the cancer was repeatedly very weak.  The reason for this 
is not clear.  One possibility is that -catenin had acquired a mutation which 
rendered it relatively resistant to IHC staining.  Regardless of the aetiology, the poor 
staining makes interpretation difficult. 
Nuclear positivity for β-catenin in the VA and CRC, but not in most of the TA, implies 
that Wnt pathway activation may be occurring at a later stage of tumourigenesis 
than in FAP adenomas. 
 
Somatic APC analysis was performed to determine whether ‘typical’ APC mutations 
were present in tumours from patients carrying germline AXIN2 mutations.  
Although DNA was extracted from 36 lesions, less than half of the desired PCR 
fragments were successfully amplified, making interpretation difficult.  Only 3 
truncating mutations were identified:  1 of these was present in cancer and another 
was present in the VA which had developed into CRC.  This raises the possibility 
that adenomas arising in AXIN2 mutation carriers might need to acquire mutation(s) 
in a gene such as APC in order to acquire sufficient Wnt pathway activation to 
progress to malignancy. 
 
We attempted to determine whether we had identified statistically significantly fewer 
APC mutations than would have been predicted in adenomas from AXIN2 mutation 
carriers.  However, it was not possible to perform such an analysis due to the lack of 
a robust control set to compare our results to.  Whilst there is a wealth of data in the 
literature documenting somatic mutations in sporadic CRC and in FAP-associated 
adenomas and CRC, there are scanty papers addressing somatic changes in 
sporadic adenomas.  Of the papers that do exist, different experimental approaches 
have been taken.  Some studies considered the whole of the coding region of APC, 
some look at exon 15 only and others address specific nucleotide sequences; some 
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of the studies sequence fresh tissue, some use frozen tissue and others use FFPE 
material; some studies investigate sporadic lesions only, others include some FAP-
associated tumours (Van Wyk et al 1999; Olschwang et al 1998; De Benedetti et al 
1994; Miyoshi et al 1992b; Powell et al 1992).     
 
The correlation between a somatic APC mutation with the presence of nuclear -
catenin staining was addressed:  in both of the cancers and the TA LGD which had 
identified somatic APC mutations (Individual 1.2 and Individual 1.1) nuclear staining 
was present. There were tumours with nuclear -catenin staining which did not 
seem to have a somatic APC mutation.  However, in all of these samples, the MCR 
was not successfully completely sequenced, so the actual somatic APC MCR 
mutation status is uncertain.  
 
It appears that tumours arising in individuals carrying the germline AXIN2 
c.1642G>T:p.Glu548* mutation may not exhibit the ‘typical’ APC mutations seen in 
patients with FAP or sporadic adenomas, although the poor coverage of the MCR 
makes it difficult to say this with certainty.  If this is true, it implies that lesions follow 
a different genetic tumourigenic pathway.  This exciting possibility is going to be 
further investigated by carrying out WES on tumour DNA, but this was not possible 
during the timescale of this project. 
 
There was no evidence of LOH in any of the tumours sampled.  If AXIN2 was a 
typical tumour suppressor gene, and if the variants identified are pathogenic, it 
would be anticipated that there would be loss of the wild-type allele in the tumours.  
This was not observed.  It is possible that the mutation is exhibiting dominant 
negative effects.  It is also possible that there is a second hit to the WT allele by a 
mechanism other than LOH, for example epigenetic silencing or a second 
mutational event. 
 
The effects of the Fearon and Short AXIN2 mutations on Wnt-pathway activation 
were examined through the use of luciferase assays in HEK293 TCF-Luc cell lines.  
Fearon-AXIN2 and Short-AXIN2 both demonstrated possibly impaired Wnt pathway 
inhibition, but this did not reach statistical significance.  Interestingly, the plasmids 
least able to inhibit the Wnt-pathway were the Short/ WT mix.  This would be 
consistent with the notion that inherited AXIN2 mutations can act via a dominant 
negative mechanism.  Previous papers have shown that mutant AXIN2 is still able 
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to dimerise with itself and with WT-AXIN2 (Mazzoni et al 2015).  If the same is true 
for the mutation we have identified, it is possible that a complex composed of WT 
and mutant AXIN2 is less efficient at promoting -catenin degradation than mutant 
AXIN2 alone. 
 
Halo47 and Halo68 have also undergone WES of blood DNA (4.3).  This did not 
identify any inherited variant that was considered more likely to be clinically 
significant than the confirmed AXIN2 mutation.  In particular no likely pathogenic 
variants were identified in known adenomatous polyposis or ectodermal dysplasia 
genes. 
 
Overall the results from the studies performed would be consistent with some 
inherited AXIN2 mutations having a role in the pathogenesis of a colorectal 
polyposis syndrome in which individuals also display signs of ectodermal dysplasia, 
in particular oligodontia.  If confirmed, this apparently very rare syndrome could be 
named AxAP:  AXIN2-Associated Polyposis.  The effects of mutant AXIN2 are likely 
to be at least partially mediated through activation of the Wnt-signalling pathway.  It 
is important that further studies are performed to confirm and characterise the 
syndrome, so that optimal clinical management can be determined.  Such further 
studies would include an improved genetic characterisation of the tumours arising in 
patients with inherited AXIN2 mutations to better understand the molecular 
pathways of tumourigenesis in these individuals.  Currently the WGP is developing 
a platform to allow WES on DNA extracted from FFPE tissue, which will be 
performed later this year. It is also important to gain a greater knowledge about any 
other effects which mutant AXIN2 may have, for example on the numbers of stem 
cells in tissue, its effects on cell proliferation and its effects on other signalling 
pathways. 
 
The AXIN2 mutation identified in this study, c.1642G>T:p.Glu548*, is not present in 
Exac, HGMD or in data from the 1000 Genomes Project.  However, somatic AXIN2 
mutations are well described in a variety of cancer types.  The COSMIC database 
reports 22 somatic nonsense mutations of AXIN2 in 46376 cancer samples tested: 
10 of these were large intestine adenocarcinoma 
(https://cancer.sanger.ac.uk/cosmic/gene/samples?all_data=&coords=AA%3AAA&d
r=&end=844&gd=&id=4988&ln=AXIN2&mut=substitution_nonsense&seqlen=844&s
rc=gene&start=1 accessed 15/05/2018).  CBioPortal reports that 1.4% of cancers 
screened had a somatic mutation of AXIN2.  243 truncating mutations are 
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described: the vast majority of these were cancers in the gastrointestinal tract 
(http://www.cbioportal.org/index.do?session_id=5aec70b3498eb8b3d565fab9 
accessed 15/05/2018). In the Exac database, there are 9 entries of loss of function 
germline mutations in AXIN2.  They are all rare – the commonest is a frameshift, 
p.Asn666Glnfs*41, which has an allele frequency of 0.0005561 and was identified in 
65/116894 alleles, being overrepresented in African populations.  Although the 
phenotype of these patients is not known, Lammi’s paper (2004) describes a 
frameshift mutation in a 13-year old boy with oligodontia, which truncates AXIN2 at 
almost the same location:  the group reported a heterozygous 1 bp insertion after 
nucleotide 1994 in exon 7, which expands one of the several mononucleotide 
repeats.  It recodes the amino acids starting at Asn666 and incorporates a stop 
codon 40 codons later.  On CBioportal there are 6 reports of a stop codon being 
inserted 41 codons after p.Asn666 in CRC 
(http://www.cbioportal.org/index.do?session_id=5aec70b3498eb8b3d565fab9 
accessed 15/05/2018).  The significance of the frameshift reported in Exac is 
therefore not determined.  It is possible that it is associated with a phenotype that 
we are not aware of, or alternatively it may be well-tolerated, possibly because it 
occurs relatively close to the C terminus of the protein. 
 
It is interesting that the colorectal phenotype in patients carrying reported specific 
AXIN2 mutations seems to be very variable, and both adenomas and HPPs seem to 
form part of the clinical spectrum.  The consistent observation in this and previous 
reports is that patients with polyposis and truncating AXIN2 mutations also have 
oligodontia.  Oral abnormalities are common in FAP patients, with a prevalence of 
17% (reviewed in Groen et al 2008).  Such abnormalities include supernumerary 
teeth, dentigerous cysts and secondary retention of teeth (reviewed in Groen et al 
2008), likely due to aberrations in Wnt signalling.  The canonical Wnt pathway plays 
an essential role in tooth initiation and morphogenesis, and also in dental cell 
differentiation (reviewed in Järvinen et al 2018).  In AXIN2 mutant patients, 
individuals appear to grow their primary dentition (baby teeth) but do not develop a 
full complement of secondary teeth.  Järvinen et al (2018) sought to investigate the 
effects of the Wnt pathway on the formation of molars in mouse models and in ex 
vivo cultures.  They showed that increasing Wnt/ β-catenin activity in dental 
mesenchyme inhibited the development of posterior molars, whereas reducing 
activity was associated with continued tooth development (Järvinen et al 2018).  
The authors concluded that the dental abnormalities observed in AXIN2 mutant 
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patients results from the modulation of Wnt/ β-catenin signalling in the dental 
mesenchyme (Järvinen et al 2018).   
 
In mice studies of AXIN2, homozygous knockout of AXIN2 leads to reduced head 
growth, due to premature fusion of cranial sutures.  This resembles craniosyntosis 
in humans (Yu et al 1995).  The dental and colorectal phenotype in such models is 
not described. 
  
5.5 Chapter Conclusions 
The aim of this chapter was to carry out genetic, in silico and functional assessment 
of mutations identified through targeted exome sequencing (Chapter 4).  Variants 
were selected in the MMR genes, POLE, POLD1 and AXIN2. 
 
Tumours from patients carrying MMR gene variants underwent MMR IHC and MSI 
testing.  There was no evidence of loss of MMR proteins or microsatellite instability 
in any of the lesions.  This leads to the conclusion that the MMR gene variants 
identified are unlikely to be clinically significant. 
 
Four patients were found to have germline variants in POLE/ POLD1. These were 
investigated through a combination of protein modelling, somatic ‘hotspot’ mutation 
screening and mutation signature analysis.  One of the variants, POLE 
p.Glu2140Lys in Halo18, is reported as benign on dbSNP.  It does not lie within any 
of the POLE functional domains and was not in the protein model used as part of 
this project.  The variant is presumed not to be clinically significant.  A POLE 
variant, p.Tyr623Cys in Halo61, remains a VUS.  Although mutation signature 
analysis was attempted, this was not successful.  Somatic mutation analysis is still 
in progress for tumours from Halo15 and Halo27.  Although this should be complete 
in the near future, at the present time the mutations identified in Halo15 and Halo27, 
c.1411A>G:p.Met471Val  and c.2861C>T:p.Thr954Met, remain as VUS. 
 
A previously unreported truncating AXIN2 mutation, c.1642G>T:p.Glu548*, was 
identified in a family with a 2-generation history of oligodontia and colorectal 
neoplasia.  The mutation segregates with the disease phenotype in an AD manner.  
It is present in DNA and cDNA and produces a truncated protein.  P.Glu548* mutant 
AXIN2 appears less able to inhibit the Wnt pathway than WT AXIN2 and could have 
dominant negative effects. 
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The study of Family A has added to evidence from other previously reported familes 
with AXIN2 mutations that there may exist a rare AXIN2-Associated Polyposis 
Syndrome, in which individuals have signs of ectodermal dysplasia and a variable 
colorectal phenotype. The effects of the mutant protein could be at least partially 
mediated through activation of the Wnt signalling pathway.  Further studies are 
required to confirm and better characterise this syndrome.  Research programmes, 
including the UK 100 000 Genomes Project that is recruiting patients with colorectal 
polyposis, may identify further affected patients with germline AXIN2 mutations.   
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Chapter 6 Thesis Discussion 
Colorectal carcinoma (CRC) is the fourth most common cancer in the United 
Kingdom (UK) and the second most common cause of cancer death (Cancer 
Research UK 2015).  The majority of colorectal carcinomas occur sporadically, but 
in 15-35% of patients, hereditary factors are important (reviewed in Mishra and Hall 
2012; Burt 2007).  These factors include the inherited polyposis syndromes, FAP, 
MAP, PPAP, NTHL1-Associated Polyposis and MSH3-Associated Polyposis.  In all 
of these syndromes, affected individuals develop multiple colorectal polyps and 
have an increased risk of developing CRC.  In order to assess whether an inherited 
disorder is present in patients with multiple polyps, it has been traditional practice to 
refer individuals with >10 polyps to a medical genetics service for genetic 
counselling and consideration of genetic testing.  In the NHS, APC and MUTYH are 
routinely screened, with increasing numbers of laboratories also screening for the 
recurrent mutations in POLE and POLD1.  Of the cohort of individuals who undergo 
genetic diagnostic testing, up to 50% do not have a mutation identified.  It is this 
group of patients that this thesis has addressed. 
 
The key hypotheses thought to underlie the patients’ phenotypes were that 
mutations may be present outside of the ORF of APC/ MUTYH, that the affected 
individuals may exhibit somatic mosaicism of APC or that further polyposis genes 
may play a role.  This thesis has not considered epigenetic effects or oligogenic 
inheritance. 
 
To address these hypotheses, firstly APC and MUTYH were interrogated.  UDS of 
the entire genomic loci was performed, qPCR analysis was utilised to study gene 
transcription, and patient-derived RNA samples underwent sequencing and AI 
analysis.   
The next stage was to carry out targeted exome sequencing of 15 genes either 
known to be, or possibly, involved in the pathogenesis of colorectal neoplasia.  
Following on from this, a subset of patients underwent WES.  The final phase of the 
project was to carry out further genetic, in silico and functional studies on the 
candidate variants most likely to be clinically significant, to obtain further evidence to 
support or refute their role in colorectal polyposis. 
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6.1 APC and MUTYH Studies 
The most interesting results from the examination of APC and MUTYH were those 
from the gene expression studies.  Four patients appeared to have evidence of 
reduced APC transcription.  These individuals all had phenotypes in keeping with a 
clinical diagnosis of FAP.  Their gene transcription results were consistent with their 
AI results, which either showed apparent loss of transcription of one APC allele 
(Halo52 and Halo53) or were uninformative (Halo46 and Halo64).  The cause of the 
reduced APC expression was determined in Halo46.  UDS identified a 5’UTR 
variant (G>A at 5:112043225), at position -c190.  Subsequent testing of family 
members confirmed that the mutation was segregating with the phenotype, and 
previously described functional studies reported the variant to be pathogenic 
through impaired binding of a transcription factor (Li et al 2016).  Predictive testing 
for this variant is now being established in the clinical diagnostic setting for 
extended family members.  
 
I sought to determine the cause of the reduced gene transcription in the remaining 3 
samples.  However, in addition to apparently normal UDS of the entire genomic 
APC locus, including the promoter regions and UTRs, karyotype analysis and 
promoter methylation studies also gave normal results.  We are planning that these 
patients and appropriate members of their families undergo whole genome 
sequencing with the aim of searching for variants in the regions of the genome 
which have not yet been examined. 
 
UDS only identified one pathogenic mutation - the APC 5’UTR variant in Halo46 
described above.  There was no evidence for any likely pathogenic variants outside 
of the ORF or for APC mosaicism in the other patients.  With regards to APC 
mosaicism, the average depth of coverage of APC using the HiSeq 2500 was 
1665.5x, so if there were any cases with significant levels of mutant alleles in blood 
DNA, they were unlikely to have been missed.  However, others have published 
evidence indicating that somatic mosaicism restricted to the gut or a section of the 
bowel may be relatively common (Jansen et al 2017; Spier et al 2016), limiting the 
usefulness of studying DNA derived from blood.   
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6.1.1 Strengths and Weaknesses of the Study of APC and 
MUTYH  
There were several strengths to this study.  DNA was obtained for all study 
participants, and RNA from the majority of individuals.  FFPE tissue was available 
for most cases when it was required for IHC analysis or for somatic DNA analysis.  
Furthermore, it was possible to access patients and their medical notes when they 
were registered with the AWMGS.  We worked closely with the WGP, which allowed 
access to NGS technologies, making it possible to examine whole genomic loci and 
to perform exome sequencing. 
 
One of the key problems encountered throughout this project was the lack of 
adequate clinical information about the patients.  Often the phenotype, 
histopathological assessment of lesions and family history were not complete, so it 
was difficult to determine whether cases were familial or sporadic, and what the true 
polyp counts/ morphology were.  We found that despite acquiring written patient 
consent to access medical records under an ethically approved study, it was often 
difficult to access clinical details for patients who were not under follow up with the 
regional genetics service in Wales.  Busy hospital services have priorities other than 
supporting research studies and the dispersion of clinical data in the NHS makes its 
retrieval time consuming.  The gradual move to digitalised records will likely benefit 
clinical research in the longer term.  The optimal information would have included a 
complete family history, the age of onset of polyposis, the cumulative numbers of 
polyps, the size and location of polyps and their microscopic morphology.  
It also often proved difficult to recruit family members of the proband.  This made 
analysis difficult as it was often not possible to ascertain whether identified variants 
were occurring de novo or were segregating with disease if multiple family members 
were affected.   
 
Part of the study involved using NGS technologies to carry out UDS.  NGS 
generates large amounts of data, and a challenge is to identify what is clinically 
significant.  In this thesis, CADD scoring was used as a tool to indicate the likelihood 
of pathogenicity and to therefore prioritise variants for further study.  Although the 
CADD score gives a measure of predicted deleteriousness, this is not the same as 
its likelihood of causing a clinical phenotype.  Furthermore, CADD scoring was used 
to appraise all variants.  Recent evidence suggests that ‘CADD scores may be 
useful for identification of pathogenic intronic or nonsynonymous variants in 
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targeted testing situations when used in combination with other data.  However 
our data suggest that CADD scores are unlikely to be useful for identifying 
disease-causing mutations in other noncoding regions in cancer-risk genes’ 
(Mather C. et al 2016), so the utility of this method in scoring variants in regions 
such as promoters/ UTRs is questionable.  The authors acknowledge that there is 
a distinction between variants that are functionally deleterious and clinically 
pathogenic (Mather C. et al 2016).  They note that there are many situations in 
which a deleterious variant does not cause clinical phenotype (Mather C. et al 
2016).  
 
6.1.2 Clinically Translatable Outcomes 
The key clinically translatable outcomes from this stage of the project are detailed 
below: 
 
1. APC promoter sequencing and sequencing of Exon 1/ 5’UTR.  In the 
clinical diagnostic setting, APC and MUTYH undergo sequence and dosage 
analysis through sequencing and MLPA respectively.  Standard protocols 
involve sequencing of the coding exons (APC and MUTYH) and dosage 
analysis of coding exons (APC and MUTYH) and promoter (APC only) 
(2.2.3.1).  It is recommended that diagnostic laboratories consider including 
the APC promoters 1A and 1B and Exon 1 in protocols for patients who 
remain NMI after sequencing of coding exons.  This would allow the 
identification of variants which could result in abnormalities of gene 
expression.   
2. RNA studies.  For NMI patients, diagnostic laboratories could consider RNA 
studies as part of their investigative tool kit.  cDNA sequencing of APC is a 
relatively simple procedure to undertake.  If abnormalities were identified, 
sequencing of the entire genomic locus of APC could be undertaken to 
determine the underlying cause.  Quantitative studies of APC transcription 
could also be considered.  However, this would first necessitate a large-
scale study to determine the normal range of APC transcription in a healthy 
cohort and to compare this to expression levels in known APC mutation 
carriers.  qPCR was used in this study to identify reduced APC transcription 
in 4 of 45 NMI patients when compared to a healthy control cohort of 40 
individuals, but for clinical applications the control cohort would need to be 
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much larger, and multiple Taqman probes would need to be used.  Again, if 
an individual was found to have reduced APC transcription, sequencing of 
the entire genomic locus could be performed to try to determine its cause.  
However, as was seen in this work, the cause isn’t always apparent.  
Through research such as the 100 000 Genomes Project, which includes a 
cohort of patients with multiple bowel polyps who were NMI following testing 
in the NHS, further clinically significant variants in gene enhancers/ 
upstream regions may be characterised. 
  
6.2 Targeted and Whole Exome Sequencing 
Targeted exome sequencing was initially carried out to interrogate 15 genes known 
to be, or possibly, involved in the pathogenesis of colorectal neoplasia.  A total of 33 
variants across 32 patients were selected for further investigation:  22 of these were 
validated.  The variants which were not validated were largely those occurring at a 
low frequency or in regions with low NGS coverage.  Whole exome sequencing 
(WES) was undertaken on a subset of 24 patients, based on their phenotype, the 
availability of relatives and those patients in whom a novel and possibly causative 
mutation had already been identified, to confirm that missed mutations in the known 
genes were not involved.  106 variants were selected for validation, and 100 of 
these were validated.  Again, the variants which were not validated were largely 
present in regions of low NGS coverage.   
 
The genes/ variants which were selected in the short term for functional 
characterisation were those identified as part of the targeted exome testing:  
variants in AXIN2, POLE, POLD1 and the MMR genes.  Although many other 
validated variants were potentially interesting, they were not taken forward for 
further studies.  The reasons for not selecting other variants included 1) lack of 
availability of relatives, 2) the variant was in a gene already associated with a 
disease phenotype other than colorectal neoplasia, 3) it was too frequent to be a 
reasonable candidate for the relatively uncommon phenotype of polyposis or 4) 
there was not sufficient evidence of a likely role in colorectal neoplasia to prioritise 
the gene concerned.  As mentioned previously, some variants were identified which 
were known to be clinically significant in contexts other than colorectal neoplasia.  
Where these were clinically actionable, they were fed back to the patient’s clinician, 
according to the study protocol.   
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6.2.1 Strengths and Weaknesses of Targeted and Whole 
Exome Sequencing in NMI Polyposis Patients 
As described above (6.1.1) the strengths to this study included the availability of 
DNA and RNA and the access to NGS technologies.  A further strength is that we 
were fortunate to have had input from international experts, Professor Seruca, and 
industry, AmbryGen, to assist in variant appraisal.  
 
The most important factors limiting progress in the search for novel variants 
associated with polyposis were the lack of additional family members and the size of 
the study cohort.  Other studies have been more successful because they were 
larger or prioritised the study of familial cases (Adam et al 2016; Weren et al 2015) 
with availability of samples from multiple affected relatives. 
 
Another issue faced was variable coverage with WES.  The mean depth of 
coverage across the 29 patients/ relatives was 61.99 reads, but this varied from 
14.02 reads (Halo66) to 139.76 reads (Halo61).  Furthermore, the percentage of the 
target region covered at 50x depth was only 43.9%.  When variants were not 
validated following Sanger sequencing, these tended to have occurred in regions of 
low coverage. 
 
Exome sequencing generates large amounts of data, including many novel variants, 
leading to a challenge in the selection of variants for further study.  CADD scores 
were one tool used for variant prioritisation in the current work, and their limitations 
have already been discussed (6.1.1).  Ultimately choices have to be made based 
upon a variant’s predicted impact on gene function, previous literature on the 
functions of the gene involved and genetic data, if available, on de novo occurrence 
or segregation with the disease phenotype.   
 
The work in this part of the project required database interrogation to aid in 
prioritising identified variants.  As described in Chapter 4 (4.4.1) it is apparent that 
genetic variants identified through clinical research projects are often not recorded 
in publicly accessible databases.  It would be excellent if all variants were recorded 
in a centralised repository, such as LOVD, as this would allow improved 
understanding of disease pathogenesis and therefore improved patient care.  With 
the advent of the 100 000 Genomes Project it is hoped that there will be improved 
understanding of the role of the genome in health and disease.  The project seeks 
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to enhance the clinical interpretation of the data and derive new findings from the 
data (https://www.genomicsengland.co.uk/faqs-about-gecip/ accessed 10/5/2018).   
 
6.2.2 Recommendations Resulting from Exome Sequencing 
1. Ensure attempts are made to recruit family members at the onset of the 
study.  Affected and/ or unaffected family members are required in order to 
meaningfully evaluate variants identified in probands.  I would recommend 
that for future genetic research similar to this, family members should be 
recruited to studies at their onset, if at all possible. 
2. Record all variants in a pubic database.  The aim of all clinical research 
should be to improve patient care.  We were very fortunate throughout this 
study to have had input from world experts and from Industry, for example 
AmbryGen.  The optimal situation would be to record all variants identified 
through genetic research in a publicly-available repository, as described in 
sections 4.4.1 and 6.2.1.   
 
6.3 Functional Characterisation of Variants Identified in the 
Mismatch Repair Genes, POLE, POLD1 and AXIN2 
The final phase of this project sought to further characterise variants in the MMR 
genes, POLE and POLD1 and AXIN2 to gain evidence either for or against their 
clinical significance. 
 
6.3.1 The MMR Genes 
Three patients were found to carry germline variants in one of the MMR genes 
(Halo26, Halo45 and Halo70).  Tumour samples were available for all three patients.  
The pathogenic effects of the mutations were examined through IHC analysis of the 
MMR proteins and MSI testing of tumour DNA.  In all cases, MMR IHC was normal, 
and all lesions tested were microsatellite stable.  This lead to the conclusion that the 
variants are unlikely to be pathogenic.  This in keeping with their prior probability of 
pathogenicity scores (5.2.6.1) which were all <0.95. 
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6.3.2 POLE and POLD1 
Four patients were found to carry germline mutations in POLE or POLD1 (Halo15, 
Halo18, Halo27 and Halo61).  Basic in silico and functional studies were initially 
carried out.  These included structural modelling to try and predict whether the 
mutations could theoretically impair the functioning of the proteins and studies on 
tumour samples to assess their MSI status and to test for the somatic ‘hot spot’ 
mutations which have been reported in tumours from carriers of pathogenic POLE 
mutations (Palles et al 2013).  Based on structural modelling, the p.Glu2140Lys 
mutation in Halo18 was deemed unlikely to have functional consequences so was 
not taken further forward.   
 
The ‘gold standard’ of variant assessment was to determine the ‘mutation signature’ 
of the tumours arising in carriers of mutations in the pol genes.  Known pathogenic 
mutations impair the proofreading activity of the polymerases, and they are 
associated with a hypermutated genetic signature in tumours.  Somatic genetic 
analysis was performed in collaboration with Professor Ian Tomlinson and Dr. Claire 
Palles (Oxford University/ Birmingham University).  SmMIPs were used to capture 
30 genes.  Unfortunately, sequencing was not successful for Halo61, so 
p.Tyr623Cys remains a VUS.  There was a seven-month delay between preparing 
the samples for sequencing and obtaining the initial results from sequencing.  This 
was due to factors beyond our control (the relocation of the Tomlinson group from 
Oxford to Birmingham).  However, it has meant that we currently only have the raw 
sequencing results for Halo15, for which bioinformatic analysis is awaited.  The 
tumour sequencing results for Halo27 are pending.  Therefore, at the present time, 
the variants identified in Halo15 and Halo27, c.1411A>G:p.Met471Val  and 
c.2861C>T:p.Thr954Met still remain as VUS. 
 
6.3.3 AXIN2 c.1642G>T:p.Glu548* 
Two sisters participating in this study were found to carry a germline mutation in 
AXIN2, c.1642G>T:p.Glu548*.  When further family members were recruited, this 
was confirmed to segregate with occurrence of colorectal neoplasia in an AD 
manner.  All individuals affected by colorectal neoplasia also had a history of 
oligodontia, and there were variable signs of ectodermal dysplasia.  These findings 
are in keeping with previous reports in the literature describing AXIN2 mutations in 
the context of colorectal polyposis (Marvin et al 2011; Lammi et al 2004).  Further 
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work investigating this mutation confirmed that it was present in patient-derived 
RNA samples and that it was capable of producing a protein approximately 30k DA 
smaller than the wild-type protein.  The protein appeared to be more stable then 
wild-type protein, again in keeping with the previous literature (Mazzoni et al 2015).  
Assessment of the mutation’s impact on Wnt-pathway activation was investigated 
using the luciferase assay in HEK293 TCF-Luc cell lines.  Results showed that 
Short-AXIN2, WT/ Short-AXIN2 and Fearon-AXIN2 all had impaired ability to inhibit 
Wnt-pathway activation, although this was only statistically significant for the WT/ 
Short-AXIN2 mix. 
 
To further investigate the mutation, β-catenin IHC was performed on tumours arising 
in carriers of germline AXIN2 mutations.  There was evidence of nuclear β-catenin, 
but only in a very small proportion of tumours, and it was more overt in higher-grade 
lesions.  This suggested that there is Wnt-pathway activation in colorectal tumours 
from the AXIN2 mutation carriers investigated, but that it may be occurring at a later 
stage of tumourigenesis compared to sporadic or FAP-associated lesions and/ or it 
may be a subtler effect.  
 
I attempted to screen the APC MCR to determine whether somatic mutations in 
APC were present, as this is a common finding in FAP-associated and sporadic 
colorectal neoplasia.  Unfortunately, the quality and quantity of DNA extracted from 
tumours was poor, and MCR sequencing was incomplete.  Nonetheless, there 
appeared to be fewer somatic APC mutations than would have been expected in the 
adenomas, although this was not confirmed statistically due to the lack of a robust 
control set.  This raises the possibility that there may be a novel genetic pathway of 
tumourigenesis in carriers of germline AXIN2-mutations, such that APC mutations 
are not required for the initial stages of tumourigenesis.  This will be further 
investigated through WES of tumour DNA. 
 
To summarise, we have identified a family in which a truncating AXIN2 mutation is 
segregating with colorectal neoplasia and oligodontia in an AD manner.  It is not 
clear whether the additional signs of ectodermal dysplasia, thin hair and nail 
abnormalities, are part of the phenotype or are incidental findings.  The results 
obtained from in vitro studies are in keeping with the effects of the mutation at least 
being partially mediated through activation of the canonical Wnt-signalling pathway. 
Interestingly, a key extra-intestinal finding appears to be oligodontia.  The role of the 
Wnt-pathway in tooth formation has been discussed in Chapter 5 (5.4.1). 
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The results of our study are consistent with previous reports in the literature – 
notably that truncating AXIN2 mutations have been found to segregate with 
colorectal neoplasia and oligodontia in an AD manner (Marvin et al 2011; Lammi et 
al 2004).  The colorectal phenotype was variable in our family, like that reported in 
other families.  The polyp count is variable, the presence or absence of CRC is 
variable, and the morphology of the lesions present is variable:  both adenomas and 
HPPs/ serrated lesions have been described.  In this study, colorectal tumours 
arising in the context of a germline AXIN2 mutation were characterised by IHC and 
molecular genetic analysis.  This pointed to potential differences from sporadic or 
FAP-related tumours.  However, further characterisation is required to confirm or 
refute these differences.  It is possible that adenomas may result from activation of 
the Wnt-signalling pathway, whereas HPPs/ serrated lesions may be the result of 
effects on other signalling pathways impacted by AXIN2, for example through Ras/ 
ERK signalling pathways or SAPK/ JNK pathways (Mazzoni and Fearon 2014).   
 
There is mounting evidence for the existence of an AXIN2-Associated Polyposis 
Syndrome.  Although it is likely to be rare, its true prevalence may be 
underestimated due to the variable GI phenotype.  It is possible that AXIN2 
mutations are highly penetrant with regards to the dental phenotype but are of 
variable penetrance in terms of the colorectal phenotype.  To further characterise 
the syndrome, it might be sensible to aim to identify patients through dental clinics 
rather than through gastroenterology/ colorectal surgery.  
 
6.4 Thesis Conclusions 
The aim of this study was to identify novel genes/ mechanisms of disease in a 
cohort of patients with colorectal polyposis who had not had a mutation identified in 
a clinical genetics diagnostic setting. 
 
A total of 60 NMI polyposis patients were included in this project.  Putative 
pathogenic mutations/ disease mechanisms have been identified in 8 of these 
patients:  4 with evidence of reduced APC expression, in one of whom the 
underlying mutation has been confirmed (Halo46); 2 with variants in POLE/ POLD1 
in whom further analysis of adenomas is in progress, and 2 with mutations in 
AXIN2.     
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The phenotype of the patients recruited to this study was highly variable, in terms of 
the age of patients, the family histories, the polyp counts and morphologies.  There 
are several possible explanations as to why we did not identify mutations in more of 
the patients:  variants may be in genomic regions not yet interrogated; they may be 
restricted to a tissue not examined, for example the gut epithelium; epigenetic 
factors may have a role; some patients may have their phenotype as a result of 
oligogenic inheritance and some patients may have numerous sporadic lesions and 
represent one end of a normal distribution of sporadic lesions in the non-
predisposed population. 
 
There are clinical recommendations that result from this project, namely that APC 
promoter/ Exon 1 screening is carried out for patients who remain NMI after 
standard genetic testing protocols and that RNA studies are considered for NMI 
patients.  With further characterisation it is possible that a case for AXIN2 to be 
included on polyposis/ CRC gene testing panels will be made. 
 
Further work which will be done following on from this project will be to carry out 
whole genome sequencing for those patients with evidence of reduced APC 
transcription and to examine the genetic signature of tumours developing in carriers 
of AXIN2 mutations. 
 
The ultimate aim of this work is to optimise patient care and to prevent the 
development of CRC.  Once causative mutations are identified, family members can 
be screened, and appropriate clinical management instituted.  The work is already 
having an impact on the family of Halo46 and will hopefully have a positive impact 
on other families and future generations.  A relative of Halo46 has written: 
 
‘I would also like to thank you for the information you passed to … This means my 
son will be able to be checked for FAP without the initial endoscopy. Just this small 
advance has lifted a world of anxiety from my shoulders, thank you so very much 
indeed.’ 
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